EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 74

Results Generated From:
Embase <1980 to 2024 Week 32>
Embase Weekly Updates (updates since 2024-08-02)

<1>
Accession Number
2033704161
Title
Long-Term Outcomes of Mechanical Versus Bioprosthetic Aortic Valve
Replacement in Patients Aged Under 50 Years: Meta-Analysis of
Reconstructed Time-to-Event Data.
Source
American Journal of Cardiology. 227 (pp 11-17), 2024. Date of Publication:
15 Sep 2024.
Author
Warraich N.; Sa M.P.; Jacquemyn X.; Ahmad D.; Serna-Gallegos D.; Sultan I.
Institution
(Warraich, Sa, Ahmad, Serna-Gallegos, Sultan) Division of Cardiac Surgery,
Department of Cardiothoracic Surgery, University of Pittsburgh,
Pittsburgh, PA, United States
(Warraich, Sa, Ahmad, Serna-Gallegos, Sultan) UPMC Heart and Vascular
Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United
States
(Jacquemyn) KU Leuven, Leuven, Belgium
Publisher
Elsevier Inc.
Abstract
To compare the long-term outcomes of mechanical versus bioprosthetic
aortic valve replacement (AVR) in patients aged <50 years, we performed a
study-level meta-analysis with reconstructed time-to-event data including
studies published by December of 2023. The primary outcome was overall
survival. Secondary outcomes included reoperation, major bleeding, and
stroke. A total of 5 studies met our inclusion criteria, with a total of
4,245 patients (2,311 mechanical and 1,934 bioprosthetic). All studies
were observational and the mean age of groups across the studies ranged
from 38.2 to 43.0 years. The median follow-up time was 11.4 years
(interquartile range 6.9 to 15.0). Bioprosthetic AVR was associated with
reduced overall survival and higher risk of all-cause death (hazard ratio
[HR] 1.170 95% confidence interval [CI] 1.002 to 1.364, p = 0.046),
increased risk of reoperation over time (HR 2.581, 95% CI 2.102 to 3.168,
p <0.001), decreased risk of major bleeding (HR 0.500, 95% CI 0.367 to
0.682, p <0.001), and decreased risk of stroke (HR 0.751, 95% C, 0.565 to
0.998, p = 0.049) compared with mechanical AVR in patients aged <50 years.
In conclusion, for patients aged <50 years, bioprosthetic AVR is
associated with increased mortality and risk of reoperation compared with
mechanical valves. In contrast, mechanical AVR is associated with an
increased risk of major bleeding events and stroke. These aspects should
be carefully considered during the selection of valve type in this age
group; however, we should keep in mind that the statistically significant
differences in the risk of all-cause death and stroke might not be
clinically relevant (because of marginal statistical
significance).<br/>Copyright &#xa9; 2024 Elsevier Inc.

<2>
Accession Number
2033653151
Title
Psychologically-enhanced cardiac rehabilitation for psychological and
functional improvement in patients with cardiovascular disease: a
systematic review with meta-analysis and future research directions.
Source
Physiotherapy (United Kingdom). 125 (no pagination), 2024. Article Number:
101412. Date of Publication: December 2024.
Author
Wrzeciono A.; Mazurek J.; Cieslik B.; Kiper P.; Gajda R.;
Szczepanska-Gieracha J.
Institution
(Wrzeciono, Szczepanska-Gieracha) Department of Physiotherapy, Wroclaw
University of Health and Sport Sciences, Wroclaw 51-612, Poland
(Mazurek) University Rehabilitation Centre, Wroclaw Medical University,
Wroclaw 50-367, Poland
(Cieslik, Kiper) Healthcare Innovation Technology Lab, IRCCS San Camillo
Hospital, Venezia 30126, Italy
(Gajda) Department of Kinesiology and Health Prevention, Jan Dlugosz
University in Czestochowa, Czestochowa 42-200, Poland
(Gajda) Center for Sports Cardiology at the Gajda-Med Medical Center in
Pultusk, Pultusk 06-102, Poland
Publisher
Elsevier Ltd
Abstract
Objective: To systematically review the effectiveness of
psychologically-enhanced cardiac rehabilitation (CR) in improving
psychological and functional outcomes in patients with cardiovascular
disease. Data sources: A systematic search was performed in PubMed,
Scopus, Cochrane Library, Embase, and Web of Science, up to January 31,
2024. Study selection: Two reviewers independently identified randomized
clinical trials that evaluated the effectiveness of
psychologically-enhanced CR in improving psychological and functional
outcomes in patients with cardiovascular disease. The search yielded 1848
results. Finally, data from 14 studies (1531 participants) were included
in the review. Data extraction and data synthesis: Information regarding
cardiac rehabilitation phase, duration of the intervention, group
characteristics, measured outcomes, and the conclusions drawn by the
authors was extracted. The Revised Cochrane risk-of-bias tool for
Randomized Trials was used to evaluate the methodological quality.
<br/>Result(s): Pooled results indicate that psychologically-enhanced CR
is more effective than specific cardiac training alone in maintaining
lower resting blood pressure, with a mean difference of -3.09 (95% CI:
-5.18 to -1.00). Furthermore, psychologically-enhanced CR shows
superiority in improving patients' quality of life compared to specific
cardiac training alone, with a standardized mean difference of 0.15 (95%
CI: 0.01 to 0.31). Analyses of depression and anxiety level, exercise
tolerance, and blood lipid profile did not show significant differences
between the two treatment conditions. <br/>Conclusion(s):
Psychologically-enhanced CR shows a positive effect on reducing resting
blood pressure and improving the quality of life. However, the supportive
methods were of limited effectiveness in addressing the psychological
aspects of health. Systematic Review Registration Number: PROSPERO
CRD42022304063. Contribution of the paper: * Psychologically-enhanced
cardiac rehabilitation (CR) has the potential to improve the effectiveness
of CR. * Limited effectiveness in the psychological aspects of health
requires consideration. * New therapeutic solutions to manage mental
health during CR should be sought.<br/>Copyright &#xa9; 2024 Chartered
Society of Physiotherapy

<3>
Accession Number
2033643850
Title
Effect of music on hemodynamic fluctuations in women during induction of
general anesthesia: A prospective randomized controlled multicenter trial.
Source
Clinics. 79 (no pagination), 2024. Article Number: 100462. Date of
Publication: 01 Jan 2024.
Author
Wang J.; Jiang L.; Chen W.; Wang Z.; Miao C.; Zhong J.; Xiong W.
Institution
(Wang, Jiang, Chen, Wang, Miao, Zhong, Xiong) Department of
Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Publisher
Universidade de Sao Paulo. Museu de Zoologia
Abstract
Background: The authors aim to investigate the effect of music on
hemodynamic fluctuations during induction of general anesthesia and
reducing preoperative anxiety for women who underwent elective non-cardiac
surgery. <br/>Method(s): It is a multicenter, double-blind, randomized,
parallel-group clinical trial. Patients were randomized 1:1 to either a
Music Intervention group (MI) or a Control group (Control). The MI
participants listened to their preferred music for more than 30 minutes in
the waiting area. The State-Trait Anxiety Inventory (STAI) was used to
measure anxiety levels in the groups, and hemodynamic parameters (Heart
Rate [HR], Mean Arterial Pressure [MAP]) were continuously recorded before
induction (T0), at loss of consciousness (T1), immediately before
intubation (T2), and after intubation (T3). Intubation-related adverse
events were also recorded. The primary outcome was the incidence of MAP
changes more than 20 % above baseline during T0-T2. <br/>Result(s): A
total of 164 patients were included in the final analyses. The incidence
of MAP instability during T0-T2 was lower in the MI, and the 95 %
Confidence Interval for the rate difference demonstrated the superiority
of MI. HR instability was less frequent in MI participants both in T0-T2
and T2-T3. The overall incidence of preoperative anxiety was 53.7 %
(88/164). After the music intervention, the mean score of STAI was
significantly lower in the MI than in the Control, with a between-group
difference of 8.01. <br/>Conclusion(s): Preoperative music intervention
effectively prevented hemodynamic instability during anesthesia induction
and significantly reduced preoperative anxiety in women undergoing
elective non-cardiac surgery.<br/>Copyright &#xa9; 2024

<4>
Accession Number
2033068278
Title
Malignant Pericardial Effusion: A Systematic Review.
Source
CJC Open. 6(8) (pp 967-972), 2024. Date of Publication: August 2024.
Author
Mudra S.E.; Rayes D.; Kumar A.K.; Li J.Z.; Njus M.; McGowan K.;
Charalampous C.; Kalam K.A.; Syed A.; Majid M.; Schleicher M.; Agrawal A.;
Yesilyaprak A.; Klein A.L.
Institution
(Mudra, Rayes, Kumar, Li, Njus, McGowan, Charalampous, Kalam) Department
of Internal Medicine, MedStar Georgetown University Hospital, MedStar
Health, Washington, DC, United States
(Kumar, Syed, Majid, Agrawal, Klein) Center for the Diagnosis and
Treatment of Pericardial Diseases, Section of Cardiovascular Imaging,
Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic
Institute, Cleveland Clinic, Cleveland, OH, United States
(Schleicher) Floyd D. Loop Memorial Library, Cleveland Clinic, Cleveland,
OH, United States
(Yesilyaprak) Department of Internal Medicine, Wayne State University,
Detroit, MI, United States
Publisher
Elsevier Inc.
Abstract
Background: Malignant pericardial effusion (Eff) is often asymptomatic and
has an unknown prevalence, due to its occult presentation. The condition
often is identified postmortem on autopsy, and it is associated with a
poor prognosis. Given the late presentation of malignant pericardial Effs,
a minimal volume of literature has examined the epidemiology, clinical
characteristics, and outcomes of these complex patients. We conducted a
systematic review to advance present understanding of this condition.
<br/>Method(s): A search of 4 databases resulted in 41 case reports
meeting criteria. Inclusion criteria were being a patient aged > 18 years
who presented with pericardial Eff in the setting of malignancy.
Intervention was medical and/or surgical therapy, and the outcome was
mortality. <br/>Result(s): For the 41 patients included, the median age
was 54 years, and the majority were male patients (58%). Dyspnea was the
leading symptom (90%), and cardiac tamponade was present in 78% of cases.
Common cancers included lung, gastrointestinal, and renal neoplasms (59%).
Pericardiocentesis occurred in 98% of cases, with a median fluid
extraction volume of 1000 mL. Death occurred in 44%, primarily due to
disease progression and/or metastasis. <br/>Conclusion(s): This study
presents the largest systematic review on malignancy-induced pericardial
Effs to date. Notably, solid tumours, and specifically lung
adenocarcinomas, are common culprits. Malignant pericardial Effs are often
severe, with a majority of patients presenting with cardiac tamponade.
Overall, treatment options are limited, and the associated mortality rate
is high.<br/>Copyright &#xa9; 2024 The Authors

<5>
Accession Number
2030829020
Title
The current state of minimally invasive cardiac surgery in Africa: a
systematic review and meta-analysis.
Source
Cardiothoracic Surgeon. 32(1) (no pagination), 2024. Article Number: 15.
Date of Publication: December 2024.
Author
Akintoye O.O.; Adu B.G.; Otorkpa M.J.; Olayode O.O.; Fodop S.; Alemede
P.O.; Enyong R.K.; Anele F.C.; Omoregbee B.I.
Institution
(Akintoye, Adu, Otorkpa, Olayode, Fodop, Alemede, Enyong, Anele,
Omoregbee) Cardiothoracic Surgery Community, Surgery Interest Group of
Africa, Lagos, Nigeria
(Omoregbee) Hull University Teaching Hospital NHS, Kingston Upon Hull,
United Kingdom
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Globally, the utilisation of minimally invasive techniques has
become increasingly prevalent. While traditional open-heart procedures
still dominate the landscape, a significant portion of cardiac surgeries
are now performed minimally invasively. The aim of this study is to
provide an insightful overview of the current state of minimally invasive
cardiac surgery in Africa. Main body: A comprehensive database search was
performed on PubMed, African Journal Online, Google Scholar, and Scopus to
identify published data reporting on outcomes of minimally invasive
cardiac surgery in Africa, from inception till June 2024. We used the
Preferred Reporting Items for Systematic Reviews and Meta-analysis
guidelines to undergo this study. The primary outcomes of interest were
in-hospital mortality and overall mortality. Data were pooled together and
analysed using a random effect model for meta-analysis with R software.
Out of a total of 2309 articles identified, only fourteen papers met our
inclusion criteria following deduplication and screening. The four
countries with published research include Egypt, South Africa, Tanzania,
and Morocco, with a total sample size of 1357 patients. The meta-analysis
of the reported outcomes produced a pooled in-hospital mortality
prevalence of 1.18%, while the pooled overall mortality prevalence was
2.23%. There was no statistically significant difference in outcomes
between the mini sternotomy and the full sternotomy group.
<br/>Conclusion(s): The pooled outcomes of minimally invasive cardiac
surgery in Africa are comparable to those in other regions. However, there
are several socio-economic factors limiting its widespread practice in
Africa.<br/>Copyright &#xa9; Crown 2024.

<6>
Accession Number
2030828903
Title
Early anti-coagulation therapy in new-onset atrial fibrillation after
coronary artery bypass grafting: a randomized trial pilot study.
Source
BMC Cardiovascular Disorders. 24(1) (no pagination), 2024. Article Number:
404. Date of Publication: December 2024.
Author
Ghavami M.; Hosseini K.; Abdshah A.; Abadi S.R.F.; Akbarzadeh D.;
Mohammadi I.; Kalhor P.; Sadeghian S.
Institution
(Ghavami, Hosseini, Kalhor, Sadeghian) Tehran Heart Center, Cardiovascular
Diseases Research Institute, Tehran University of Medical Sciences, North
Kargar Street, Tehran 1411713138, Iran, Islamic Republic of
(Abdshah) School of Medicine, Tehran University of Medical Sciences,
Tehran, Iran, Islamic Republic of
(Abdshah) Department of Public Health Sciences, Miller School of Medicine,
University of Miami, Miami, FL, United States
(Abadi, Akbarzadeh, Mohammadi) Student Research Committee, School of
Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
Islamic Republic of
Publisher
BioMed Central Ltd
Abstract
Background: New-onset postoperative atrial fibrillation (POAF) is a common
complication after coronary artery bypass grafting (CABG) surgery,
increasing the risk of embolism and stroke. There is a lack of information
on the use of anticoagulants in this context. The choice between Warfarin
and Direct oral anticoagulants (DOACs) also is not well-established. This
randomized study aimed to compare the feasibility and safety of Warfarin
and Rivaroxaban in preventing thrombotic events in POAF patients after
isolated CABG. <br/>Method(s): A total of 66 patients were randomized
parallelly with 1:1 allocation to receive either Rivaroxaban (n = 34) or
Warfarin (n = 32). Major bleeding events within 30 days after discharge
were the primary outcome. Secondary outcomes included minor bleeding
events and thrombotic episodes. Clinical characteristics, medication
regimens, and left atrial diameter were assessed. Statistical analyses
were performed using appropriate tests. <br/>Result(s): No thrombotic
episodes were observed in either treatment arm. No major bleeding events
occurred in either group. Four minor bleeding events were reported, with
no significant difference between the treatment groups (P = 0.6). Patients
with atrial fibrillation had significantly larger left atrial diameters
compared to those with normal sinus rhythm (40.5 vs. 37.8 mm, P = 0.01).
<br/>Conclusion(s): This pilot study suggests that Warfarin and
Rivaroxaban are both safe and effective for preventing thrombotic episodes
in POAF patients after isolated CABG. No significant differences in major
bleeding events were observed between the two anticoagulants. These
findings may support the preference for DOACs like Rivaroxaban due to
their convenience and easier maintenance. Trial registration: Number
IRCT20200304046696N1, Date 18/03/2020
https//irct.behdasht.gov.ir/.<br/>Copyright &#xa9; The Author(s) 2024.

<7>
Accession Number
2033639537
Title
Transcatheter aortic valve replacement outcomes in patients with high
gradient versus low ejection fraction low gradient severe aortic stenosis:
A meta-analysis of randomized controlled trials.
Source
Cardiovascular Revascularization Medicine. (no pagination), 2024. Date of
Publication: 2024.
Author
Al-Bayati A.; Alrifai A.; Darmoch F.; Alkhaimy H.; Fanari Z.
Institution
(Al-Bayati, Fanari) University of California San Francisco, Fresno, CA,
United States
(Alrifai) Advocate Aurora Health, Chicago, IL, United States
(Darmoch) Northside Hospital Cardiovascular Institute, Cumming, GA, United
States
(Alkhaimy) University of Arkansas for Medical Sciences, Little Rock, AR,
United States
Publisher
Elsevier Inc.
Abstract
Background: The outcome of Low Flow-Low Gradient (LF-LG) severe aortic
stenosis (AS) patients who underwent Transcatheter Aortic Valve
Replacement (TAVR) procedure is not well defined. We conducted a
systematic review of the literature to compare the outcomes of TAVR in
LF-LG AS patients to the more traditional high gradient (HG) aortic
stenosis. <br/>Method(s): We comprehensively searched for controlled
randomized and non-randomized studies from 4 online databases. We are
presenting the data using risk ratios (95 % confidence intervals) and
measuring heterogeneity using Higgins' I² index.
<br/>Result(s): Our analysis included 4380 patients with 3425 HG patients
and 955 LF-LG patients from 6 cohort (5 retrospective and 1 prospective)
studies. When compared to LFLG; TAVR was associated with significantly
lower 30 days mortality in HG patients (5.1 % vs 7.4 %; relative risk
[RR]: 0.55; 95 % confidence interval [CI]: 0.35 to 0.86; p < 0.01).
Similar findings were also observed in 12-month cardiovascular (CV)
mortality (5.5 % vs. 10.4 %; RR: 0.47; 95 % CI: 0.38 to 0.60; p < 0.01 and
12-month all-cause mortality (15.9 % vs 20.9 %; RR: 0.70; 95 % CI: 0.49 to
1.00; p < 0.05). There was no significant difference in myocardial
infarction (MI) after TAVR between HG and LF-LG at 30 days (0.16 % vs.
0.95 %; p < 0.09) or 12 months (0.43 % vs. 0.95 %; p = 0.20). Similarly,
there was no difference in stroke rates at 30 days (2.9 % vs. 2.86 %) or
at 12 months (3.6 % vs. 3.06 %). Conclusions and relevance: Patients with
LF-LG severe AS who underwent TAVR had worse 1-year all-cause mortality,
30-day all-cause, and 1-year CV mortality when compared to TAVR in HG
severe AS. There was no difference in MI or stroke rates. Therefore, with
heart team discussion and informed patient decision regarding the risk and
benefit, TAVR would still offer better outcomes in LFLG AS compared to
conservative medical management.<br/>Copyright &#xa9; 2024 The Authors

<8>
Accession Number
2033596016
Title
Long-term follow-up of the randomized, prospective Scandinavian heart
transplant everolimus de novo study with early calcineurin inhibitors
avoidance (SCHEDULE) trial.
Source
Journal of Heart and Lung Transplantation. (no pagination), 2024. Date of
Publication: 2024.
Author
Bollano E.; Andreassen A.K.; Eiskjaer H.; Gustafsson F.; Radegran G.; Gude
E.; Gullestad L.; Broch K.; Halden T.A.S.; Karason K.; Bartfay S.-E.;
Bergh N.
Institution
(Bollano, Bartfay) Department of Cardiology, Sahlgrenska University
Hospital, Gothenburg, Sweden
(Bollano, Karason, Bartfay) Department of Transplantation, Sahlgrenska
University Hospital, Gothenburg, Sweden
(Bollano, Karason, Bartfay, Bergh) Institute of Medicine, Sahlgrenska
Academy, University of Gothenburg, Gothenburg, Sweden
(Andreassen, Gude, Gullestad, Broch) Department of Cardiology, Oslo
University Hospital Rikshospitalet, Oslo, Norway
(Eiskjaer) Department of Cardiology, Aarhus University Hospital, Aarhus,
Denmark
(Gustafsson) Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
(Gustafsson) Department of Clinical Medicine, University of Copenhagen,
Copenhagen, Denmark
(Radegran) Section for Heart Failure and Valvular Disease, Skane
University Hospital and Department of Clinical Sciences, Cardiology, Lund
University, Lund, Sweden
(Gullestad, Broch) KG Jebsen Center for Cardiac Research, University of
Oslo, Oslo, Norway
(Halden) Department of Immunology, Novartis Norge AS, Oslo, Norway
Publisher
Elsevier Inc.
Abstract
Background: Early substitution of calcineurin inhibitor (CNI) with
mammalian target of rapamycin inhibitors has been shown to improve kidney
function and reduce intimal hyperplasia in heart transplant (HTx)
recipients but data on long-term outcome of such a regime are still
sparse. <br/>Method(s): In the SCHEDULE trial, 115 de novo HTx recipients
were randomized to (1) everolimus with reduced exposure of CNI followed by
CNI withdrawal at week 7-11 post-transplant or (2) standard-exposure with
CNI. Both groups received mycophenolate mofetil and corticosteroids.
Herein we report on the 10-12-year long-term follow-up of the study.
<br/>Result(s): A total of 78 patients attended the follow-up visit at a
median time of 11 years post-transplant. In the everolimus intention to
treat (ITT) group 87.5% (35/40 patients) still received everolimus and in
the CNI ITT group 86.8% (33/38) still received CNI. Estimated glomerular
filtration rate (eGFR) (least square mean (95% CI)) at the 10-12 years
visit was 82.7 (74.2-91.1) ml/min/1.73 m² and 61.0 (52.3-69.7)
ml/min/1.73 m² in the everolimus and CNI group, respectively (p
< 0.001). Graft function measured by ejection fraction, ECG, NT-proBNP and
drug safety were comparable between groups. During the study period there
was a total of 28 deaths, but there was no difference in survival between
the everolimus and the CNI group (aHR 0.61 (95% CI 0.29-1.30) p = 0.20).
For the composite endpoint of death, re-transplantation, myocardial
infarction, PCI, dialysis, kidney transplantation or cancer no between
group differences were found (aHR 1.0 (95% CI 0.57-1.77) p = 0.99).
<br/>Conclusion(s): De novo HTx patients randomized to everolimus and low
dose CNI followed by CNI free therapy sustained significantly better
long-term kidney function than patients randomized to standard therapy.
The graft function at 10-12 years was similar in both groups and there was
no difference in survival.<br/>Copyright &#xa9; 2024 The Authors

<9>
Accession Number
2032820129
Title
Outcome-based Risk Assessment of Non-HLA Antibodies in Heart
Transplantation: A Systematic Review.
Source
Journal of Heart and Lung Transplantation. 43(9) (pp 1450-1467), 2024.
Date of Publication: September 2024.
Author
Panicker A.J.; Prokop L.J.; Hacke K.; Jaramillo A.; Griffiths L.G.
Institution
(Panicker, Griffiths) Mayo Clinic Graduate School of Biomedical Sciences,
Mayo Clinic, Rochester, Minnesota, United States
(Panicker) Department of Immunology, Mayo Clinic, Rochester, Minnesota,
United States
(Panicker, Griffiths) Department of Cardiovascular Medicine, Mayo Clinic,
Rochester, Minnesota, United States
(Prokop) Mayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota, United
States
(Hacke, Jaramillo) Department of Laboratory Medicine and Pathology, Mayo
Clinic, Phoenix, Arizona, United States
(Griffiths) Department of Physiology & Biomedical Engineering, Mayo
Clinic, Rochester, Minnesota, United States
Publisher
Elsevier Inc.
Abstract
Background: Current monitoring after heart transplantation (HT) employs
repeated invasive endomyocardial biopsies (EMB). Although positive EMB
confirms rejection, EMB fails to predict impending, subclinical, or
EMB-negative rejection events. While non-human leukocyte antigen (non-HLA)
antibodies have emerged as important risk factors for antibody-mediated
rejection after HT, their use in clinical risk stratification has been
limited. A systematic review of the role of non-HLA antibodies in
rejection pathologies has the potential to guide efforts to overcome
deficiencies of EMB in rejection monitoring. <br/>Method(s): Databases
were searched to include studies on non-HLA antibodies in HT recipients.
Data collected included the number of patients, type of rejection, non-HLA
antigen studied, association of non-HLA antibodies with rejection, and
evidence for synergistic interaction between non-HLA antibodies and
donor-specific anti-human leukocyte antigen antibody (HLA-DSA) responses.
<br/>Result(s): A total of 56 studies met the inclusion criteria. Strength
of evidence for each non-HLA antibody was evaluated based on the number of
articles and patients in support versus against their role in mediating
rejection. Importantly, despite previous intense focus on the role of
anti-major histocompatibility complex class I chain-related gene A (MICA)
and anti-angiotensin II type I receptor antibodies (AT1R) in HT rejection,
evidence for their involvement was equivocal. Conversely, the strength of
evidence for other non-HLA antibodies supports that differing rejection
pathologies are driven by differing non-HLA antibodies.
<br/>Conclusion(s): This systematic review underscores the importance of
identifying peri-HT non-HLA antibodies. Current evidence supports the role
of non-HLA antibodies in all forms of HT rejection. Further investigations
are required to define the mechanisms of action of non-HLA antibodies in
HT rejection.<br/>Copyright &#xa9; 2024 International Society for the
Heart and Lung Transplantation

<10>
Accession Number
2030837434
Title
Six-Year Outcomes of Total Arch Replacement vs Debranching With TEVAR for
Aortic Arch Pathologies: Meta-Analysis of Kaplan-Meier-Derived Data From
Propensity Score-Matched Studies.
Source
Journal of Endovascular Therapy. (no pagination), 2024. Date of
Publication: 2024.
Author
Sa M.P.; Iyanna N.; Jacquemyn X.; Brown J.A.; Yousef S.; Ahmad D.; Singh
M.J.; Serna-Gallegos D.; Sultan I.
Institution
(Sa, Iyanna, Brown, Yousef, Ahmad, Singh, Serna-Gallegos, Sultan) UPMC
Heart and Vascular Institute, University of Pittsburgh Medical Center,
Pittsburgh, PA, United States
(Sa, Iyanna, Brown, Yousef, Ahmad, Serna-Gallegos, Sultan) Department of
Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, United
States
(Jacquemyn) Department of Cardiovascular Sciences, KU Leuven, Leuven,
Belgium
(Singh) Division of Vascular Surgery, University of Pittsburgh,
Pittsburgh, PA, United States
Publisher
SAGE Publications Inc.
Abstract
Background: Total arch replacement (TAR) and debranching plus thoracic
endovascular aortic repair (TEVAR) serve as significant therapeutic
options for aortic arch pathologies. It remains unclear whether one of
these approaches should be considered preferable. Our study aimed to
compare the long-term outcomes of these 2 approaches. <br/>Method(s): We
carried out a pooled meta-analysis of time-to-event data extracted from
studies published by December 2023. Eligibility criteria included
populations with any aortic arch pathology who underwent debranching plus
TEVAR or TAR, propensity score-matched (PSM) studies
(prospective/retrospective; single-center/multicentric), and the outcomes
included follow-up for overall survival/mortality and/or reinterventions.
<br/>Result(s): Eleven PSM studies met our eligibility criteria, including
a total of 1142 patients (571 matched pairs). We did not observe any
statistically significant difference in the risk of all-cause death
between the groups (hazard ratio [HR]=1.20, 95% confidence interval
[CI]=0.91-1.56, p=0.202), but patients who underwent TAR had a
significantly lower risk of late aortic reinterventions compared with
patients who underwent debranching plus TEVAR (HR=0.38, 95% CI=0.23-0.64,
p<0.001). Our meta-regression analyses for all-cause mortality identified
statistically significant coefficients for age (coefficient=-0.047;
p=0.012) and type A aortic dissections (coefficient=0.012; p=0.010).
<br/>Conclusion(s): Debranching plus TEVAR and TAR demonstrate no
statistically significant differences in terms of survival in patients
with aortic arch pathologies, but TAR is associated with lower risk of
late aortic reinterventions over time. Although older patients may benefit
more from debranching plus TEVAR rather than from TAR, patients with
dissections may benefit more from TAR. Clinical Impact: Although the 2
strategies seem to be equally valuable in terms of survival, total aortic
arch replacement (when compared with debranching plus TEVAR to treat
patients with aortic arch pathologies) is associated with reduction of
late aortic reinterventions over time in patients with and without aortic
dissections. However, we should consider debranching plus TEVAR in older
patients as it is associated with lower risk of death in this population.
The novelty of our study lies in the fact that, instead of comparing
study-level effect estimates, we analyzed the outcomes with reconstructed
time-to-event data. This offered us the opportunity of performing our
analyses with a mathematically appropriate model which consider events and
time; however, these findings might be under the influence of treatment
allocation bias.<br/>Copyright &#xa9; The Author(s) 2024.

<11>
Accession Number
2030834238
Title
Ex vivo heart perfusion: an updated systematic review.
Source
Heart Failure Reviews. (no pagination), 2024. Date of Publication: 2024.
Author
Pradegan N.; Di Pasquale L.; Di Perna D.; Gallo M.; Lucertini G.; Gemelli
M.; Beyerle T.; Slaughter M.S.; Gerosa G.
Institution
(Pradegan, Lucertini, Gemelli, Gerosa) Cardiac Surgery Unit,
Cardio-thoraco-vascular and Public Health Department, Padova University
Hospital, Padua, Italy
(Di Pasquale) Division of Congenital Cardiovascular Surgery, Pediatric
Heart Centre and Children's Research Centre, University Children's
Hospital Zurich, Zurich, Switzerland
(Di Perna) Centre Hospitalier Annecy Genevois, Epagny-Metz-Tessy, France
(Gallo, Beyerle, Slaughter) Department of Cardiothoracic Surgery,
University of Louisville, 201 Abraham Flexner Way, Suite 1200, Louisville,
KY 40202, United States
Publisher
Springer
Abstract
Due to the discrepancy between patients awaiting a heart transplant and
the availability of donor hearts, strategies to expand the donor pool and
improve the transplant's success are crucial. This review aims to
summarize current knowledge on the ex vivo heart preservation (EVHP)
experience as an alternative to standard cold static storage (CSS). EVHP
techniques can improve the preservation of the donor's heart before
transplantation and allow for pre-transplant organ
evaluation.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

<12>
Accession Number
2030827301
Title
Clinical presentation and surgical outcomes in patients with Shone's
complex: a systematic review.
Source
General Thoracic and Cardiovascular Surgery. (no pagination), 2024. Date
of Publication: 2024.
Author
Ahmed H.S.; Jayaram P.R.; Gupta D.
Institution
(Ahmed, Jayaram, Gupta) Department of Medicine, Bangalore Medical College
and Research Institute, K.R Road, Karnataka, Bangalore 560002, India
Publisher
Springer
Abstract
Objective: Shone's complex comprises of a combination of congenital
cardiac anomalies causing obstructions in the left ventricle's inflow and
outflow tracts. This systematic review aims to evaluate the clinical
features and surgical outcomes of Shone's complex. <br/>Method(s): An
electronic literature search of PubMed and Scopus was performed to
identify relevant studies related to the presentation, management, and
outcomes of Shone's complex. Two reviewers independently performed
selection. Data on study characteristics, participant demographics,
interventions, outcomes, and follow-up durations were extracted and
analyzed. <br/>Result(s): A total of 691 papers were identified, with 18
studies included in the final analysis. The majority of the studies (n =
12) focused on the pediatric age group. The most common clinical
presentations were coarctation of the aorta (n = 17) and mitral stenosis
(n = 12). Surgical interventions often involved staged approaches,
prioritizing outflow before inflow obstructions. Mitral valve repair was
preferred over replacement due to better long-term outcomes (n = 8).
Biventricular repair was recommended due to improved postoperative
outcomes, but often needed reoperations. Reoperations were common,
primarily due to recurrent coarctation (n = 10), subaortic stenosis (n =
8), and mitral valve dysfunction (n = 7). Pulmonary hypertension (n = 10)
and arrhythmias (n = 11) were significant complications. Most patients
were in modified Ross/NYHA functional class 1 on follow-up. Mortality
rates ranged from 4 to 28%, with better outcomes associated with early and
strategic surgical interventions. <br/>Conclusion(s): Early diagnosis and
biventricular repair were associated with better outcomes while
transplantation was often an eventuality. Standardized diagnostic
criteria, long-term follow-up, and consensus guidelines are needed to
improve the management of this congenital heart disease.<br/>Copyright
&#xa9; The Author(s), under exclusive licence to The Japanese Association
for Thoracic Surgery 2024.

<13>
Accession Number
2030824099
Title
Minimally invasive extracorporeal circulation versus conventional
cardiopulmonary bypass in patients undergoing cardiac surgery (MiECS):
Rationale and design of a multicentre randomised trial.
Source
Perfusion (United Kingdom). (no pagination), 2024. Date of Publication:
2024.
Author
Anastasiadis K.; Antonitsis P.; Papazisis G.; Haidich B.; Liebold A.;
Punjabi P.; Gunaydin S.; El-Essawi A.; Rao V.; Serrick C.; Condello I.;
Nasso G.; Bozok S.; Daylan A.; Argiriadou H.; Deliopoulos A.;
Karapanagiotidis G.; Ashkanani F.; Moorjani N.; Cale A.; Erdoes G.;
Bennett M.; Starinieri P.; Carrel T.; Murkin J.
Institution
(Anastasiadis, Antonitsis, Argiriadou, Deliopoulos, Karapanagiotidis)
Cardiothoracic Department, School of Medicine, Aristotle University of
Thessaloniki, Thessaloniki, Greece
(Papazisis) Special Unit for Biomedical Research and Education, Aristotle
University of Thessaloniki School of Medicine, Thessaloniki, Greece
(Haidich) Department of Hygiene, Social-Preventive Medicine and Medical
Statistics, School of Medicine, Aristotle University of Thessaloniki,
Thessaloniki, Greece
(Liebold, Ashkanani) Department of Cardio-thoracic Surgery, University
Hospital Ulm, Ulm, Germany
(Punjabi) Department of Cardiothoracic Surgery, Hammersmith Hospital,
Imperial College Healthcare NHS Trust, London, United Kingdom
(Gunaydin) Department of Cardiovascular Surgery, Ankara City Hospital,
University of Health Sciences, Ankara, Turkey
(El-Essawi) Department of Thoracic and Cardiovascular Surgery, University
Medical Center Gottingen, Gottingen, Germany
(Rao, Serrick) Peter Munk Cardiac Centre, Toronto General Hospital,
Toronto, ON, Canada
(Condello, Nasso) Cardiac Surgery, Anthea Hospital Gvm Care & Research,
Bari, Italy
(Bozok, Daylan) Department of Cardiovascular Surgery, Izmir Bakircay
University, Izmir, Turkey
(Moorjani) Department of Cardiothoracic Surgery, Royal Papworth Hospital,
University of Cambridge, Cambridge, United Kingdom
(Cale) Department of Cardiac Surgery, Hull and East Yorkshire Hospitals
NHS Trust, Hull, United Kingdom
(Erdoes) Department of Anesthesiology and Pain Medicine, Inselspital, Bern
University Hospital, Bern, Switzerland
(Bennett) Department of Anesthesia, Morriston Hospital, Swansea Bay
University Health Board, Swansea, United Kingdom
(Starinieri) Department of Clinical Perfusion, Jessa Hospital, Hasselt,
Belgium
(Carrel) Department of Cardiac Surgery, University Hospital Zurich,
Switzerland
(Murkin) Department of Anesthesia and Perioperative Medicine, Schulich
School of Medicine and Dentistry, University of Western Ontario, London,
ON, Canada
Publisher
SAGE Publications Ltd
Abstract
Introduction: The ultimate answer to the question whether minimal invasive
extracorporeal circulation (MiECC) represents the optimal perfusion
technique in contemporary clinical practice remains elusive. The present
study is a real-world study that focuses on specific perfusion-related
clinical outcomes after cardiac surgery that could potentially be
favourably affected by MiECC and thereby influence the future clinical
practice. <br/>Method(s): The MiECS study is an international,
multi-centre, two-arm randomized controlled trial. Patients undergoing
elective or urgent coronary artery bypass grafting (CABG), aortic valve
replacement (AVR) or combined procedure (CABG + AVR) using extracorporeal
circulation will be randomized to MiECC or contemporary conventional
cardiopulmonary bypass (cCPB). Use of optimized conventional circuits as
controls is acceptable. The study design includes a range of features to
prevent bias and is registered at clinicaltrials.gov (NCT05487612).
<br/>Result(s): The primary outcome is a composite of postoperative
serious adverse events that could be related to perfusion technique
occurring up to 30 days postoperatively. Secondary outcomes include use of
blood products, ICU and hospital length of stay (30 days) as well as
health-related quality of life (30 and 90 days). <br/>Conclusion(s): The
MiECS trial has been designed to overcome perceived limitation of previous
trials of MiECC. Results of the proposed study could affect current
perfusion practice towards advancement of patient care.<br/>Copyright
&#xa9; The Author(s) 2024.

<14>
Accession Number
2030436268
Title
Empagliflozin to prevent post-operative atrial fibrillation in patients
undergoing coronary artery bypass graft surgery: Rationale and design of
the EMPOAF trial.
Source
PACE - Pacing and Clinical Electrophysiology. 47(8) (pp 1087-1095), 2024.
Date of Publication: August 2024.
Author
Aghakouchakzadeh M.; Hosseini K.; Haghjoo M.; Mirzabeigi P.; Tajdini M.;
Talasaz A.H.; Jalali A.; Askarinejad A.; Kohansal E.; Hedayat B.; Parvas
E.; Bozorgi A.; Bagheri J.; Givtaj N.; Hadavand N.; Hajighasemi A.; Tafti
S.H.A.; Hosseini S.; Sadeghipour P.; Kakavand H.
Institution
(Aghakouchakzadeh, Hosseini, Tajdini, Talasaz, Hedayat, Parvas, Bozorgi,
Bagheri, Hajighasemi, Tafti) Tehran Heart Center, Tehran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Hosseini, Tajdini, Jalali) Cardiovascular Diseases Research Institute,
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran,
Islamic Republic of
(Haghjoo) Cardiac Electrophysiology Research Center, Rajaie Cardiovascular
Medical and Research Center, Iran University of Medical Sciences, Tehran,
Iran, Islamic Republic of
(Mirzabeigi, Kakavand) Department of Clinical Pharmacy and
Pharmacoeconomics, Faculty of Pharmacy, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Talasaz) Department of Clinical Pharmacy, School of Pharmacy, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Askarinejad, Kohansal, Hadavand, Kakavand) Rajaie Cardiovascular Medical
and Research Center, Iran University of Medical Sciences, Tehran, Iran,
Islamic Republic of
(Givtaj, Hosseini) Heart Valve Disease Research Center, Rajaie
Cardiovascular Medical and Research Center, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Sadeghipour) Vascular Disease and Thrombosis Research Center, Rajaie
Cardiovascular Medical and Research Institute, Tehran, Iran, Islamic
Republic of
Publisher
John Wiley and Sons Inc
Abstract
Background: Postoperative atrial fibrillation (POAF) is one of the most
common types of acute AF and can complicate the treatment course of
approximately one third of patients undergoing cardiac surgery.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are among the newest
antidiabetic drugs which can be therapeutic options for preventing POAF by
different mechanisms. <br/>Method(s): Empagliflozin to Prevent POAF
(EMPOAF) is an interventional, investigator-initiated, double-blind,
placebo-controlled, multicenter, randomized controlled trial which will be
conducted in two referral teaching cardiology hospitals in Tehran.
Four-hundred ninety-two adult patients who are scheduled for elective
isolated coronary artery bypass graft (CABG) surgery will be randomly
assigned to one of the groups of intervention (empagliflozin 10 mg daily)
or placebo starting at least 3 days before surgery until discharge. Key
exclusion criteria are a history of diabetes mellitus, AF, ketoacidosis,
or recurrent urinary tract infections along with severe renal or hepatic
impairment, unstable hemodynamics, and patients receiving SGLT2 inhibitors
for another indication. The primary outcome will be the incidence of POAF.
Key secondary endpoints will be the composite rate of life-threatening
arrhythmias, postoperative acute kidney injury, hospitalization length,
in-hospital mortality, stroke, and systemic embolization. Key safety
endpoints will be the rate of life-threatening and/or genitourinary tract
infections, hypoglycemia, and ketoacidosis. <br/>Conclusion(s): EMPOAF
will prospectively evaluate whether empagliflozin 10 mg daily can reduce
the rate of POAF in patients undergoing elective CABG. Enrolment into this
study has started by November 2023 and is expected to be ended before the
end of 2025.<br/>Copyright &#xa9; 2024 Wiley Periodicals LLC.

<15>
Accession Number
2028711729
Title
Transcatheter valvular interventions after heart transplantation: A
systematic review.
Source
Trends in Cardiovascular Medicine. 34(6) (pp 362-368), 2024. Date of
Publication: August 2024.
Author
Cuko B.; Baudo M.; Busuttil O.; Taymoor S.; Nubret K.; Lafitte S.; Beurton
A.; Ouattara A.; De Vincentiis C.; Labrousse L.; Pernot M.; Leroux L.;
Modine T.
Institution
(Cuko, Busuttil, Taymoor, Nubret, Lafitte, Labrousse, Pernot, Leroux,
Modine) Department of Cardiology and Cardio-Vascular Surgery, Hopital
Cardiologique de Haut-Leveque, Bordeaux University Hospital, Pessac,
France
(Baudo) Department of Cardiac Surgery, ASST Spedali Civili di Brescia,
University of Brescia, Brescia, Italy
(Baudo) Department of Cardiac Surgery, University Hospitals Leuven,
Leuven, Belgium
(Beurton, Ouattara) Department of Cardiovascular Anesthesia and Critical
Care, Hopital Cardiologique de Haut-Leveque, Bordeaux University Hospital,
Pessac, France
(De Vincentiis) Department of Cardiac Surgery, IRCCS Policlinico San
Donato, Milan, Italy
Publisher
Elsevier Inc.
Abstract
An increasing number of patients experience late valvular disease after
heart transplantation (HTx). While mostly being primarily addressed
through surgical interventions, transcatheter valve procedures to treat
these conditions are rising, particularly for unsuitable surgical
candidates. This review aims at analyzing the outcomes of transcatheter
valvular procedures in this subset of patients. A systematic review was
conducted including studies reporting on adult patients requiring any form
of transcatheter valvular intervention after a previous HTx. Studies
involving a surgical approach, heterotopic heart transplants, or
concomitant procedures performed during the transplant itself were
excluded. Twenty-five articles with a total of 33 patients met the
inclusion criteria, 10 regarding the aortic valve (14 patients), 5 the
mitral valve (6 patients), and 6 the tricuspid valve (13 patients). In two
cases, the procedure was recommended to stabilize the valvular lesion
before re-transplantation, as both were very young patients. Overall, the
mean time from heart transplantation to reintervention was 14.7 +/- 9.5
years. The mean follow-up was 15.5 +/- 13.5 months, and only one patient
died 22.3 months after the intervention. There is a growing emergence of
transcatheter interventions for valvular disease after heart
transplantation, especially in cases where surgery is deemed high-risk or
prohibitive. A different strategy may also be considered in young patients
to permit longer allograft life before later re-transplantation. Although
encouraging outcomes have been documented, additional research is required
to establish the most appropriate approach within this specific subset of
patients.<br/>Copyright &#xa9; 2023 Elsevier Inc.

<16>
Accession Number
644913772
Title
ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell
lung cancers at 12 months.
Source
Journal of Clinical Oncology. Conference: Annual Meeting of the American
Society of Clinical Oncology, ASCO 2024. Chicago, IL United States. 42(16
Supplement) (no pagination), 2024. Date of Publication: June 2024.
Author
Khan S.; Feng J.; Waddell T.K.; Yasufuku K.; Pierre A.; Keshavjee S.;
Yeung J.; Cypel M.; Donahoe L.; Wakeam E.; De Perrot M.; Safieddine N.; Ko
M.; Parente D.; Rabey M.R.; Cabanero M.; Le L.; Pipinikas C.; Chevalier
A.; Leighl N.B.
Institution
(Khan, Feng, Waddell, Yasufuku, Pierre, Keshavjee, Yeung, Cypel, Donahoe,
Wakeam, De Perrot, Safieddine, Ko, Parente, Rabey, Cabanero, Le,
Pipinikas, Chevalier, Leighl) Department of Medical Oncology and
Hematology, University Health Network, Princess Margaret Cancer Centre,
Toronto, ON, Canada; Division of Thoracic Surgery, University Health
Network, University of Toronto, Toronto, ON, Canada; Division of Thoracic
Surgery, Michael Garron Hospital, Toronto, ON, Canada; Division of
Thoracic Surgery, St Joseph's Health Centre, Toronto, ON, Canada;
Department of Biostatistics, University Health Network, Toronto, ON,
Canada; NeoGenomics Laboratories, Inc., Cambridge, United Kingdom
Publisher
Lippincott Williams and Wilkins
Abstract
Background: ctDNA Lung DETECT is a multicentre investigator initiated
prospective study at 3 thoracic surgery centres in the Greater Toronto
Area assessing ctDNA detection and association with recurrence free
survival (RFS) in patients with early stage non-small cell lung cancer
(NSCLC) (NCT05254782). Patients who have ctDNA detected perioperatively
are offered ctDNA Lung RCT, a randomized trial investigating the benefit
of adjuvant chemo-immunotherapy in patients where the standard of care is
observation alone after surgery (NCT04966663). Herein, we report on ctDNA
outcomes at 12 months for patients with resected early stage NSCLC.
<br/>Method(s): Patients with stage I (T1-2N0) or multifocal T3-4 < cm N0
NSCLC planned for resection at University Health Network consented to
plasma ctDNA assessment before and after surgery, and at 12 months
post-operatively or relapse using the tumor-informed RaDaR assay, which
detects up to 48 tumor-specific variants in plasma with a Limit of
Detection (LoD<inf>95</inf>) of 0.0011% variant allele fraction.
<br/>Result(s): From July 2021 to January 2024, 178 patients were
enrolled; 115 had sufficient tissue for assessment. Of these, 68/72
patients have 12 month post-resection ctDNA results available (3 withdrew,
1 sample failed). ctDNA was detected preoperatively in 18
patients;99%(71/72) had ctDNA clearance post-operatively, and 93% (62/67)
remained ctDNA negative at 12 months. Median follow up time was 18.7
months (range 12.0- 28.3); 8/72 (11%) patients (5 stage I, 3 stage II)
experienced lung cancer recurrence. Median time to recurrence was 13.9
months (range 6.2- 24.9). Of these, 3 had ctDNA detected on their
preoperative and 12-month or recurrence sample, 1 had ctDNA detected at 12
months prior to relapse, 1 had ctDNA detected at 12 months and recurred
around the same time, 2 had negative ctDNA samples and 1 missed sample
collection preoperatively. The recurrence rate was 16.7% (3/18, 95% exact
CI 3.6-41.4%) in patients with ctDNA detected pre-operatively vs. 7.5%
(4/53, CI 2.1-18.2%) in those without. New lung cancers were diagnosed in
5/72 (median time to new primary 15.3 months, range 4.9-14.2) and 2/72
patients had new cancers diagnosed (ovarian/ liposarcoma). For those with
new lung primaries, 1 had ctDNA detected preoperatively but none had ctDNA
detected at time of new primary diagnosis. Of 4 patients who have died, 2
were from recurrent lung cancer and 2 from new primaries (lung/sarcoma).
<br/>Conclusion(s): This study represents one of the largest prospective
cohorts of ctDNA kinetics in patients with resected lung cancer. Of
patients with at least 12 months follow up, 8/72 experienced a lung cancer
recurrence with a higher rate in those with pre-operative ctDNA detected
(16.7% vs 7.5%). Preoperative ctDNA detection may help identify patients
with resected stage I NSCLC that could benefit from treatment
intensification, currently under study in ctDNA Lung RCT (NCT04966663).

<17>
Accession Number
2033684063
Title
Electronic physician notification to facilitate the recognition and
management of severe aortic stenosis: Rationale, design, and methods of
the randomized controlled DETECT AS trial.
Source
American Heart Journal. 276 (pp 39-48), 2024. Date of Publication: October
2024.
Author
Abou-Karam R.; Tanguturi V.; Cheng F.; Elmariah S.
Institution
(Abou-Karam, Cheng) Department of Medicine, Cardiovascular Research
Center, Massachusetts General Hospital, Harvard Medical School, Boston,
MA, United States
(Abou-Karam, Cheng) Cardiovascular Disease Initiative, Broad Institute of
MIT and Harvard, Cambridge, MA, United States
(Tanguturi) Department of Medicine, Cardiology Division, Massachusetts
General Hospital, Boston, MA, United States
(Elmariah) Department of Medicine, Cardiovascular Division, University of
California-San Francisco, San Francisco, CA, United States
Publisher
Elsevier Inc.
Abstract
Background: Symptomatic severe aortic stenosis causes substantial
morbidity and mortality when left untreated, yet recent data suggest its
undertreatment. <br/>Objective(s): To evaluate the efficacy of electronic
physician notification to facilitate the guideline-directed management of
patients with severe aortic stenosis. Hypothesis: We hypothesize that
patients with severe aortic stenosis who are in the care of physicians who
receive the notification are more likely to undergo aortic valve
replacement within one year. Methods/Design: The Electronic Physician
Notification to Facilitate the Recognition and Management of Severe Aortic
Stenosis (DETECT AS) trial is a randomized controlled trial and quality
improvement initiative designed to evaluate the efficacy of electronic
provider notification versus usual clinical care in the management of
patients with severe aortic stenosis. Providers ordering an echocardiogram
with findings potentially indicative of severe aortic stenosis are
randomized to receive electronic notification with customized guideline
recommendations for the management of severe aortic stenosis or usual care
(no notification). Randomization continues until 940 patients are
enrolled. <br/>Setting(s): Multicentered, academic health system.
<br/>Outcome(s): The primary endpoint is the proportion of patients with
severe aortic stenosis receiving an aortic valve replacement within one
year of the index echocardiogram. Secondary endpoints include mortality,
heart failure hospitalization, transthoracic echocardiogram utilization,
aortic stenosis billing code, and cardiology/Valve Team referral.
<br/>Conclusion(s): The DETECT AS trial will provide insight into whether
electronic notification of providers on the presence of severe aortic
stenosis and associated clinical guideline recommendations will facilitate
recognition and guideline-directed management of severe aortic stenosis.
Trial Registration: ClinicalTrials.gov, NCT05230225,
https://clinicaltrials.gov/ct2/show/NCT05230225.<br/>Copyright &#xa9; 2024
Elsevier Inc.

<18>
Accession Number
2033675580
Title
Postoperative pain management after thoracic transplantations.
Source
Current Opinion in Anaesthesiology. (no pagination), 2024. Date of
Publication: 2024.
Author
Lobo C.; Tufegdzic B.
Institution
(Lobo, Tufegdzic) Anesthesiology Institute, Cleveland Clinic Abu Dhabi,
Abu Dhabi, United Arab Emirates
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose of review Heart and lung transplantation evolution marked
significant milestones. Pioneering efforts of Dr Christiaan Barnard with
the first successful heart transplant in 1967, followed by advancements in
heart-lung and single-lung transplants by Drs Bruce Reitz, Norman Shumway,
and Joel Cooper laid the groundwork for contemporary organ
transplantation, offering hope for patients with end-stage heart and
pulmonary diseases. Recent findings Pretransplant opioid use in heart
transplant recipients is linked to higher mortality and opioid dependence
posttransplant. Effective pain control is crucial to reduce opioid-related
adverse effects and enhance recovery. However, research on specific pain
management protocols for heart transplant recipients is limited. In lung
transplantation effective pain management is crucial. Studies emphasize
the benefits of multimodal strategies, including thoracic epidural
analgesia and thoracic paravertebral blocks, to enhance recovery and
reduce opioid use. Perioperative pain control challenges in lung
transplantation are unique and necessitate careful consideration to
prevent complications and improve outcomes. Summary This review emphasizes
the importance of tailored pain management in heart and lung transplant
recipients. It advocates for extended follow-up and alternative analgesics
to minimize opioid dependency and enhance quality of life. Further
high-quality research is needed to optimize postoperative analgesia and
improve patient outcomes.<br/>Copyright &#xa9; 2024 Lippincott Williams
and Wilkins. All rights reserved.

<19>
Accession Number
644917393
Title
The efficacy of magnesium sulphate in preventing laryngospasm in
paediatric patients undergoing general anaesthesia: A systematic review
and meta-analysis of randomised control trials.
Source
Anaesthesia, critical care & pain medicine. (pp 101413), 2024. Date of
Publication: 30 Jul 2024.
Author
Rasheed M.A.; Memon D.; Jimenez C.K.; Zafar A.; Shiwani H.
Institution
(Rasheed) University of Galway, Galway, Ireland
(Memon) Great Ormond Street Hospital for Children, London, United Kingdom
(Jimenez, Zafar) Cork University Hospital, Cork, Ireland
(Shiwani) Manchester Royal Infirmary, Manchester, United Kingdom
Abstract
BACKGROUND: Laryngospasm is sustained closure of the airways and can be a
life-threatening condition. Magnesium sulphate is postulated to reduce the
incidence of laryngospasm if administered peri-operatively. This
systematic review and meta-analysis was performed to assess the efficacy
of magnesium sulphate in preventing peri-operative laryngospasm in
paediatric patients undergoing non-cardiac surgery. <br/>METHOD(S): Four
databases and a trial registry were searched. Inclusion criteria were
paediatric patients undergoing general anaesthesia. Exclusion criteria
were patients who underwent cardiopulmonary bypass during surgery. The
intervention of interest was the peri-operative administration of
magnesium sulphate. The intervention was compared to either a placebo or
other pharmacological agent. The primary outcome was the incidence of
laryngospasm. A meta-analysis of all studies was performed. Sub-group
analysis was subsequently performed. <br/>RESULT(S): A total of 953
patients from 13 trials were included in this study. Nine RCTs
administered magnesium intravenously and 4 RCTs administered magnesium
locally. Laryngospasm rates were 6% lower in the magnesium group (OR 0.48
[95% CI 0.25-0.96], p=0.04) compared to control in the pooled data.
Subgroup analysis showed laryngospasm rates were lower by 12.5% (Odds
Ratio 0.26 [CI 0.09-0.76], p=0.01) in the local magnesium group. Subgroup
analysis of studies that only administered intravenous magnesium did not
show a statistically significant difference in the incidence of
laryngospasm (OR 0.73 [95% CI 0.33-1.63], p=0.44). <br/>CONCLUSION(S):
This review shows a potential role for magnesium in the prevention of
laryngospasm in paediatric patients undergoing general anaesthesia. There
is a correlation between local administration of magnesium and reduction
in laryngospasm rates. Further studies are required to assess the efficacy
of intravenous magnesium in prevention of laryngospasm. REGISTRATION:
Prospective Register of Systematic Reviews (PROSPERO); PROSPERO ID
CRD42022307868
(https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022307868)
.<br/>Copyright &#xa9; 2024. Published by Elsevier Masson SAS.

<20>
Accession Number
2030785517
Title
Effect of nano-curcumin supplementation on cardiometabolic risk factors,
physical and psychological quality of life, and depression in patients
with coronary slow flow phenomenon: a randomized double-blind clinical
trial.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 515. Date of
Publication: December 2024.
Author
Soltani M.; Hosseinzadeh-Attar M.J.; Rezaei M.; Alipoor E.;
Vasheghani-Farahani A.; Yaseri M.; Rezayat S.M.
Institution
(Soltani, Hosseinzadeh-Attar, Rezaei, Alipoor) Department of Clinical
Nutrition, School of Nutritional Sciences and Dietetics, Tehran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
(Hosseinzadeh-Attar, Vasheghani-Farahani) Department of Clinical Cardiac
Electrophysiology, Tehran Heart Center, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Alipoor, Vasheghani-Farahani) Cardiac Primary Prevention Research Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Yaseri) Department of Epidemiology and Biostatistics, School of Public
Health, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Rezayat) Department of Medical Nanotechnology, School of Advanced
Technologies in Medicine, Tehran University of Medical Sciences, Tehran,
Iran, Islamic Republic of
(Rezayat) Department of Pharmacology, School of Medicine, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
BioMed Central Ltd
Abstract
Background: Extensive evidence has suggested the cardio-protective
properties of the polyphenol curcumin. The aim of this study was to
investigate the effects of a highly bioavailable curcumin supplement on
cardiometabolic risk factors, health-related quality of life, and
depression in patients with coronary slow flow phenomenon (CSFP).
<br/>Method(s): This randomized double-blind placebo-controlled clinical
trial was conducted in 42 patients with CSFP (age 35-70 years, 25 <= body
mass index < 40 kg/m²). Patients received either 80 mg/day
nano-curcumin or placebo for 12 weeks. Serum levels of visfatin,
high-sensitivity C-reactive protein (hs-CRP), and glycemic indices were
measured before and after the intervention. The short form 36-item quality
of life (SF-36) and Beck's Depression Inventory-II (BDI-II) questionnaires
were assessed, as well. <br/>Result(s): No significant improvements were
observed in circulating hs-CRP and visfatin following the intervention. A
significant increase was observed in pre- to post-fasting blood glucose (-
0.9 +/- 12.2 vs. 7.7 +/- 12.4 mg/dl, p = 0.02) and hemoglobin A1C (- 0.1
+/- 0.8 vs. 0.5 +/- 0.8%, p = 0.04) levels, in the placebo compared with
the intervention group. Physical (8.2 +/- 8.1 vs. - 1.2 +/- 6.5, p <
0.001) and mental (6.8 +/- 11.8 vs. - 1.1 +/- 10.4, p = 0.02) component
summary scores were significantly improved in the nano-curcumin than the
placebo group. Additionally, the number of patients with lower degrees of
depression was significantly better in the intervention than the placebo
group following the supplementation (p = 0.046). <br/>Conclusion(s):
Curcumin supplementation prevented deterioration of glycemic control and
improved physical and psychological quality of life and depression in
patients with CSFP. Trial registration: Iranian Registry of Clinical
Trials (IRCT20131125015536N8), June 19, 2019.<br/>Copyright &#xa9; The
Author(s) 2024.

<21>
Accession Number
2029083969
Title
Edoxaban for the treatment of hypercoagulability and cerebral
thromboembolism associated with cancer: A randomized clinical trial of
biomarker targets.
Source
International Journal of Stroke. 19(6) (pp 645-653), 2024. Date of
Publication: July 2024.
Author
Chung J.-W.; Hwang J.; Kim H.J.; Seo W.-K.; Ahn M.-J.; Saver J.L.; Bang
O.Y.
Institution
(Chung, Kim, Seo, Bang) Department of Neurology, Samsung Medical Center,
School of Medicine, Sungkyunkwan University, Seoul, South Korea
(Hwang) Department of Neurology, School of Medicine, Kyungpook National
University Chilgok Hospital, Daegu, South Korea
(Ahn) Division of Hematology/Oncology, Samsung Medical Center, School of
Medicine, Sungkyunkwan University, Seoul, South Korea
(Saver) Department of Neurology, David Geffen School of Medicine at UCLA,
Los Angeles, CA, United States
Publisher
SAGE Publications Inc.
Abstract
Background: This study aimed compare efficacy of edoxaban and enoxaparin
upon biomarkers of hypercoagulability in patients with cancer-related
embolic stroke of undetermined source (ESUS). <br/>Method(s): In this
open-label, randomized, pilot trial, patients with cancer-related ESUS
within 30 days of diagnosis were randomly assigned (1:1) to receive
edoxaban (60 mg once daily) or enoxaparin (1 mg/kg twice daily) for 90
days. The primary endpoint was interval change of serum D-dimer level
between days 0 and 7. The secondary endpoints were microembolic signals
detected by transcranial Doppler at 7 and 90 days, the modified Rankin
scale score, and stroke recurrence during 90 days. Safety outcomes
included major bleeding and all-cause death at 90 days. <br/>Result(s): Of
303 patients with ischemic stroke and cancer, 40 fully met enrollment
criteria and were randomized. Baseline D-dimer levels were numerically
higher in the edoxaban group (22.9 +/- 15.9 mug/mL vs 16.9 +/- 16.9
mug/mL). D-dimer level change (%) between days 0 and 7 was similar in the
two groups (53.2 +/- 25.7 vs 52.2 +/- 52.0; P = 0.11). Microembolic
signals were detected in 41.1% and 43.8% at baseline, 41.2% and 42.9% at
day 7, and 25.0% and 28.6% at day 90 in the edoxaban and enoxaparin
groups, respectively. Non-significantly higher major bleeding (35.0% vs
10.0%, P = 0.06) and 90-day mortality (40.0% vs 25.0%, P = 0.31) were
noted in the edoxaban group. <br/>Conclusion(s): Edoxaban and enoxaparin
were comparable with respect to the biomarkers of hypercoagulability and
cerebral thromboembolism. Larger trials are warranted to compare effects
of edoxaban and enoxaparin upon recurrent stroke and major bleeding in
patients with cancer-related ESUS. Trial registration: clinicaltrials.gov
Identifier: NCT03570281
(https://clinicaltrials.gov/ct2/show/NCT03570281)<br/>Copyright &#xa9;
2024 World Stroke Organization.

<22>
Accession Number
2033638192
Title
Effectiveness of ultrasound-guided rhomboid intercostal and sub-serratus
block for perioperative analgesia in male patients undergoing combined
power-assisted liposuction with pull-through excision of the gland for
breast definition and reshaping.
Source
Minerva Anestesiologica. 90(7-8) (pp 626-634), 2024. Date of Publication:
July 2024.
Author
Wahdan A.S.; Loza G.E.; Alayyaf H.A.; Wahdan W.S.; Salama A.K.; Mohamed
M.M.
Institution
(Wahdan, Loza, Salama, Mohamed) Department of Anesthesia Surgical ICU and
Pain Management, Faculty of Medicine, Cairo University, Cairo, Egypt
(Alayyaf) Department of Anesthesia, Al-Hada Armed Forces Hospital, Taif,
Saudi Arabia
(Wahdan) Department of Plastic and Reconstructive Surgery, Faculty of
Medicine, Cairo University, Cairo, Egypt
Publisher
Edizioni Minerva Medica
Abstract
BACKGROUND: The newly introduced ultrasound guided interfacial rhomboid
intercostal and sub-serratus (RISS) block technique demonstrated promising
efficacy in managing perioperative pain among patients undergoing
abdominal and thoracic procedures. Thus, this study investigated the
efficiency of bilateral ultrasound-guided RISS (US-RISS) as a
perioperative pain control technique in male subjects receiving
gynecomastia surgery. <br/>METHOD(S): This prospective randomized study
involved sixty patients who underwent gynecomastia surgery. Individuals
were randomly divided into two groups: the RISSgroup (N.=30) and the
control group (N.=30). After anesthesia induction, the patients received
bilateral US-RISSusing 40 mLof 0.25% levobupivacaine, or conventional
intravenous analgesia with no intervention, respectively. The primary
outcome was the overall morphine consumption in 24 hours, and the
secondary endpoints involved the time elapsed till rescue analgesia was
requested, the quality of recovery after 24 hours and side effects'
incidence. <br/>RESULT(S): Morphine consumption was noticeably decreased
in the RISSgroup compared to the control group, with 14.07+/-4.91 mg and
35.83+/-1.70 mg mean values, respectively (P<0.001). Furthermore, in the
RISSgroup, the initial rescue analgesia request occurred significantly
later than in the control group, with mean values of 15.58+/-1.41 hours
and 0.96+/-0.63 hours, respectively (P<0.001). Additionally, within the
RISSgroup, there was a high quality of recovery observed, with a low
incidence of opioid-related adverse events in comparison to the control
group. <br/>CONCLUSION(S): Bilateral US-RISS block is a beneficial
intervention in gynecomastia surgery for pain management and improves the
quality of recovery.<br/>Copyright &#xa9; 2024 Edizioni Minerva Medica.
All rights reserved.

<23>
[Use Link to view the full text]
Accession Number
644812407
Title
Effect of nitric oxide delivery via cardiopulmonary bypass circuit on
postoperative oxygenation in adults undergoing cardiac surgery (NOCARD
trial): a randomised controlled trial.
Source
European journal of anaesthesiology. 41(9) (pp 677-686), 2024. Date of
Publication: 01 Sep 2024.
Author
Azem K.; Novakovsky D.; Krasulya B.; Fein S.; Iluz-Freundlich D.; Uhanova
J.; Kornilov E.; Eidelman L.A.; Kaptzon S.; Gorfil D.; Aravot D.; Barac
Y.; Aranbitski R.
Institution
(Azem) From the Department of Anaesthesia (KA, DN, BK, SF, DI-F, EK, LAE,
RA), Department of Cardiovascular and Thoracic Surgery, Rabin Medical
Centre, Beilinson Hospital, Petah Tikva (SK, DG, DA, YB), Department of
Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba
(JU), Department of Neurobiology, Weizmann Institute of Science, Rehovot
(EK), and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
Israel (KA, DN, BK, SF, DI-F, EK, LAE, SK, DG, DA, YB, RA)
Abstract
BACKGROUND: Cardiac surgery involving cardiopulmonary bypass induces a
significant systemic inflammatory response, contributing to various
postoperative complications, including pulmonary dysfunction, myocardial
and kidney injuries. <br/>OBJECTIVE(S): To investigate the effect of
Nitric Oxide delivery via the cardiopulmonary bypass circuit on various
postoperative outcomes. DESIGN: A prospective, single-centre,
double-blinded, randomised controlled trial. SETTING: Rabin Medical
Centre, Beilinson Hospital, Israel. PATIENTS: Adult patients scheduled for
elective cardiac surgery were randomly allocated to one of the study
groups. INTERVENTIONS: For the treatment group, 40 ppm of nitric oxide was
delivered via the cardiopulmonary bypass circuit. For the control group,
nitric oxide was not delivered. OUTCOME MEASURES: The primary outcome was
the incidence of hypoxaemia, defined as a p a O2 /FiO 2 ratio less than
300 within 24 h postoperatively. The secondary outcomes were the
incidences of low cardiac output syndrome and acute kidney injury within
72 h postoperatively. <br/>RESULT(S): Ninety-eight patients were included
in the final analysis, with 47 patients allocated to the control group and
51 to the Nitric Oxide group. The Nitric Oxide group exhibited
significantly lower hypoxaemia rates at admission to the cardiothoracic
intensive care unit (47.1 vs. 68.1%), P = 0.043. This effect, however,
varied in patients with or without baseline hypoxaemia. Patients with
baseline hypoxaemia who received nitric oxide exhibited significantly
lower hypoxaemia rates (61.1 vs. 93.8%), P = 0.042, and higher p a O2
/FiO 2 ratios at all time points, F (1,30) = 6.08, P = 0.019. Conversely,
this benefit was not observed in patients without baseline hypoxaemia. No
significant differences were observed in the incidence of low cardiac
output syndrome or acute kidney injury. No substantial safety concerns
were noted, and toxic methaemoglobin levels were not observed.
<br/>CONCLUSION(S): Patients with baseline hypoxaemia undergoing cardiac
surgery and receiving nitric oxide exhibited lower hypoxaemia rates and
higher p a O2 /FiO 2 ratios. No significant differences were found
regarding postoperative pulmonary complications and overall outcomes.
TRIAL REGISTRATION: NCT04807413.<br/>Copyright &#xa9; 2024 European
Society of Anaesthesiology and Intensive Care. Unauthorized reproduction
of this article is prohibited.

<24>
Accession Number
644019740
Title
Inspiratory Muscle Training in Phase 1 and 2 Postoperative Cardiac
Rehabilitation Following Coronary Artery Bypass Graft Surgery: Systematic
Review With Meta-Analysis.
Source
Physical therapy. 104(7) (no pagination), 2024. Date of Publication: 02
Jul 2024.
Author
Araujo C.O.; Araujo Alves C.C.; Dos Santos F.R.A.; Cahalin L.P.; Cipriano
G.F.B.; Cipriano G.
Institution
(Araujo, Araujo Alves, Dos Santos, Cipriano, Cipriano) University of
Brasilia (Faculty of Ceilandia), Graduate Program in Science and
Technology in Health, DF, Brasilia, Brazil
(Cahalin) Unievangelica, Graduate Program in Human Movement and
Rehabilitation, GO, Anapolis, Brazil
(Cipriano, Cipriano) University of Brasilia (Faculty of Ceilandia),
Graduate Program in Rehabilitation Sciences Brasilia, DF, Brazil
(Cipriano) University of Miami, Department of Physical Therapy, Leonard M.
Miller School of Medicine, Miami, FL, United States
Abstract
OBJECTIVE: This study aimed to determine the effects of inspiratory muscle
training (IMT) on exercise capacity, respiratory muscle strength, length
of hospital stay (LOS), and quality of life (QOL) following coronary
artery bypass graft surgery. <br/>METHOD(S): The search was conducted in
accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses and the Cochrane Handbook and included the databases
MEDLINE, EMBASE, CINAHL, Scopus, and CENTRAL. The review included
randomized controlled trials utilizing IMT during phase 1 or 2
postoperative cardiac rehabilitation (PoCR) versus alternative treatment
(active or passive control) in patients following coronary artery bypass
graft surgery. <br/>RESULT(S): Fifteen studies were included (11 phase 1
studies, 4 phase 2 studies) with no reported adverse events. In phase 1
PoCR, IMT reduced the LOS (-1.02 days; 95% CI=-2.00 to -0.03) and
increased exercise capacity (6-minute walk distance) (+75.46 m; 95%
CI=52.34 to 98.57), and maximal inspiratory pressure (MIP) (10.46 cm H2O;
95% CI=2.83 to 18.10), but had no effect on maximal expiratory pressure.
In phase 2 PoCR, IMT increased 6-minute walk distance (45.84 m; 95%
CI=10.89 to 80.80), MIP (-23.19 cm H2O; 95% CI=-31.31 to -15), maximal
expiratory pressure (20.18 cm H2O; 95% CI=9.60 to 30.76), and QOL (-11.17;
95% CI=-17.98 to -4.36), with no effect on peak oxygen uptake. There was a
high risk of bias for MIP (75% of the phase 1 studies) and 6MWT (1 of 4
phase 2 studies). The quality of the evidence ranged from very low to
moderate. <br/>CONCLUSION(S): IMT significantly improves exercise
capacity, respiratory muscle strength, LOS, and QOL in phase 1 and 2 PoCR.
IMPACT: IMT may benefit patients during phase 1 and 2 of PoCR, considering
the safety, low cost, and potential benefits.<br/>Copyright &#xa9; The
Author(s) 2024. Published by Oxford University Press on behalf of the
American Physical Therapy Association. All rights reserved. For
permissions, please e-mail: journals.permissions@oup.com.

<25>
Accession Number
2030828988
Title
The implementation of EMI-Heart, a family-tailored early motor
intervention in infants with complex congenital heart disease, in
practice: a feasibility RCT.
Source
Pilot and Feasibility Studies. 10(1) (no pagination), 2024. Article
Number: 105. Date of Publication: December 2024.
Author
Mitteregger E.; Dirks T.; Theiler M.; Kretschmar O.; Latal B.
Institution
(Mitteregger, Latal) Child Development Center, University Children's
Hospital Zurich, Steinwiesstrasse 75, Zurich CH-8032, Switzerland
(Mitteregger, Latal) Children's Research Center, University Children's
Hospital Zurich, Zurich, Switzerland
(Mitteregger, Kretschmar, Latal) University of Zurich, Zurich, Switzerland
(Dirks) Lecturer Emerita, Paediatric, Physiotherapy, Groningen,
Netherlands
(Theiler) Swiss Parents' Association for Children with Heart Disease
(Elternvereinigung fur das Herzkranke Kind), Aarau, Switzerland
(Kretschmar) Department of Pediatric Cardiology, University Children's
Hospital Zurich, Zurich, Switzerland
Publisher
BioMed Central Ltd
Abstract
Background: Children with congenital heart disease (CHD) who undergo
open-heart surgery are at risk of developmental impairment, including
motor delay, which contributes to parental concerns. Additionally, parents
experience prolonged stress associated with their child's disease. There
is a lack of early motor interventions in infants with CHD accounting for
parental burdens. We developed a family-tailored early motor intervention
(EMI-Heart), aiming to promote motor development in infants with CHD and
family well-being. The primary aim was to evaluate the feasibility of the
study design and the intervention. The secondary aim was to evaluate
differences between the intervention and the control group in motor
outcomes and family well-being at baseline (3-5 months), post-treatment
(6-8 months), and at follow-up (12 months). <br/>Method(s): In this
single-centre feasibility randomized control trial (RCT), infants with CHD
after open-heart surgery without genetic or major neurological
comorbidities were randomly allocated to EMI-Heart or the control group
(standard of care). EMI-Heart's key elements promote postural functional
activities and encourage parental sensitivity to infants' motor and
behaviour cues. Infants assigned to EMI-Heart received nine sessions of
early motor intervention at home, in the hospital, and online for a
duration of 3 months by a paediatric physiotherapist. We performed
descriptive statistics for feasibility and secondary outcomes.
<br/>Result(s): The recruitment rate was 59% (10/17), all participating
families completed the study (10/10), and the intervention duration was
3.9 months (+/- 0.54), including nine intervention sessions per family.
Median acceptability to parents was 3.9 (1 = not agree-4 = totally agree,
Likert scale). The paediatric physiotherapist considered the intervention
as feasible. The comparison of motor outcomes did not show differences
between groups. However, we detected improved reliable change scores in
family well-being outcomes for families of the intervention group compared
to the controls. <br/>Conclusion(s): Our research indicates that EMI-Heart
is a feasible intervention for infants with CHD after open-heart surgery.
The intervention was highly acceptable both to parents and to the
paediatric physiotherapist. Online treatment sessions offer a valuable
alternative to home and hospital visits. This feasibility RCT provides a
foundation for a future full trial. Trial registration:
ClinicalTrials.gov, NCTT04666857. Registered 23.11.2020.<br/>Copyright
&#xa9; The Author(s) 2024.

<26>
Accession Number
2033680540
Title
The reporting of race and ethnicity in cardiothoracic surgery literature.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2024.
Date of Publication: 2024.
Author
Jindani R.; Rodriguez-Quintero J.H.; Olivera J.; Ries S.; Stiles B.M.;
Antonoff M.B.
Institution
(Jindani, Rodriguez-Quintero, Olivera, Stiles) Department of
Cardiothoracic Surgery, Montefiore Medical Center/Albert Einstein College
of Medicine, Bronx, NY, United States
(Ries, Antonoff) Department of Thoracic and Cardiovascular Surgery,
University of Texas MD Anderson Cancer Center, Houston, Tex, United States
Publisher
Elsevier Inc.

<27>
Accession Number
2033647892
Title
Left Atrial Appendage Occlusion as a Strategy for Reducing Stroke Risk in
Nonvalvular Atrial Fibrillation.
Source
Cardiology in Review. (no pagination), 2024. Date of Publication: 2024.
Author
Moras E.; Gandhi K.; Yakkali S.; Frishman W.H.; Aronow W.S.
Institution
(Moras, Gandhi) Department of Internal Medicine, Icahn School of Medicine
at Mount Sinai, New York, NY, United States
(Yakkali) Department of Medicine, Jacobi Medical Center, Albert Einstein
College of Medicine, New York, NY, United States
(Frishman) Department of Medicine, New York Medical College, Valhalla, NY,
United States
(Aronow) Departments of Cardiology and Medicine, Westchester Medical
Center and New York Medical College, Valhalla, NY, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Nonvalvular atrial fibrillation (AF) is a common rhythm disorder of
middle-Aged to older adults that can cause ischemic strokes and systemic
embolism. Stroke prevention is a crucial aspect of management, considering
the increasing AF population and the associated morbidity and mortality.
The left atrial appendage (LAA) has been identified as a predominant
source of AF-Associated thrombus and stroke, with at least 90% of the
thrombi originating from this anatomical structure. Lifelong use of oral
anticoagulants reduces the risk of these ischemic events but increases the
risk of major and clinically relevant hemorrhages. In addition, these
medications also require strict compliance for efficacy and have high
failure rates in higher-risk patients. LAA occlusion (LAAO) has emerged as
an alternative strategy for stroke prevention with encompassing various
percutaneous and surgical techniques. Randomized controlled trials
evaluating this intervention have shown promising results in stroke
reduction replacing anticoagulation therapy. In this review, we aim to
provide a comprehensive overview on the anatomy of the LAA and its role in
thrombus formation, the emergence of various LAAO techniques and devices,
and provide evidence on the role of LAAO in the reduction of stroke risk
among patients with nonvalvular AF.<br/>Copyright &#xa9; 2024 Wolters
Kluwer Health, Inc. All rights reserved.

<28>
Accession Number
2030840705
Title
Electronic Glycemic Management System Improved Glycemic Control and
Reduced Complications in Patients With Diabetes Undergoing Coronary Artery
Bypass Surgery: A Randomized Controlled Trial.
Source
Journal of Diabetes Science and Technology. (no pagination), 2024. Date
of Publication: 2024.
Author
Camara de Souza A.B.; Toyoshima M.T.K.; Cukier P.; Lottenberg S.A.; Bolta
P.M.P.; Lima E.G.; Serrano Junior C.V.; Nery M.
Institution
(Camara de Souza, Cukier, Lottenberg, Nery) Department of Endocrinology
and Metabolism, Hospital das Clinicas da Faculdade de Medicina da
Universidade de Sao Paulo, Sao Paulo, Brazil
(Toyoshima) Oncoendocrinology Service, Instituto do Cancer do Estado de
Sao Paulo Octavio Frias de Oliveira, Hospital das Clinicas da Faculdade de
Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
(Bolta, Lima, Serrano Junior) Instituto do Coracao, Hospital das Clinicas
da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
Publisher
SAGE Publications Inc.
Abstract
Background: In-hospital hyperglycemia poses significant risks for patients
with diabetes mellitus undergoing coronary artery bypass graft (CABG)
surgery. Electronic glycemic management systems (eGMSs) like InsulinAPP
offer promise in standardizing and improving glycemic control (GC) in
these settings. This study evaluated the efficacy of the InsulinAPP
protocol in optimizing GC and reducing adverse outcomes post-CABG.
<br/>Method(s): This prospective, randomized, open-label study was
conducted with 100 adult type 2 diabetes mellitus (T2DM) patients
post-CABG surgery, who were randomized into two groups: conventional care
(gCONV) and eGMS protocol (gAPP). The gAPP used InsulinAPP for insulin
therapy management, whereas the gCONV received standard clinical care. The
primary outcome was a composite of hospital-acquired infections, renal
function deterioration, and symptomatic atrial arrhythmia. Secondary
outcomes included GC, hypoglycemia incidence, hospital stay length, and
costs. <br/>Result(s): The gAPP achieved lower mean glucose levels (167.2
+/- 42.5 mg/dL vs 188.7 +/- 54.4 mg/dL; P =.040) and fewer patients-day
with BG above 180 mg/dL (51.3% vs 74.8%, P =.011). The gAPP received an
insulin regimen that included more prandial bolus and correction insulin
(either bolus-correction or basal-bolus regimens) than the gCONV (90.3% vs
16.7%). The primary composite outcome occurred in 16% of gAPP patients
compared with 58% in gCONV (P <.010). Hypoglycemia incidence was lower in
the gAPP (4% vs 16%, P =.046). The gAPP protocol also resulted in shorter
hospital stays and reduced costs. <br/>Conclusion(s): The InsulinAPP
protocol effectively optimizes GC and reduces adverse outcomes in T2DM
patients' post-CABG surgery, offering a cost-effective solution for
inpatient diabetes management.<br/>Copyright &#xa9; 2024 Diabetes
Technology Society.

<29>
Accession Number
644903152
Title
Advancements in Donation after Circulatory Death Heart Procurement and
Preservation: A Comprehensive Review of Recent Innovations.
Source
Surgical technology international. 44 (no pagination), 2024. Date of
Publication: 31 Jul 2024.
Author
Condello I.
Institution
(Condello) Department of Cardiac Surgery, Anthea Hospital GVM Care <
Research, Bari, Italy
Abstract
INTRODUCTION: The persistent shortage of donor hearts for transplantation
has prompted exploration into Donation after Circulatory Death (DCD) as a
promising avenue for organ procurement. This comprehensive review aims to
examine recent advancements in DCD heart procurement and preservation
techniques to address the critical need for donor organs and improve
transplant outcomes. MATERIALS AND METHODS: A systematic review was
conducted to identify relevant studies and innovations related to DCD
heart procurement and preservation. Electronic databases including PubMed,
MEDLINE, and Google Scholar were searched using keywords such as "DCD
heart donation," "organ preservation," and "transplantation." Studies with
statistical analyses on transplant outcomes were included for further
evaluation. <br/>RESULT(S): A meta-analysis of DCD heart transplantation
outcomes revealed a statistically significant increase in successful
transplants utilizing hearts procured after circulatory death (p<0.05).
Normothermic machine perfusion demonstrated a 20% reduction in ischemic
time compared to traditional cold storage methods, leading to improved
post-transplant cardiac function and reduced rates of primary graft
dysfunction. These findings highlight the potential of DCD heart
procurement and preservation techniques to address the critical shortage
of donor hearts while enhancing transplant outcomes. <br/>CONCLUSION(S):
Recent innovations in DCD heart procurement and preservation techniques
show promise in overcoming the challenges of donor organ scarcity and
improving transplant success rates. Continued research and development in
this field are essential to further optimize these techniques and meet the
growing demand for donor hearts worldwide.

<30>
Accession Number
644901970
Title
Comparative effectiveness of antiplatelet therapies for saphenous venous
graft occlusion and cardiovascular outcomes: a network meta-analysis.
Source
Minerva cardiology and angiology. (no pagination), 2024. Date of
Publication: 01 Aug 2024.
Author
Hasan S.U.; Pervez A.; Afreen M.; Imam B.; Shah S.D.; Shah A.A.; Siddiqui
S.A.; Zubair M.M.; Osho A.
Institution
(Hasan) Ophthalmology Department, Aga Khan University, Karachi, Pakistan
(Pervez) Center for Clinical Best Practices, Aga Khan University, Karachi,
Pakistan
(Afreen) Department of Neurosurgery, Shifa International Hospital,
Islamabad, Pakistan
(Imam) Department of Cardiology, Dr Ruth KM Pfau Civil Hospital, Karachi,
Pakistan
(Shah, Shah) Department of Cardiology, Dow University of Health Sciences,
Karachi, Pakistan
(Siddiqui) Department of Cardiology, Baqai Medical University, Karachi,
Pakistan
(Zubair) Department of Cardiology, Cedars-Sinai Medical Center, Los
Angeles, CA, United States
(Osho) Department of Cardiology, Massachusetts General Hospital, Boston,
MA, United States
Abstract
INTRODUCTION: The ideal antiplatelet therapy to maintain graft patency
after coronary artery bypass graft surgery (CABG) remains controversial.
This review of randomized controlled trials (RCTs) aims to compare aspirin
monotherapy, ticagrelor monotherapy, dual antiplatelet therapy (DAPT) with
aspirin and ticagrelor (Asp+Tica) or with aspirin and clopidogrel
(Asp+Clopi) to evaluate differences in post-CABG saphenous vein graft
(SVG) occlusion, internal mammary artery (IMA) occlusion, myocardial
infarction (MI), bleeding, and all-cause mortality (ACM) rates. EVIDENCE
ACQUISITION: The literature review was conducted on several electronic
databases, including Medline, Embase, and Cochrane Central, from inception
to August 10, 2022. Data was extracted using a predefined proforma. A
Bayesian random-effects model was used for calculating point effect
estimates (odds ratio and standard deviation). Quality assessment was done
using the Cochrane RoB-2 tool. EVIDENCE SYNTHESIS: Ten RCTs comprising
2139 patients taking anti-platelets post-CABG were included. For
preventing SVG occlusion, Asp+Tica showed the lowest mean AR of
0.144+/-0.068. Asp+Tica also showed a trend toward lesser postoperative MI
risk and lower ACM rates, with a mean AR of 0.040+/-0.053 and
0.018+/-0.029, respectively. For maintaining IMA graft patency, Asp+Clopi
showed the lowest mean AR of 0.092+/-0.053. Ticagrelor had the lowest mean
AR of 0.049+/-0.075, with Asp+Tica showing a similar mean AR of
0.049+/-0.045 for postoperative major bleeding risk. <br/>CONCLUSION(S):
Our analysis demonstrates that Asp+Tica can be the ideal therapy for
patients undergoing CABG using SVG as it decreases the risk of post-CABG
SVG occlusion and is not associated with a significantly higher risk for
major bleeding.

<31>
Accession Number
2033575774
Title
Prognostic value of right ventricular involvement in hypertrophic
cardiomyopathy: A systematic review and meta-analysis.
Source
International Journal of Cardiology. 413 (no pagination), 2024. Article
Number: 132390. Date of Publication: 15 Oct 2024.
Author
Figliozzi S.; Masci P.-G.; Monti L.; Stankowski K.; Tondi L.; Aivalioti
E.; Mavraganis G.; Francone M.; Condorelli G.; Olivotto I.; Georgiopoulos
G.
Institution
(Figliozzi, Monti, Stankowski, Francone, Condorelli) IRCCS Humanitas
Research Hospital, Via Alessandro Manzoni 56, Rozzano, Milan 20089, Italy
(Masci) School of Biomedical Engineering and Imaging Sciences-Faculty of
Life Sciences and Medicine, King's College London, Westminster Bridge Rd,
England, London SE1 7EH, United Kingdom
(Monti, Stankowski, Francone, Condorelli) Department of Biomedical
Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve
Emanuele, Milan, Italy
(Tondi) Multimodality Cardiac Imaging Section, IRCCS Policlinico San
Donato, San Donato Milanese, Milan, Italy
(Tondi) Department of Radiology, IRCCS Foundation Ca' Granda Ospedale
Maggiore Policlinico, University of Milan, Milan, Italy
(Aivalioti, Mavraganis, Georgiopoulos) Department of Clinical
Therapeutics, National and Kapodistrian University of Athens, Greece
(Olivotto) Department of Experimental and Clinical Medicine, Careggi
University Hospital, Florence, Italy
(Olivotto) Pediatric Cardiology, Meyer Children's University Hospital
IRCCS, Florence, Italy
Publisher
Elsevier Ireland Ltd
Abstract
Background: Right ventricular (RV) involvement has been reported in one
out of three patients with hypertrophic cardiomyopathy (HCM), however its
prognostic significance remains unknown. We aimed to assess the prognostic
value of RV involvement in patients with HCM through a systematic review
and meta-analysis. <br/>Method(s): A literature search was performed on
PubMed, ClinicalTrials.gov and Cochrane Library databases from inception
through November 15, 2023. Original articles enrolling HCM patients >18
years old and evaluating the association of RV parameters routinely
assessed in clinical practice through trans-thoracic echocardiography or
cardiac magnetic resonance (i.e., RV hypertrophy, volumes, systolic
function, and late gadolinium enhancement) and the risk of a pre-defined
composite endpoint including i) all cause death; ii) cardiac death; iii)
heart transplantation; iv) heart failure-related hospitalization; v)
atrial fibrillation; vi) ventricular tachycardia; and vii) stroke were
retrieved. We pooled the effect of RV imaging variables on the combined
clinical endpoint in terms of hazard ratio (HR) with 95% confidence
interval (CI). <br/>Result(s): The meta-analysis included 12 articles and
4634 patients. The pooled analysis demonstrated that the presence of RV
systolic dysfunction conveyed an increased risk of adverse outcomes (HR
2.46; 95% CI 1.80-3.35; P < 0.001), whereas other RV imaging parameters
were not significantly associated with patients' prognosis, except for
RV-fractional area change analyzed as a continuous variable (HR 0.96 per %
increase; 95% CI 0.93-0.995; P = 0.025). <br/>Conclusion(s): Our results
pinpoint a prognostic role of RV dysfunction, independent of left
ventricular involvement, in patients with HCM, and future longitudinal
studies, including multi-parametric RV assessment, are encouraged to
provide clinically-relevant data to refine risk stratification in patients
with HCM.<br/>Copyright &#xa9; 2024

<32>
Accession Number
2032759431
Title
Efficacy and safety of ongericimab given by prefilled syringe or
autoinjector in primary hypercholesterolemia and mixed hyperlipidemia.
Source
Nutrition, Metabolism and Cardiovascular Diseases. 34(9) (pp 2217-2225),
2024. Date of Publication: September 2024.
Author
Zhao W.; Cheng Z.; Ji X.; Pei Z.; Yang K.; Huang Z.; Wu Y.; Wang G.; Wang
M.; Zhao Y.; Bai X.; Zhao S.
Institution
(Zhao, Zhao) Department of Cardiovascular Medicine, The Second Xiangya
Hospital, Central South University, Hunan, Changsha, China
(Cheng) Department of Endocrinology and Metabolism, The Fourth Hospital of
Harbin Medical University, Heilongjiang, Harbin, China
(Ji) Department of Cardiology, Daqing People's Hospital, Heilongjiang,
Daqing, China
(Pei) Department of Cardiology, Third Hospital of Nanchang, Jiangxi,
Nanchang, China
(Yang) Department of Cardiology, Jingzhou Central Hospital, Hubei,
Jingzhou, China
(Huang) Department of Cardiology, The First Affiliated Hospital of Wenzhou
Medical University, Zhejiang, Wenzhou, China
(Wu) Department of Cardiology, The Second Affiliated Hospital of Nanchang
University, Jiangxi, Nanchang, China
(Wang) Department of Cardiology, The First Affiliated Hospital of Jinzhou
Medical University, Liaoning, Jinzhou, China
(Wang, Zhao, Bai) Shanghai Junshi Biosciences Co., Ltd., Shanghai, China
Publisher
Elsevier B.V.
Abstract
Background and aims: Limited evidence exist regarding the association
between ongericimab, a novel recombinant humanized anti-PCSK9 monoclonal
antibody, and primary hypercholesterolemia and mixed dyslipidemia. This
study aimed to evaluate the efficacy and safety of ongericimab
administered by prefilled syringe (PFS) or autoinjector (AI) in Chinese
patients with primary hypercholesterolemia and mixed dyslipidemia on
stable optimized lipid-lowering therapy. <br/>Methods and Results: A total
of 255 patients on stable optimized lipid-lowering therapy were randomized
in a 2:1:2:1 ratio to receive PFS for the subcutaneous injection of
ongericimab 150 mg every 2 weeks (Q2W) or a matching placebo, or AI for
the subcutaneous injection of ongericimab 150 mg Q2W or a matching
placebo. The primary efficacy endpoint was the percent change in
low-density lipoprotein cholesterol (LDL-C) levels from baseline to week
12. Safety was also evaluated. At week 12, the least squares mean percent
changes were -72.7% (3.9%) for PFS and -71.1% (3.8%) for AI (all P <
0.001) compared to respective matching placebo groups. Beneficial effects
were also seen for all secondary lipid parameters, notably with robust
reduction in Lp (a). Treatment-emergent adverse events (TEAEs) and serious
AEs with ongericimab were reported in 46.2% and 2.4% of patients, compared
to 44.2% and 3.5% with placebo. <br/>Conclusion(s): In Chinese patients
with primary hypercholesterolemia and mixed dyslipidemia, a 12-week
treatment regimen with ongericimab administered by PFS or AI significantly
reduced LDL-C and other lipid parameters, proving to be safe and well
tolerated. Patients experienced consistent effects from PFS or AI devices.
Clinical trial registration: CTR20220027; January 11, 2022;
http://www.chinadrugtrials.org.cn/index.html.<br/>Copyright &#xa9; 2024
The Italian Diabetes Society, the Italian Society for the Study of
Atherosclerosis, the Italian Society of Human Nutrition and the Department
of Clinical Medicine and Surgery, Federico II University

<33>
Accession Number
2032759184
Title
Statin therapy and cardiovascular protection in type 2 diabetes: The role
of baseline LDL-Cholesterol levels. A systematic review and meta-analysis
of observational studies.
Source
Nutrition, Metabolism and Cardiovascular Diseases. 34(9) (pp 2021-2033),
2024. Date of Publication: September 2024.
Author
Soroush N.; Nekouei Shahraki M.; Mohammadi Jouabadi S.; Amiri M.; Aribas
E.; Stricker B.H.; Ahmadizar F.
Institution
(Soroush, Nekouei Shahraki, Mohammadi Jouabadi, Amiri, Aribas, Stricker,
Ahmadizar) Department of Epidemiology, Erasmus MC, University Medical
Center, Rotterdam, Netherlands
(Mohammadi Jouabadi) Pharmacology and Vascular Medicine Center, Department
of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam,
Netherlands
(Ahmadizar) Department of Data Science and Biostatistics, Julius Global
Health, University Medical Center Utrecht, Utrecht, Netherlands
Publisher
Elsevier B.V.
Abstract
Aim: The guidelines recommend statins to prevent cardiovascular events in
patients with type 2 diabetes (T2D) however, the importance of baseline
LDL-Cholesterol (LDL-C) levels remains controversial. This study aimed to
determine the association of statin use in T2D patients with major adverse
cardiovascular events (MACE) and all-cause mortality and whether this
association differs by baseline LDL-C levels. Data synthesis: Medline,
Embase, and Web of Science were systematically searched from inception
until January 2022. Observational studies in patients with T2D comparing
statin users vs non-users, with reports of the baseline LDL-C levels, were
included. Random-effects meta-analysis and meta-regression were performed
to estimate the overall effect on the risk of all-cause mortality and MACE
(a composite of myocardial infarction, heart failure, stroke, and
revascularization events) and the modification in the association by
baseline LDL-C levels. We categorized studies according to their baseline
LDL-C levels into 1) <100 mg/dl (2.59 mmol/l), 2) 100-130 mg/dl (2.59-3.37
mmol/l) and 3) >130 mg/dl (3.37 mmol/l) categories. A total of 9 cohort
studies (n = 403,411 individuals) fulfilled our criteria. The follow-up
duration ranged from 1.7 to 8 years. The overall combined estimate showed
that statin therapy was associated with a significantly lower risk of MACE
(Hazard Ratio (HR): 0.70 [95% CI 0.59 to 0.83], Absolute risk reduction
percentage (ARR%): 3.19% [95%CI 0.88 to 5.50%) and all-cause mortality
(HR: 0.60 [95% CI 0.46 to 0.79], ARR%: 5.23% [95% CI 2.18 to 8.28%), but
varied, albeit not statistically significant, by baseline LDL-C levels.
Studies with baseline LDL-C levels higher than 130 mg/dl had the greatest
reduction of MACE (HR: 0.58 [95% CI 0.37 to 0.90]) and all-cause mortality
risk (HR: 0.51 [95% CI [ 0.29 to 0.90]). The HRs of MACE in studies with
LDL-C levels of 100-130 mg/dl and <100 mg/dl categories were respectively
(0.70 [95% CI 0.59 to 0.83]) and (0.83 [95% CI [0.68 to 1.00]); and that
of all-cause mortality were respectively (0.62 [95% CI 0.38 to 1.01]) and
(0.67 [95% CI [0.44 to 1.02]). Statin use changes the HRs of MACE (0.99
[95%CI, 0.98 to 0.99]; P = 0.04) and all-cause mortality (0.99 [95% CI
0.98 to 1.01]; P = 0.8) per each mg/dl increase in baseline LDL-C level in
meta-regression analyses. <br/>Conclusion(s): Statin therapy in patients
with T2D was associated with reduced risk of MACE and all-cause mortality.
Significant differences across studies with different baseline LDL-C
levels were not observed.<br/>Copyright &#xa9; 2024 The Authors

<34>
Accession Number
2030535280
Title
Clinical and biological effects of different energetic surgical devices
currently used for mini-invasive anatomical lung resections for the
treatment of NSCLC: a prospective interventional study.
Source
Surgical Endoscopy. 38(8) (pp 4753-4761), 2024. Date of Publication:
August 2024.
Author
Catelli C.; D'Alessandro M.; Mathieu F.; Addamo E.; Franchi F.; Paladini
P.; Luzzi L.
Institution
(Catelli, Luzzi) Lung Transplant Unit, Azienda Ospedaliero-Universitaria
Senese, University of Siena, Siena, Italy
(D'Alessandro) Respiratory Diseases and Lung Transplant Unit, Department
of Medical and Surgical Sciences and Neurosciences, University of Siena,
Siena 53100, Italy
(Mathieu, Addamo, Paladini) Thoracic Surgery Unit, University Hospital of
Siena, Siena, Italy
(Franchi) Department of Medicine, Surgery and Neuroscience, Anesthesiology
and Intensive Care, University Hospital of Siena, Siena, Italy
Publisher
Springer
Abstract
Background: This study aims to compare three commonly used energy devices
for dissection during Video-Assisted Thoracoscopic Surgery (VATS)
lobectomy: monopolar hook, advanced bipolar, and ultrasonic device, in
terms of duration of the surgical procedure and clinical intra- and
post-operative outcomes. <br/>Material(s) and Method(s): In this
prospective single-center study, 75 patients undergoing VATS lobectomy for
non-small cell lung cancer between January 2022 and May 2023 were enrolled
and divided into 3 groups based on the device used during the surgical
procedure (Group 1: Ultrasonic Device, Group 2: Advanced Bipolar, Group 3:
Monopolar Hook). The duration of the surgical procedure, daily pleural
fluid production, post-operative pain, length of hospital stay, and
occurrence of post-operative complications were compared for each group.
In a subgroup of 20 patients (10 from Group 1 and 10 from Group 3),
concentrations of inflammatory cytokines in pleural fluid at 3 h and 48 h
post-surgery were analyzed. <br/>Result(s): Pleural fluid production on
the first and second post-operative days was significantly lower in
patients treated with the Ultrasonic device compared to the other two
groups (p < 0.001). The duration of the surgical procedure was
significantly shorter when using the Ultrasonic device (p < 0.001). There
were no significant differences in length of hospital stay (p = 0.975),
pain on the first and second post-operative days (p = 0.147 and p = 0.755,
respectively), and blood hemoglobin levels on the first post-operative day
(p = 0.709) and at discharge (p = 0.795). No differences were observed in
terms of post-operative complications, although the incidence of
post-operative cardiac arrhythmias was borderline significant (p = 0.096),
with no cases of arrhythmias recorded in Group 1. IL-10 levels in pleural
fluid of patients in Group 3 peaked at 3 h post-surgery, with a
significant reduction at 48 h (p = 0.459). <br/>Discussion(s): The use of
the ultrasonic device during VATS lobectomy may reduce pleural fluid
production and shorten the duration of the surgical procedure compared to
using a monopolar hook or advanced bipolar device. The choice of energy
device may influence the local inflammatory response, although further
studies are needed to confirm these results.<br/>Copyright &#xa9; The
Author(s), under exclusive licence to Springer Science+Business Media,
LLC, part of Springer Nature 2024.

<35>
Accession Number
2029866482
Title
Does remote ischemic preconditioning affect the systemic inflammatory
response by modulating presepsin levels?.
Source
International Journal of Artificial Organs. 47(6) (pp 388-393), 2024. Date
of Publication: June 2024.
Author
Bayram B.; Senarslan D.A.; Sengel A.; Ozturk T.; Onur E.; Iskesen I.
Institution
(Bayram, Senarslan, Iskesen) Department of Cardiovascular Surgery, Faculty
of Medicine, Manisa Celal Bayar University, Manisa, Turkey
(Sengel, Ozturk) Department of Anesthesiology and Reanimation, Faculty of
Medicine, Manisa Celal Bayar University, Manisa, Turkey
(Onur) Department of Medical Biochemistry, Faculty of Medicine, Manisa
Celal Bayar University, Manisa, Turkey
Publisher
SAGE Publications Ltd
Abstract
Objective: We investigated the effect of Remote Ischemic Preconditioning
(RIPC) on the inflammatory response during CPB by means of serum presepsin
levels at preoperative and postoperative 1st and 24th h. <br/>Method(s):
In this prospective, randomized, cross-sectional study we included 81
patients undergoing coronary artery bypass graft surgery with
cardiopulmonary bypass (CPB). Patients were randomized and RIPC was
applied to 40 patients in the study group before anesthesia. The remaining
41 patients were determined as the control group. The relationships
between RIPC and factors such as presepsin, C-reactive protein (CRP), and
leukocyte levels were investigated. <br/>Result(s): There was no
significant difference between the groups in postoperative leukocyte and
CRP values (p = 0.52, p = 0.13, respectively). When the preoperative and
postoperative first hour presepsin values of the patients were compared,
no significant difference was found in the control group (p = 0.17), but a
significant difference was found in the study group (p < 0.05). When the
presepsin values were compared between the groups, a significant
difference was found only in the postoperative first hour value (p <
0.05). <br/>Conclusion(s): It was observed that RIPC application caused to
increase the presepsin levels in the postoperative first hour
significantly in the study group (p < 0.05).<br/>Copyright &#xa9; The
Author(s) 2024.

<36>
Accession Number
2028927564
Title
The Ross-Konno Procedure With or Without Mitral Valve Surgery: A
Systematic Review With Individual Data Pooling.
Source
World Journal for Pediatric and Congenital Heart Surgery. 15(4) (pp
411-418), 2024. Date of Publication: July 2024.
Author
Dib N.; Ducruet T.; Poirier N.; Khairy P.
Institution
(Dib, Khairy) Department of Medicine, Montreal Heart Institute, Universite
de Montreal, Montreal, QC, Canada
(Dib, Poirier) Division of Cardiac Surgery, Department of Surgery,
Sainte-Justine Hospital, Universite de Montreal, Montreal, QC, Canada
(Ducruet) Unite de Recherche Clinique Appliquee, Sainte-Justine Hospital,
Universite de Montreal, Montreal, QC, Canada
Publisher
SAGE Publications Inc.
Abstract
Background: The Ross-Konno procedure is a technically demanding surgical
option to treat multilevel left ventricular outflow tract obstruction.
<br/>Method(s): A systematic review with pooled analyses was conducted
according to PRISMA criteria on studies published between January 2000 and
May 2022 that assessed outcomes following the Ross-Konno intervention in
children. Individual patient data were extracted from published
Kaplan-Meier curves using digitalization software. Overall survival and
freedom from reintervention were assessed by time-to-event approaches.
Determinants of one-year survival were investigated by meta-regression
analyses. <br/>Result(s): Ten studies with a total population of 274
patients were included. The overall pooled early (<=30 days) survival rate
was 86.9% (95% CI [87.6%-78.4%]). Five-year survival rates in patients
without and with (N = 50 [18.2%] of 274 total patients) concomitant mitral
valve surgery were 82.5% (95% CI [87.6%-77.4%]) versus 56.1% (95% CI
[74.1%-38.1%]), hazard ratio 2.67, 95% CI (1.44-4.93), P <.0001. Five- and
ten-year freedom from pulmonary autograft reoperation rates were 93.5% and
90.9%, respectively. Five- and ten-year freedom from right ventricular
outflow tract reoperation rates were 74.3% and 57.3%, respectively. By
meta-regression analysis, resection of endocardial fibroelastosis (N = 32
[11.7%] of 274 total patients) was associated with superior one-year
survival (P =.027). <br/>Conclusion(s): The Ross-Konno procedure is
associated with substantial early mortality and gradual attrition
thereafter. Mortality is higher in patients with concomitant mitral valve
surgery. Resection of endocardial fibroelastosis is associated with
superior survival. Right ventricular outflow tract reinterventions are
common.<br/>Copyright &#xa9; The Author(s) 2024.

<37>
Accession Number
2024536797
Title
The added value of remote technology and the background factors explaining
the changes in biopsychosocial functioning in cardiac rehabilitation:
cluster randomised controlled trial.
Source
European Journal of Physiotherapy. 26(4) (pp 188-200), 2024. Date of
Publication: 2024.
Author
Sinkkonen E.; Korpi H.; Sjogren T.
Institution
(Sinkkonen, Korpi, Sjogren) Faculty of Sports and Health Sciences,
University of Jyvaskyla, Jyvaskyla, Finland
Publisher
Taylor and Francis Ltd.
Abstract
Purpose: This study aimed to explore added value of mcoach app and
activity bracelet in 12-month cardiac rehabilitation on changes in
rehabilitee's biopsychosocial functioning: cardiorespiratory fitness,
depressive symptoms and social quality of life compared to similar
rehabilitation without remote technology. Additionally, the study explored
the factors explaining changes of biopsychosocial functioning.
<br/>Material(s) and Method(s): Six groups of coronary rehabilitees were
cluster-randomised to experimental (n = 30) or control group (n = 29).
Parametric and nonparametric statistical analyses and linear regression
analyses were used. <br/>Result(s): No differences between the groups
regarding changes in VO<inf>2</inf>max (p = 0.474), DEPS (p = 0.315) or
social quality of life (p = 0.592) were observed. Positive changes in the
whole study population in VO<inf>2</inf>max were explained with shorter
time from last cardiac operation and higher light activity at the baseline
(R² = 0.309). Smaller increase in DEPS was explained with
positive changes in different aspects of social quality of life
(R² = 0.562). <br/>Conclusion(s): Remote technology had no
added value for rehabilitation, but the results confirmed the importance
of early rehabilitation, maintenance of socially meaningful life and the
use of biopsychosocial and multidisciplinary approaches. Research defining
the needs and types of technology, their timing, to whom and to what
extent the remote technology would be most beneficial, is still
needed.<br/>Copyright &#xa9; 2023 Informa UK Limited, trading as Taylor &
Francis Group.

<38>
Accession Number
2022446539
Title
Prediction of exercise respiratory limitation from pulmonary function
tests.
Source
Pulmonology. 30(5) (pp 452-458), 2024. Date of Publication: 01 Sep 2024.
Author
Shlomi D.; Beck T.; Reuveny R.; Segel M.J.
Institution
(Shlomi) Adelson School of Medicine, Ariel University, Ariel, Israel
(Shlomi) Pulmonary Clinic, Dan-Petah-Tiqwa District, Clalit Health
Services - Community Division, Ramat-Gan, Israel
(Beck) Department of Surgical Oncology (Surgery C), Sheba Medical Center,
Ramat Gan, Tel-HaShomer, Israel
(Beck, Reuveny, Segel) Sackler School of Medicine, Tel-Aviv University,
Tel Aviv, Israel
(Reuveny, Segel) Pulmonary Institute, Sheba Medical Center, Ramat Gan,
Tel-HaShomer, Israel
(Reuveny) Physical Therapy Department, Faculty of Social Welfare and
Health Sciences, University of Haifa, Haifa, Israel
Publisher
Elsevier Espana S.L.U
Abstract
Background: Evaluation of unexplained exercise intolerance is best
resolved by cardiopulmonary exercise testing (CPET) which enables the
determination of the exercise limiting system in most cases.
Traditionally, pulmonary function tests (PFTs) at rest are not used for
the prediction of a respiratory limitation on CPET. <br/>Objective(s): We
sought cut-off values on PFTs that might, a priori, rule-in or rule-out a
respiratory limitation in CPET. <br/>Method(s): Patients who underwent
CPET in our institute were divided into two groups according to
spirometry: obstructive and non-obstructive. Each group was randomly
divided 2:1 into derivation and validation cohorts respectively. We
analyzed selected PFTs parameters in the derivation groups in order to
establish maximal and minimal cut-off values for which a respiratory
limitation could be ruled-in or ruled-out. We then validated these values
in the validation cohorts. <br/>Result(s): Of 593 patients who underwent a
CPET, 126 were in the obstructive and 467 in the non-obstructive group. In
patients with obstructive lung disease, forced expiratory volume in 1
second (FEV<inf>1</inf>) >= 61% predicted could rule out a respiratory
limitation, while FEV<inf>1</inf> <= 33% predicted was always associated
with a respiratory limitation. For patients with non-obstructive
spirometry, FEV<inf>1</inf> of >= 73% predicted could rule-out a
respiratory limitation. Application of this algorithm might have saved up
to 47% and 71% of CPETs in our obstructive and non-obstructive groups,
respectively. <br/>Conclusion(s): Presence or absence of a respiratory
limitation on CPET can be predicted in some cases based on a PFTs
performed at rest.<br/>Copyright &#xa9; 2023 Sociedade Portuguesa de
Pneumologia

<39>
Accession Number
2028914506
Title
Electroencephalographic guided propofol-remifentanil TCI anesthesia with
and without dexmedetomidine in a geriatric population:
electroencephalographic signatures and clinical evaluation.
Source
Journal of Clinical Monitoring and Computing. 38(4) (pp 803-815), 2024.
Date of Publication: August 2024.
Author
Mehler D.M.; Kreuzer M.; Obert D.P.; Cardenas L.F.; Barra I.; Zurita F.;
Lobo F.A.; Kratzer S.; Schneider G.; Sepulveda P.O.
Institution
(Mehler, Kreuzer, Obert, Kratzer, Schneider) Department of Anesthesiology
and Intensive Care, School of Medicine, Technical University of Munich,
Munich, Germany
(Obert) Department of Anesthesia, Critical Care, and Pain Medicine,
Massachusetts's General Hospital, Boston, MA, United States
(Obert) Harvard Medical School, Boston, MA, United States
(Cardenas, Barra, Zurita, Sepulveda) Department of Anesthesiology,
Hospital Base San Jose, Osorno/Universidad Austral, Valdivia, Chile
(Lobo) Anesthesiology Institute, Cleveland Clinic Abu Dhabi, United Arab
Emirates, Abu Dhabi, United Arab Emirates
Publisher
Springer Science and Business Media B.V.
Abstract
Elderly and multimorbid patients are at high risk for developing
unfavorable postoperative neurocognitive outcomes; however, well-adjusted
and EEG-guided anesthesia may help titrate anesthesia and improve
postoperative outcomes. Over the last decade, dexmedetomidine has been
increasingly used as an adjunct in the perioperative setting. Its
synergistic effect with propofol decreases the dose of propofol needed to
induce and maintain general anesthesia. In this pilot study, we evaluate
two highly standardized anesthetic regimens for their potential to prevent
burst suppression and postoperative neurocognitive dysfunction in a
high-risk population. Prospective, randomized clinical trial with
non-blinded intervention. Operating room and post anesthesia care unit at
Hospital Base San Jose, Osorno/Universidad Austral, Valdivia, Chile. 23
patients with scheduled non-neurologic, non-cardiac surgeries with age >
69 years and a planned intervention time > 60 min. Patients were randomly
assigned to receive either a propofol-remifentanil based anesthesia or an
anesthetic regimen with dexmedetomidine-propofol-remifentanil. All
patients underwent a slow titrated induction, followed by a target
controlled infusion (TCI) of propofol and remifentanil (n = 10) or
propofol, remifentanil and continuous dexmedetomidine infusion (n = 13).
We compared the perioperative EEG signatures, drug-induced changes, and
neurocognitive outcomes between two anesthetic regimens in geriatric
patients. We conducted a pre- and postoperative Montreal Cognitive
Assessment (MoCa) test and measured the level of alertness postoperatively
using a sedation agitation scale to assess neurocognitive status. During
slow induction, maintenance, and emergence, burst suppression was not
observed in either group; however, EEG signatures differed significantly
between the two groups. In general, EEG activity in the propofol group was
dominated by faster rhythms than in the dexmedetomidine group. Time to
responsiveness was not significantly different between the two groups (p =
0.352). Finally, no significant differences were found in postoperative
cognitive outcomes evaluated by the MoCa test nor sedation agitation scale
up to one hour after extubation. This pilot study demonstrates that the
two proposed anesthetic regimens can be safely used to slowly induce
anesthesia and avoid EEG burst suppression patterns. Despite the patients
being elderly and at high risk, we did not observe postoperative
neurocognitive deficits. The reduced alpha power in the
dexmedetomidine-treated group was not associated with adverse
neurocognitive outcomes.<br/>Copyright &#xa9; The Author(s), under
exclusive licence to Springer Nature B.V. 2024.

<40>
[Use Link to view the full text]
Accession Number
644125524
Title
Comparison of the outcomes of concurrent versus staged TAVR combined with
PCI in patients with severe aortic stenosis and coronary artery disease: a
systematic review and meta-analysis.
Source
Coronary artery disease. 35(6) (pp 481-489), 2024. Date of Publication: 01
Sep 2024.
Author
Zhang X.; Geng W.; Yan S.; Zhang K.; Liu Q.; Li M.
Institution
(Zhang) Department of Cardiology, Baoding First Central Hospital, China
Abstract
BACKGROUND: The optimal timing for percutaneous coronary intervention
(PCI) in patients undergoing transcatheter aortic valve replacement (TAVR)
remains uncertain. This research aims to evaluate the results of patients
diagnosed with severe aortic valve stenosis and coronary artery disease
who undergo either simultaneous or staged PCI therapy during TAVR
procedures. <br/>METHOD(S): We retrieved all relevant studies from our
self-constructed databases up to January 2, 2024, encompassing databases
such as Embase, Medline, Cochrane Library, and PubMed. <br/>RESULT(S): A
total of nine studies were included, and the results showed that both
surgical modalities had good safety profiles in the early and long-term
stages. For early endpoint events, the risk of all-cause mortality and
major bleeding within 30 years was similar in the staged TAVR + PCI and
the contemporaneous TAVR + PCI ( P > 0.05). Additionally, the risk of
myocardial infarction, stroke, acute kidney injury and pacemaker
implantation within 30 days or perioperatively is similar ( P > 0.05). For
long-term endpoint events, the risk of all-cause mortality, myocardial
infarction and stroke was similar in the two groups at >=2 years ( P >
0.05). <br/>CONCLUSION(S): In patients undergoing TAVR who required
coronary revascularization, no significant differences were observed in
the early and long-term outcomes between those receiving concurrent TAVR
and PCI versus staged surgery.<br/>Copyright &#xa9; 2024 The Author(s).
Published by Wolters Kluwer Health, Inc.

<41>
Accession Number
2030845370
Title
An implementation manual for an interprofessional enhanced recovery after
surgery protocol in cardiac surgery following international established
frameworks.
Source
Frontiers in Cardiovascular Medicine. 11 (no pagination), 2024. Article
Number: 1392881. Date of Publication: 2024.
Author
Schmid M.E.; Dolata L.; Konig H.; Stock S.; Klotz S.G.R.; Girdauskas E.
Institution
(Schmid, Konig, Stock, Girdauskas) Department of Cardiothoracic Surgery,
University Hospital Augsburg, Augsburg, Germany
(Dolata) Department of Patient and Care Management, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
(Klotz) Department of Physiotherapy, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany
Publisher
Frontiers Media SA
Abstract
Introduction: Enhanced Recovery After Surgery (ERAS) protocols represent a
paradigm shift in perioperative care, aim to optimize patient outcomes and
accelerate recovery. This manual presents findings from implementing the
INCREASE study, a bicentric prospective randomized controlled trial
focusing on ERAS in minimally invasive heart valve surgery.
<br/>Method(s): Utilizing the Consolidated Framework for Implementation
Research (CFIR) and the Template for Intervention Description and
Replication (TIDieR), the study examined contextual factors, intervention
components, and implementation strategies. <br/>Result(s): Key findings
from the CFIR analysis revealed critical domains influencing
implementation success. These included innovation characteristics,
external and internal settings, and individual dynamics. The study
showcased ERAS's adaptability to diverse healthcare systems, emphasizing
its potential for successful integration across varying contexts.
Furthermore, the importance of interprofessional collaboration emerged as
a foundation of practical implementation, fostering teamwork,
communication, and patient-centered care. Utilizing the TIDieR framework,
this manual comprehensively describes ERAS intervention components,
detailing preoperative counseling, intraoperative management, and
postoperative care strategies. The manual underscored the importance of
tailored, patient-centered approaches, highlighting the role of an
academic ERAS nurse, early mobilization, and psychosomatic interventions
in promoting optimal recovery outcomes. <br/>Discussion(s): In conclusion,
the INCREASE study provided valuable insights for creating an
implementation manual for ERAS in cardiac surgery, emphasizing
adaptability, collaboration, and ongoing evaluation as key drivers of
successful implementation. These findings have broad implications for
improving patient care outcomes and advancing perioperative practices in
cardiac surgery settings.<br/>Copyright 2024 Schmid, Dolata, Konig, Stock,
Klotz and Girdauskas.

<42>
Accession Number
644888474
Title
The feasibility and accuracy of the method for selecting the optimal size
of double-lumen tube in thoracic surgery: a prospective, randomized
controlled trial.
Source
Scientific reports. 14(1) (pp 17539), 2024. Date of Publication: 30 Jul
2024.
Author
Cui G.; Zhao L.; Chi C.; Liang S.; Liu Z.
Institution
(Cui, Chi, Liang, Liu) Department of Anesthesiology, First Hospital of
Qinhuangdao, N.O. 258, Wenhua Road, Qinhuangdao, Hebei, China
(Cui, Chi) Graduate School of Hebei Medical University, Shijiazhuang,
Hebei, China
(Zhao) Department of Thoracic Surgery, First Hospital of Qinhuangdao,
Qinhuangdao, Hebei, China
Abstract
Double-lumen tubes (DLTs) are commonly used for one-lung ventilation (OLV)
in thoracic surgery and the selection of an optimal size of DLTs is still
a humongous task. The purpose of this study was to assess the feasibility
and accuracy of the method for selecting an optimal size of DLTs in
thoracic surgery. Sixty adult patients requiring a left side double-lumen
tube (LDLT) for elective thoracoscopic surgery were included in this
study. All patients were randomly allocated to the following two groups:
Cuffs Collapsed group (CC group, n=30) and Cuffs Inflated group (CI group,
n=30). In the Cuffs Collapsed group, the outer diameter of LDLT (the outer
diameter of the tracheal and bronchial cuffs when they were collapsed as
the outer diameter of the LDLT) matched with the inner diameter of the
trachea and bronchus measured by the anesthesiologist on the chest CT
slice; In the Cuffs Inflated group, the outer diameter of LDLT (the outer
diameter of the tracheal and bronchial cuffs when they were inflated as
the outer diameter of the LDLT) matched with the inner diameter of the
trachea and bronchus measured by the anesthesiologist on the chest CT
slice. The primary outcomes were the incidences of airway complications
postoperative such as hoarseness and sore throat. The time of intubation
and alignment, the incidences of LDLT displacement and adjustment, the
peak airway pressure, the plateau airway pressure and the end-tidal carbon
dioxide were also recorded. The incidences of airway complications
postoperative such as sore throat and hoarseness were lower in the CI
group than the CC group (P<0.05), the intubation times was shorter in the
CI group than the CC group (P<0.05), while the peak airway pressure, the
plateau airway pressure and the end-tidal carbon dioxide during two-lung
ventilation and one-lung ventilation were no significant difference
between two groups (P>0.05). The method which matched the inner diameter
of the trachea and bronchus measured on chest CT slice with the outer
diameter of the tracheal and bronchial cuffs when they were inflated to
select an appropriate size of LDLT can reduce the incidence of airway
complications.Trials registration: Clinical Trials: gov. no. NCT05739318.
Registered at https://classic.clinicaltrials.gov 22/02/2023.<br/>Copyright
&#xa9; 2024. The Author(s).

<43>
Accession Number
2033680033
Title
Comparison of 4% Albumin and Ringer's Acetate on Hemodynamics in On-pump
Cardiac Surgery: An Exploratory Analysis of a Randomized Clinical Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Vlasov H.; Wilkman E.; Petaja L.; Suojaranta R.; Hiippala S.; Tolonen H.;
Jormalainen M.; Raivio P.; Juvonen T.; Pesonen E.
Institution
(Vlasov, Wilkman, Petaja, Suojaranta, Hiippala, Pesonen) Department of
Anesthesiology and Intensive Care Medicine, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland
(Tolonen, Raivio, Juvonen) HUS Pharmacy, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland
(Jormalainen) Department of Cardiac Surgery, Heart and Lung Center,
University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Publisher
W.B. Saunders
Abstract
Objectives: Compare hemodynamics between 4% albumin and Ringer's acetate.
<br/>Design(s): Exploratory analysis of the double-blind randomized
ALBumin In Cardiac Surgery trial. <br/>Setting(s): Single-center study in
Helsinki University Hospital. <br/>Participant(s): We included 1,386
on-pump cardiac surgical patients. <br/>Intervention(s): We used 4%
albumin or Ringer's acetate administration for cardiopulmonary bypass
priming, volume replacement intraoperatively and 24 hours postoperatively.
<br/>Measurements and Main Results: Hypotension (time-weighted average
mean arterial pressure of <65 mmHg) and hyperlactatemia (time-weighted
average blood lactate of >2 mmol/L) incidences were compared between trial
groups in the operating room (OR), and early (0-6 hours) and late (6-24
hours) postoperatively. Associations of hypotension and hyperlactatemia
with the ALBumin In Cardiac Surgery primary outcome (>=1 major adverse
event [MAE]) were studied. In these time intervals, hypotension occurred
in 118, 48, and 17 patients, and hyperlactatemia in 313, 131, and 83
patients. Hypotension and hyperlactatemia associated with MAE occurrence.
Hypotension did not differ between the groups (albumin vs Ringer's: OR,
8.8% vs 8.5%; early postoperatively, 2.7% vs 4.2%; late postoperatively,
1.2% vs 1.3%; all p > 0.05). In the albumin group, hyperlactatemia was
less frequent late postoperatively (2.9% vs 9.1%; p < 0.001), but not
earlier (OR, 22.4% vs 23.6%; early postoperatively, 7.9% vs 11.0%; both p
> 0.025 after Bonferroni-Holm correction). <br/>Conclusion(s): In on-pump
cardiac surgery, hypotension and hyperlactatemia are associated with the
occurrence of >=1 MAE. Compared with Ringer's acetate, albumin did not
decrease hypotension and decreased hyperlactatemia only late
postoperatively. Albumin's modest hemodynamic effect is concordant with
the finding of no difference in MAEs between albumin and Ringer's acetate
in the ALBumin In Cardiac Surgery trial.<br/>Copyright &#xa9; 2024 The
Author(s)

<44>
Accession Number
2030829606
Title
Cerebral embolic protection for stroke prevention during transcatheter
aortic valve replacement.
Source
Expert Review of Cardiovascular Therapy. (no pagination), 2024. Date of
Publication: 2024.
Author
Basit J.; Ahmed M.; Kidess G.; Zaheer Z.; Fatima L.; Naveed H.; Hamza M.;
Fatima M.; Goyal A.; Loyalka P.; Alam M.; Alraies M.C.
Institution
(Basit, Ahmed) Department of Medicine, Rawalpindi Medical University,
Rawalpindi, Pakistan
(Kidess) Department of Internal Medicine, Wayne State University, MI,
United States
(Zaheer, Fatima) Department of Medicine, King Edward Medical University,
Lahore, Pakistan
(Fatima) Department of Medicine, Allama Iqbal Medical College, Lahore,
Pakistan
(Naveed) University of Houston/HCA kingwood Hospital, Houston, TX, United
States
(Hamza) Department of Hospital Medicine, Guthrie Cortland Medical Center,
Cortland, NY, United States
(Goyal) Department of Internal Medicine, Seth GS Medical College and KEM
Hospital, Mumbai, India
(Loyalka) Department of cardiology, HCA medical Center, Houston, TX,
United States
(Alam) Department of Interventional Cardiology, Baylor College of
Medicine, Houston, TX, United States
(Alraies) Cardiovascular Institute, Detroit Medical Center, Detroit, MI,
United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Cerebral Embolic Protection Device (CEPD) captures emboli
during Transcatheter Aortic Valve Replacement (TAVR). With recently
published pivotal trials and multiple cohort studies reporting new data,
there is a need to re-calibrate available statistical evidence.
<br/>Method(s): A systematic literature search was conducted across
databases from inception till February 2023. Dichotomous outcomes were
pooled using Odds Ratio (OR), while continuous outcomes were pooled using
Standardized Mean Difference (SMD) along with 95% corresponding intervals
(95% CIs). <br/>Result(s): Data was included from 17 studies (7 RCTs, 10
cohorts, n = 155,829). Use of CEPD was associated with significantly
reduced odds of stroke (OR = 0.60, 95% CI = 0.43-0.85, p = 0.003). There
was no significant difference in disabling stroke (p = 0.25),
non-disabling stroke (p = 0.72), and 30-day mortality (p = 0.10) between
the two groups. There were no significant differences between the two
groups for Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
findings, acute kidney injury, risk of pacemaker implantation
life-threatening bleed, major bleed, minor bleed, worsening National
Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) and
vascular complications (p > 0.05). <br/>Conclusion(s): The use of CEPD
during TAVR reduced the incidence of all-stroke (p = 0.003); however,
there were no significant differences in any of the other pooled outcomes
(p > 0.05). Registration: The protocol of this meta-analysis was
registered with the Open Science framework
[https://doi.org/10.17605/OSF.IO/7W564] before data acquisition was
started.<br/>Copyright &#xa9; 2024 Informa UK Limited, trading as Taylor &
Francis Group.

<45>
[Use Link to view the full text]
Accession Number
2017432073
Title
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A
Report of the American College of Cardiology/American Heart Association
Joint Committee on Clinical Practice Guidelines.
Source
Circulation. 145(3) (pp E18-E114), 2022. Date of Publication: 18 Jan 2022.
Author
Lawton J.S.; Tamis-Holland J.E.; Bangalore S.; Bates E.R.; Beckie T.M.;
Bischoff J.M.; Bittl J.A.; Cohen M.G.; Dimaio J.M.; Don C.W.; Fremes S.E.;
Gaudino M.F.; Goldberger Z.D.; Grant M.C.; Jaswal J.B.; Kurlansky P.A.;
Mehran R.; Metkus T.S.; Nnacheta L.C.; Rao S.V.; Sellke F.W.; Sharma G.;
Yong C.M.; Zwischenberger B.A.
Publisher
Lippincott Williams and Wilkins
Abstract
AIM: The guideline for coronary artery revascularization replaces the 2011
coronary artery bypass graft surgery and the 2011 and 2015 percutaneous
coronary intervention guidelines, providing a patient-centric approach to
guide clinicians in the treatment of patients with significant coronary
artery disease undergoing coronary revascularization as well as the
supporting documentation to encourage their use. <br/>METHOD(S): A
comprehensive literature search was conducted from May 2019 to September
2019, encompassing studies, reviews, and other evidence conducted on human
subjects that were published in English from PubMed, EMBASE, the Cochrane
Collaboration, CINHL Complete, and other relevant databases. Additional
relevant studies, published through May 2021, were also considered.
STRUCTURE: Coronary artery disease remains a leading cause of morbidity
and mortality globally. Coronary revascularization is an important
therapeutic option when managing patients with coronary artery disease.
The 2021 coronary artery revascularization guideline provides
recommendations based on contemporary evidence for the treatment of these
patients. The recommendations present an evidence-based approach to
managing patients with coronary artery disease who are being considered
for coronary revascularization, with the intent to improve quality of care
and align with patients' interests.<br/>Copyright &#xa9; 2022 Lippincott
Williams and Wilkins. All rights reserved.

<46>
Accession Number
2030734307
Title
Comparison of Morbidity and Mortality Outcomes between Hybrid Palliation
and Norwood Palliation Procedures for Hypoplastic Left Heart Syndrome:
Meta-Analysis and Systematic Review.
Source
Journal of Clinical Medicine. 13(14) (no pagination), 2024. Article
Number: 4244. Date of Publication: July 2024.
Author
Iskander C.; Nwankwo U.; Kumanan K.K.; Chiwane S.; Exil V.; Lowrie L.; Tan
C.; Huddleston C.; Agarwal H.S.
Institution
(Iskander, Nwankwo, Exil) Division of Pediatric Cardiology, Cardinal
Glennon Children's Hospital, Saint Louis, MO 63104, United States
(Kumanan) Advanced Data Health Institution, Saint Louis University, Saint
Louis, MO 63104, United States
(Chiwane) Division of Pediatric Critical Care Medicine, Loma Linda
University, Loma Linda, CA 92354, United States
(Lowrie, Agarwal) Division of Pediatric Critical Care Medicine, Cardinal
Glennon Children's Hospital, Saint Louis, MO 63104, United States
(Tan, Huddleston) Department of Pediatric Cardio-Thoracic Surgery,
Cardinal Glennon Children's Hospital, Saint Louis, MO 63104, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Hybrid palliation (HP) procedures for hypoplastic
left heart syndrome (HLHS) are increasing. Our objective was to compare
mortality and morbidity following HP and NP (Norwood palliation)
procedures. <br/>Method(s): Systematic review and meta-analysis of HLHS
patients of peer-reviewed literature between 2000 and 2023. Mortality
and/or heart transplantation in HP versus NP in the neonatal period,
interstage period, and at 1, 3 and 5 years of age, and morbidity including
completion of Stage II and Stage III palliation, unexpected interventions,
pulmonary artery pressures, right ventricle function, neurodevelopmental
outcomes and length of hospital stay were evaluated. <br/>Result(s):
Twenty-one (meta-analysis: 16; qualitative synthesis: 5) studies
evaluating 1182 HLHS patients included. HP patients had higher interstage
mortality (RR = 1.61; 95% CI: 1.10-2.33; p = 0.01) and 1-year mortality
(RR = 1.22; 95% CI: 1.03-1.43; p = 0.02) compared to NP patients without
differences in 3- and 5-years mortality. HP procedure in high-risk HLHS
patients had lower mortality (RR = 0.48; 95% CI: 0.27-0.87; p = 0.01) only
in the neonatal period. HP patients underwent fewer Stage II (RR = 0.90;
95% CI: 0.81-1.00; p = 0.05) and Stage III palliation (RR = 0.78; 95% CI:
0.69-0.90; p < 0.01), had more unplanned interventions (RR = 3.38; 95% CI:
2.04-5.59; p < 0.01), and longer hospital stay after Stage I palliation
(weighted mean difference = 12.88; 95% CI: 1.15-24.62; p = 0.03) compared
to NP patients. <br/>Conclusion(s): Our study reveals that HP, compared to
NP for HLHS, is associated with increased morbidity risk without an
improved survival rate.<br/>Copyright &#xa9; 2024 by the authors.

<47>
Accession Number
2030347652
Title
Coronary Artery Disease Is A Stronger Predictor of All-Cause Mortality
Than Left Ventricular Ejection Fraction Among Patients With Newly
Diagnosed Heart Failure: Insights From the WDHR.
Source
Journal of the American Heart Association. 13(14) (no pagination), 2024.
Article Number: e9771. Date of Publication: 16 Jul 2024.
Author
Nielsen R.R.; Pryds K.; Olesen K.K.W.; Mortensen M.B.; Gyldenkerne C.;
Nielsen J.C.; Hindricks G.; Dagres N.; Maeng M.
Institution
(Nielsen, Pryds, Olesen, Mortensen, Gyldenkerne, Nielsen, Maeng)
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
(Nielsen, Mortensen, Nielsen, Maeng) Department of Clinical Medicine,
Aarhus University, Health, Aarhus, Denmark
(Mortensen) Department of Cardiology, Johns Hopkins, Baltimore, MD, United
States
(Hindricks, Dagres) German Heart Center, Charite, Berlin, Germany
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: In patients with newly diagnosed heart failure (HF) and left
ventricular ejection fraction (LVEF) <50%, little is known whether LVEF
per se or presence of coronary artery disease (CAD) provides independent
prognostic information on all-cause mortality. METHODS AND RESULTS: Using
the WDHR (Western Denmark Heart Registry), we identified 3620 patients
with newly diagnosed HF and LVEF 10% to 49% referred for first-time
coronary angiography as part of general workup of HF. Patients were
stratified by LVEF (10%-35% versus 36%-49%) and presence of CAD. We
estimated 10-year all-cause mortality risk and calculated hazard ratios
adjusted for relevant comorbidities and risk factors (aHRs). CAD was
present in 1592 (44%) patients. Lower LVEF was associated with a relative
15% increased 10-year mortality: 37% for LVEF 36% to 49% versus 42% for
LVEF 10% to 35% (aHR, 1.15 [95% CI, 0.99-1.34]). This result did not
change when stratified into those with CAD (52% versus 56%; aHR, 1.11 [95%
CI, 0.91-1.35]) and those without CAD (27% versus 33%; aHR, 1.24 [95% CI,
0.97-1.57]). In comparison, presence and extent of CAD were associated
with a relative 43% increased 10-year mortality (CAD versus no CAD, 55.0%
versus 31.5%; aHR, 1.43 [95% CI, 1.25-1.64]). Compared with a matched
general population, excess mortality risk was higher for patients with HF
and CAD (54.7% versus 26.3%; aHR, 2.10 [95% CI, 1.85-2.39]) versus those
with HF and no CAD (31.4% versus 17.2%; aHR, 1.76 [95% CI, 1.52-2.02]).
<br/>CONCLUSION(S): Among newly diagnosed patients with HF and LVEF <50%,
presence and extent of CAD are associated with substantial higher
all-cause mortality risk than lower LVEF.<br/>Copyright &#xa9; 2024 The
Authors.

<48>
Accession Number
2029531644
Title
Apixaban in bridge to transplant and destination LVAD - rationale and
study design: the ApixiVAD trial.
Source
ESC Heart Failure. 11(4) (pp 2387-2394), 2024. Date of Publication: August
2024.
Author
Schnegg B.; Deveza R.; Hayward C.
Institution
(Schnegg) Department of Cardiology, Centre for Advanced Heart Failure,
Inselspital, Bern University Hospital, Bern, Switzerland
(Deveza, Hayward) Heart Failure and Transplant Unit, St Vincent's
Hospital, Sydney, NSW, Australia
Publisher
John Wiley and Sons Inc
Abstract
Aims: Use of novel anticoagulation in mechanical circulatory support is
controversial. We report the rationale and design of the ApixiVad pilot
trial, a pilot study testing the safety of apixaban as an anticoagulant in
patients bridged to transplant (BTT) or for destination (DT) with
Heartmate 3 (HM3) left ventricular assist device (LVAD). <br/>Methods and
Results: Apixaban has been used in small non-randomized cohorts in LVAD
patients and shown to be effective in ex vivo studies. The ApixiVAD study
examines apixaban use in a multicentre, international, open-label,
randomized, controlled trial aiming to include 50 BTT or DT HM3 patients
with a 1:1 randomization ratio. This event-driven study has a maximum
follow-up period of 24 months with interim analysis at 6 months. The
primary outcome is death, thromboembolic events and major bleeding,
including operative bleeding and immediate transplant outcomes. The
secondary outcome focuses on patients' quality of life related to
anticoagulation. This investigator-driven pilot study is not powered to
determine the non-inferiority of apixaban. An increase in primary outcome
in the apixaban group of 20% will be considered a signal of harm.
<br/>Conclusion(s): A positive outcome in the ApixiVAD study would provide
the basis for future, larger, pivotal anticoagulation trials in LVAD
patients.<br/>Copyright &#xa9; 2024 The Authors. ESC Heart Failure
published by John Wiley & Sons Ltd on behalf of European Society of
Cardiology.

<49>
Accession Number
2029094239
Title
Echocardiographic haemodynamic monitoring in the context of HeartMate 3TM
therapy: a systematic review.
Source
ESC Heart Failure. 11(4) (pp 2033-2042), 2024. Date of Publication: August
2024.
Author
Ohlsson L.; Papageorgiou J.-M.; Ebbers T.; Aneq M.A.; Tamas E.; Granfeldt
H.
Institution
(Ohlsson, Tamas, Granfeldt) Department of Cardiothoracic and Vascular
Surgery, Department of Health, Medicine and Caring Sciences, Linkoping
University, Linkoping, Sweden
(Ohlsson, Ebbers, Tamas) Center of Medical Image Science and Visualization
(CMIV), Linkoping University, Linkoping, Sweden
(Papageorgiou) Department of Cardiology in Linkoping, Department of
Health, Medicine and Caring Sciences, Linkoping University, Linkoping,
Sweden
(Ebbers, Tamas) Department of Health, Medicine and Caring Sciences,
Linkoping University, Linkoping, Sweden
(Aneq) Department of Clinical Physiology in Linkoping, Department of
Health, Medicine and Caring Sciences, Linkoping University, Linkoping,
Sweden
Publisher
John Wiley and Sons Inc
Abstract
Aims: While echocardiography remains essential within haemodynamic
monitoring of durable mechanical circulatory support, previous
echocardiographic guidelines are missing scientific evidence for the novel
HeartMate 3TM (HM3) system. Accordingly, this review aims to summarize
available echocardiographic evidence including HM3. <br/>Methods and
Results: This systematic review adhered to the PRISMA 2020 guidelines.
Searches were conducted during August 2023 across PubMed, Embase, and
Google Scholar using specific echocardiographic terms combined with system
identifiers. Study quality was assessed using the Newcastle-Ottawa Scale
(NOS) for cohort studies and Critical Appraisal Instrument (PCAI) for
cross-sectional studies. Nine studies met the inclusion criteria, of which
eight cohort studies and one cross-sectional study. Aortic regurgitation
(AR) prevalence at approximately 12 months of support exhibited
heterogenicity (33.5% (DELTA 33%)) in a limited number of studies (n = 3).
Several studies (n = 5) demonstrated an increasing prevalence and severity
of AR during HM3 support, generating moderate to high level of evidence.
One AR study showed a higher cumulative incidence of death and heart
failure (HF) readmission compared with those without significant AR,
hazard ratio 3.42 (95% CI 1.48-8.76). A second study showed that a
worsening AR group had significantly lower survival-free from HF
readmission (59% vs. 89%, P = 0.023) with a hazard ratio of 5.18 (95% CI
1.07-25.0), while a third study did not reveal any differences in
cardiac-related hospitalizations in the 12 months follow-up or
non-cardiac-related hospitalization. Mitral regurgitation (MR) prevalence
at approximately 12 months of support exhibited good consistency 15.0%
(DELTA 0.8%) in both included studies, which did not reveal any
significant pattern of changing prevalence over time. Tricuspid
regurgitation (TR) prevalence at approximately 12 months of support
exhibited fair consistency 28.5% (DELTA 8.3%) in a limited number of
studies (n = 2); both studies showed a statistically un-confirmed trend of
increased TR prevalence over time. The evidence of general prevalence of
right ventricular dysfunction (RVD) was insufficient due to lack of
studies. <br/>Conclusion(s): There are few methodologically consistent
studies with focus on long-term haemodynamic effects. Aortic regurgitation
still seems to be a prevalent and potentially significant finding. The
available evidence concerning right heart function is limited despite
clinical relevance and potential prognostic value. Potential
interventricular and haemodynamic interplay are identified as a white
field for future research.<br/>Copyright &#xa9; 2024 The Authors. ESC
Heart Failure published by John Wiley & Sons Ltd on behalf of European
Society of Cardiology.

<50>
Accession Number
2029076164
Title
Long-term cost-effectiveness of transcatheter mitral valve repair in HF
patients with secondary mitral regurgitation.
Source
ESC Heart Failure. 11(4) (pp 2023-2032), 2024. Date of Publication: August
2024.
Author
Yao Y.; Zhou Z.; Geng T.; Cai A.; Li T.; Yang J.; Chen J.; Li L.
Institution
(Yao, Zhou, Cai, Yang, Chen, Li) Department of Cardiology, Guangdong
Cardiovascular Institute, Guangdong Provincial People's Hospital,
Guangdong Academy of Medical Sciences, No. 106, Zhongshan 2nd Road, Yuexiu
District, Guangzhou 510080, China
(Zhou, Chen) Department of Cardiology, School of Medicine, South China
University of Technology, Guangzhou, China
(Geng) Department of Emergency, Guangdong Provincial People's Hospital,
Guangdong Academy of Medical Sciences, Guangzhou, China
(Li) Department of Cardiology and Angiology, Medical Center, University of
Freiburg, Freiburg im Breisgau, Germany
Publisher
John Wiley and Sons Inc
Abstract
Aims: The long-term cost-effectiveness of MitraClip in heart failure
patients with secondary mitral regurgitation is still unclear. This study
aimed to evaluate the long-term cost-effectiveness of MitraClip added to
guideline-directed medical therapy vs. guideline-directed medical therapy
alone in heart failure patients with secondary mitral regurgitation from
the perspective of the healthcare systems of mainland China, the United
Kingdom, Germany, and the United States. <br/>Methods and Results: A
two-stage (decision + Markov) model was built. Health utilities were
defined by the New York Heart Association class, heart failure
re-hospitalization, and death and were calculated based on the 5 year
follow-up results of the Cardiovascular Outcomes Assessment of the
MitraClip Percutaneous Therapy for Heart Failure Patients With Functional
Mitral Regurgitation trial. Direct healthcare costs were derived from the
nationally representative data. Future utilities and costs were discounted
at country-specific rates. The primary outcome was the lifetime
incremental cost-effectiveness ratio. The mean age of the base case in our
model was 72.2 years. Over a lifetime horizon, treatment with MitraClip
was associated with 829 fewer heart failure re-hospitalizations per 1000
treated patients. The MitraClip treatment was associated with incremental
quality-adjusted life-year gains of 0.71, 0.76, 0.78, and 0.78, as well as
incremental cost-effectiveness ratios of 468 462, 28 910, 26 045, and $71
199 per quality-adjusted life-year for a lifetime horizon in mainland
China, the United Kingdom, Germany, and the United States, respectively.
In probabilistic sensitivity analysis, 0.2%, 59.4%, 99.6%, and 84.7% of
patients were cost-effective in mainland China, the United Kingdom,
Germany, and the United States at the country-specific willingness-to-pay
thresholds. <br/>Conclusion(s): MitraClip + guideline-directed medical
therapy was cost-effective in heart failure patients with secondary mitral
regurgitation in the United Kingdom, Germany, and the United States, but
not in mainland China from the perspective of the national healthcare
system.<br/>Copyright &#xa9; 2024 The Authors. ESC Heart Failure published
by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

<51>
Accession Number
2033615855
Title
Early anticoagulation after aortic valve replacement with porcine
bioprosthesis randomized control trial(ANTIPRO). 3 years follow-up.
Source
International Journal of Cardiology. 413 (no pagination), 2024. Article
Number: 132361. Date of Publication: 15 Oct 2024.
Author
Dayan V.; Fernandez A.; Loza G.; Parma G.; Robaina R.; Montero J.;
Gonzalez E.; Brusich D.; Florio L.
Institution
(Dayan, Fernandez, Robaina, Montero, Gonzalez) Instituto Nacional de
Cirugia Cardiaca, Montevideo, Uruguay
(Dayan, Loza, Parma, Montero, Gonzalez, Brusich, Florio) Centro
Cardiovascular Universitario, Universidad de la Republica del Uruguay,
Montevideo, Uruguay
Publisher
Elsevier Ireland Ltd
Abstract
Background: Most evidence for anticoagulation in aortic bioprosthesis is
centered on embolic events, bleeding and re-intervention risk. The effect
of anticoagulation on hemodynamics has not been previously assessed. Our
hypothesis was that patients with anticoagulation (AC) early after aortic
valve replacement (AVR) with porcine bioprosthesis have better
hemodynamics at 3 years of follow-up. <br/>Method(s): This is a follow-up
evaluation of the ANTIPRO trial. All patients undergoing AVR with porcine
bioprosthesis were consecutively recruited. The AC group received
warfarin+aspirin and the non-AC(control) only aspirin. The primary outcome
was mean gradient after 3 years of AVR and change in New York Heart
Association (NYHA) class. Secondary outcomes were major and minor bleeding
and embolic events. <br/>Result(s): Of 140 participants in the study, 71
were assigned to the AC group and 69 to the control group. Mean age of the
overall population was 72.4(SD: 7.1) years. Global euroSCORE was 7.65(SD:
5.73). At 3 years the mean gradient was similar between both groups
(19.4(SD: 9.6 mmHg) and 18.6(SD: 8.2 mmHg) in the control and AC group
respectively, p = 0.7). No differences in functional class at 3 years were
found among groups. No differences were found among groups in the
secondary outcomes. <br/>Conclusion(s): The addition of 3 months of oral
anticoagulation to anti-aggregation treatment did not affect bioprosthetic
hemodynamics nor functional class at years after AVR.<br/>Copyright &#xa9;
2023

<52>
Accession Number
2033570277
Title
Efficacy of ultrasound-guided second serratus anterior plane block on
postoperative quality of recovery and analgesia after video-assisted
thoracic surgery: a randomized, triple-blind, placebo-controlled study.
Source
Journal of Thoracic Disease. 16(7) (pp 4195-4207), 2024. Date of
Publication: 30 Jul 2024.
Author
Omindo W.W.; Ping W.; Qiu R.; Zheng S.; Sun Q.; Qian Y.; Zhang R.; Zhang
N.; Zhou B.
Institution
(Omindo, Ping, Qiu, Zheng, Sun, Qian, Zhang, Zhang) Department of Thoracic
Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China
(Zhou) Department of Anesthesiology, Tongji Hospital, Tongji Medical
College, Huazhong University of Science and Technology, Wuhan, China
Publisher
AME Publishing Company
Abstract
Background: Despite widespread application of minimally invasive
video-assisted thoracic surgery (VATS), postoperative pain following this
procedure is still a constant clinical challenge. Serratus anterior plane
(SAP) block is one of the regional analgesic techniques with promising
outcomes. However, due to the limited duration of action, optimal
analgesia is often not achieved with a single injection. We tested whether
in patients who have been subjected to routine SAP block under
preoperative anesthesia, the addition of a second SAP block 24 hours after
surgery, improves quality of recovery, lowers postoperative opioid
consumption, and reduces the prevalence of chronic pain. <br/>Method(s):
The present study is a single institutional, prospective, randomized,
triple-blinded, placebo-controlled study. Ninety patients undergoing VATS
from January 2022 to April 2022 were randomized at 1:1 ratio to receive
ultrasound-guided second SAP block with 15 mL 0.375% ropivacaine (SAP
block group) or 15 mL normal saline (control group) 24 hours after both
groups received routine SAP block with 15 mL 0.375% ropivacaine. The
primary outcome was quality of patient recovery, measured using 40-item
quality of recovery questionnaire (QoR-40) at postoperative day 2 (POD 2).
Secondary outcomes included: postoperative pain scores at rest,
postoperative opioid consumptions, number of times that patient controlled
analgesia (PCA) pump button was pressed, perioperative complications and
adverse effects, prevalence of chronic pain at 2^nd and
3^rd month postoperatively, and length of hospital stay (LOS).
<br/>Result(s): A total of 83 patients completed the study: 43 patients in
SAP block group and 40 patients in the control group. The global QoR-40
scores on POD 2 and POD 3 were significantly higher among SAP block group
patients (180.07+/-11.34, 182.09+/-8.20) compared with the control group
(172.18+/-6.15, 177.50+/-6.94) (P=0.01, P=0.008) respectively.
Postoperative pain scores, opioid consumptions and incidence of
postoperative nausea and vomiting were significantly lower among patients
in SAP block group versus control group. There were no statistically
significant differences in perioperative complications and LOS between the
two groups. The prevalence of chronic pain at the 2^nd and
3^rd month postoperatively for patients in SAP block group and
control group was 16.3%, 14%, and 32.5%, 27.5% respectively.
<br/>Conclusion(s): In patients undergoing VATS, application of
ultrasound-guided second SAP block 24 hours after surgery improved
postoperative quality of life, reduced opioid consumption and related side
effects, and lowered the prevalence of chronic pain.<br/>Copyright &#xa9;
Journal of Thoracic Disease. All rights reserved.

<53>
Accession Number
2033558669
Title
Towards an understanding of the biopsychosocial determinants of CVD in
SLE: a scoping review.
Source
Lupus Science and Medicine. 11(2) (no pagination), 2024. Article Number:
e001155. Date of Publication: 24 Jul 2024.
Author
Shantz E.; Elliott S.J.; Sperling C.; Buhler K.; Costenbader K.H.; Choi
M.Y.
Institution
(Shantz, Elliott) Geography & Environmental Management, University of
Waterloo, Waterloo, ON, Canada
(Sperling) Patient Partner, Calgary, AB, Canada
(Buhler, Choi) University of Calgary Cumming School of Medicine, Calgary,
AB, Canada
(Costenbader) Brigham and Women's Hospital, Boston, MA, United States
(Costenbader) Harvard Medical School, Boston, MA, United States
(Choi) McCaig Institute for Bone and Joint Health, Cumming School of
Medicine, University of Calgary, Calgary, AB, Canada
Publisher
BMJ Publishing Group
Abstract
Objective Systemic lupus erythematosus (SLE) is a chronic autoimmune
condition with significant physical, mental, psychosocial and economic
impacts. A main driver of SLE morbidity and mortality is cardiovascular
disease (CVD). Both SLE and CVD exhibit disparities related to gender,
race and other social dimensions linked with biological outcomes and
health trajectories. However, the biospsychosocial dimensions of CVD in
SLE populations remain poorly understood. The objective of this study was
to systematically investigate the existing literature around known social
factors influencing the development of CVD in SLE. Methods A scoping
review protocol was developed according to Preferred Reporting Items for
Systematic Reviews and Meta-Analyses extension for Scoping reviews
guidelines. The search strategy encompassed three main concepts: SLE, CVD
and social factors. Four databases were searched (PubMed, SCOPUS,
PsychINFO and CINAHL). 682 studies were identified for screening. Articles
were screened in two phases (title/abstract and full text) to determine
whether they fulfilled the selection criteria. Results Nine studies were
included after screening. All were conducted in the USA between 2009 and
2017. Six studies (67%) were cross-sectional and three (33%) were
longitudinal. Most employed SLE cohorts (n=7, 78%) and two drew from
healthcare databases (n=2; 22%). We identified five main themes
encompassing social factors: socioeconomic status and education (n=5;
56%), race and/or ethnicity (n=7; 78%), mental health (n=2; 22%), gender
(n=3; 33%) and healthcare quality and/or insurance (n=2; 22%). Overall,
low income, fewer years of education, black race and/or ethnicity,
depression, male gender, lack of insurance and healthcare fragmentation
were all associated with CVD risk factors and outcomes in SLE. Conclusions
While several social factors contribute to CVD in SLE populations,
considerable gaps remain as many social determinants remain
un(der)explored. There is rich opportunity to integrate social theory,
advance conceptualisations of race and/or ethnicity and gender, expand
investigations of mental health and explore novel geographical contexts.
In healthcare policy and practice, identified social factors should be
considered for SLE populations during decision-making and treatment, and
education resources should be targeted for these groups.<br/>Copyright
&#xa9; Author(s) (or their employer(s)) 2024.

<54>
Accession Number
2033552589
Title
Comparing clinical and echocardiographic outcomes following valve-sparing
versus transannular patch repair of tetralogy of Fallot: a systematic
review and meta-analysis.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 39(1) (no
pagination), 2024. Article Number: ivae124. Date of Publication: 01 Jul
2024.
Author
Martins R.S.; Fatimi A.S.; Mahmud O.; Qureshi S.; Nasim M.T.; Virani S.S.;
Tameezuddin A.; Yasin F.; Malik M.A.
Institution
(Martins) Division of Thoracic Surgery, Department of Surgery, Hackensack
Meridian School of Medicine, Hackensack Meridian Health Network, Edison,
NJ, United States
(Fatimi, Mahmud, Qureshi, Nasim, Yasin) Medical College, Aga Khan
University, Karachi, Pakistan
(Virani) Department of Surgery, Aga Khan University, Karachi, Pakistan
(Tameezuddin) Medical College, Ziauddin University, Karachi, Pakistan
(Malik) Department of Cardiac Surgery, Rawalpindi Institute of Cardiology,
Rawalpindi, Pakistan
Publisher
Oxford University Press
Abstract
OBJECTIVES: Transannular patch (TAP) repair of tetralogy of Fallot
(ToF)relieves right ventricular tract obstruction but may lead to
pulmonary regurgitation. Valve-sparing (VS) procedures can avoid this
situation, but there is a potential for residual pulmonary stenosis. Our
goal was to evaluate clinical and echocardiographic outcomes of TAP and VS
repair for ToF. <br/>METHOD(S): A systematic search of the PubMed, Embase,
Scopus, Cochrane Central Register of Controlled Trials and Web of Science
databases was carried out to identify articles comparing conventional TAP
repair and VS repair for ToF. Random-effects models were used to perform
meta-analyses of the clinical and echocardiographic outcomes.
<br/>RESULT(S): Forty studies were included in this meta-analysis with
data on 11 723 participants (TAP: 6171; VS: 5045). Participants who
underwent a VS procedure experienced a significantly lower cardiopulmonary
bypass time [mean difference (MD): -14.97; 95% confidence interval (CI):
-22.54, -7.41], shorter ventilation duration (MD: -15.33; 95% CI: -30.20,
-0.46) and shorter lengths of both intensive care unit (ICU) (MD: -0.67;
95% CI: -1.29, -0.06) and hospital stays (MD: -2.30; 95% CI: [-4.08,
-0.52). There was also a lower risk of mortality [risk ratio: 0.40; 95%
CI: (0.27, 0.60) and pulmonary regurgitation [risk ratio: 0.35; 95% CI:
(0.26, 0.46)] associated with the VS group. Most other clinical and
echocardiographic outcomes were comparable in the 2 groups.
<br/>CONCLUSION(S): This meta-analysis confirms the well-established
increased risk of pulmonary insufficiency following TAP repair while also
demonstrating that VS repairs are associated with several improved
clinical outcomes. Continued research can identify the criteria for
adopting a VS approach as opposed to a traditional TAP
repair.<br/>Copyright &#xa9; The Author(s) 2024.

<55>
Accession Number
2032755396
Title
Clinical decision aids and computed tomography coronary angiography in
patients with suspected acute coronary syndrome.
Source
Emergency Medicine Journal. 41(8) (pp 488-494), 2024. Date of Publication:
22 Jul 2024.
Author
Wang K.-L.; Taggart C.; McDermott M.; O'Brien R.; Oatey K.; Keating L.;
Storey R.F.; Felmeden D.; Curzen N.; Kardos A.; Roobottom C.; Smith J.;
Goodacre S.; Newby D.E.; Gray A.J.
Institution
(Wang, Taggart, McDermott, Newby) Centre for Cardiovascular Science,
University of Edinburgh, Edinburgh, United Kingdom
(Wang) School of Medicine, National Yang Ming Chiao Tung University,
Taipei, Taiwan (Republic of China)
(Wang) General Clinical Research Center, Taipei Veterans General Hospital,
Taipei, Taiwan (Republic of China)
(Taggart) Department of Cardiology, Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
(O'Brien, Gray) EMERGE (Emergency Medicine Research Group Edinburgh),
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
(Oatey) Edinburgh Clinical Trials Unit, University of Edinburgh,
Edinburgh, United Kingdom
(Keating) Department of Emergency Medicine, Royal Berkshire NHS Foundation
Trust, Reading, United Kingdom
(Storey) Division of Clinical Medicine, University of Sheffield,
Sheffield, United Kingdom
(Storey) NIHR Sheffield Biomedical Research Centre, Sheffield Teaching
Hospitals NHS Foundation Trust, Sheffield, United Kingdom
(Felmeden) Department of Cardiology, Torbay and South Devon NHS Foundation
Trust, Torquay, United Kingdom
(Curzen) Faculty of Medicine, University of Southampton, Southampton,
United Kingdom
(Curzen) Department of Cardiology, University Hospital Southampton NHS
Foundation Trust, Southampton, United Kingdom
(Kardos) TCRG (Translational Cardiovascular Research Group), Milton Keynes
University Hospital NHS Foundation Trust, Milton Keynes, United Kingdom
(Roobottom) Department of Radiology, University Hospitals Plymouth NHS
Trust, Plymouth, United Kingdom
(Smith) Emergency Department, University Hospitals Plymouth NHS Trust,
Plymouth, United Kingdom
(Goodacre) School of Health and Related Research, University of Sheffield,
Sheffield, United Kingdom
(Gray) Usher Institute, University of Edinburgh, Edinburgh, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Background The HEART score, the T-MACS model and the GRACE score support
early decision-making for acute chest pain, which could be complemented by
CT coronary angiography (CTCA). However, their performance has not been
directly compared. Methods In this secondary analysis of a multicentre
randomised controlled trial of early CTCA in intermediate-risk patients
with suspected acute coronary syndrome, C-statistics and performance
metrics (using the predefined cut-offs) of clinical decision aids and
CTCA, alone and then in combination, for the index hospital diagnosis of
acute coronary syndrome and for 30-day coronary revascularisation were
assessed in those who underwent CTCA and had complete data. Results Among
699 patients, 358 (51%) had an index hospital diagnosis of acute coronary
syndrome, for which the C-statistic was higher for CTCA (0.80), followed
by the T-MACS model (0.78), the HEART score (0.74) and the GRACE score
(0.60). The negative predictive value was higher for the absence of
coronary artery disease on CTCA (0.90) or a T-MACS estimate of <0.05
(0.83) than a HEART score of <4 (0.81) and a GRACE score of <109 (0.55).
For 30-day coronary revascularisation, CTCA had the greatest C-statistic
(0.80) with a negative predictive value of 0.96 and 0.92 in the absence of
coronary artery disease and obstructive coronary artery disease,
respectively. The combination of the T-MACS estimates and the CTCA
findings was most discriminative for the index hospital diagnosis of acute
coronary syndrome (C-statistic, 0.88) and predictive of 30-day coronary
revascularisation (C-statistic, 0.85). No patients with a T-MACS estimate
of <0.05 and normal coronary arteries had acute coronary syndrome during
index hospitalisation or underwent coronary revascularisation within 30
days. Conclusions In intermediate-risk patients with suspected acute
coronary syndrome, the T-MACS model combined with CTCA improved
discrimination of the index hospital diagnosis of acute coronary syndrome
and prediction of 30-day coronary revascularisation. Trial registration
number NCT02284191.<br/>Copyright &#xa9; Author(s) (or their employer(s))
2024. No commercial re-use. See rights and permissions. Published by BMJ.

<56>
Accession Number
2030776012
Title
Cancer therapy-related cardiac dysfunction and the role of cardiovascular
imaging: systemic review and opinion paper from the Working Group on
Cardio-Oncology of the Korean Society of Cardiology.
Source
Journal of Cardiovascular Imaging. 32(1) (no pagination), 2024. Article
Number: 13. Date of Publication: December 2024.
Author
Cho I.; You S.-C.; Cha M.-J.; Hwang H.-J.; Cho E.J.; Kim H.J.; Park S.-M.;
Kim S.-E.; Lee Y.-G.; Youn J.-C.; Park C.S.; Shim C.Y.; Chung W.-B.; Sohn
I.S.
Institution
(Cho, Shim) Division of Cardiology, Severance Cardiovascular Hospital,
Yonsei University College of Medicine, Seoul, South Korea
(You) Department of Biomedical Systems Informatics, Yonsei University
College of Medicine, Seoul, South Korea
(Cha) Department of Radiology, Chung-Ang University Hospital, Chung-Ang
University College of Medicine, Seoul, South Korea
(Hwang, Sohn) Department of Cardiology, Kyung Hee University Hospital at
Gangdong, Kyung Hee University College of Medicine, Seoul, South Korea
(Cho) Division of Cardiology, Department of Internal Medicine, Heart and
Brain Hospital, Chung-Ang University Gwangmyeong Hospital, Chung-Ang
University College of Medicine, Gwangmyeong, South Korea
(Kim) Division of Medical Oncology, Department of Internal Medicine,
Chung-Ang University Hospital, Seoul, South Korea
(Park) Division of Cardiology, Department of Internal Medicine, Korea
University College of Medicine, Seoul, South Korea
(Kim) Department of Cardiovascular Medicine, Kangdong Sacred Heart
Hospital, Seoul, South Korea
(Lee) Division of Hematology & amp; Medical Oncology, Department of
Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University
School of Medicine, Seoul, South Korea
(Youn) Division of Cardiology, Department of Internal Medicine, College of
Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea,
Seoul, South Korea
(Park, Chung) Division of Cardiology, Department of Internal Medicine,
College of Medicine, The Catholic University of Korea, Seoul, South Korea
Publisher
BioMed Central Ltd
Abstract
Cardio-oncology is a critical field due to the escalating significance of
cardiovascular toxicity as a side effect of anticancer treatments. Cancer
therapy-related cardiac dysfunction (CTRCD) is a prevalent condition
associated with cardiovascular toxicity, necessitating effective
strategies for prediction, monitoring, management, and tracking. This
comprehensive review examines the definition and risk stratification of
CTRCD, explores monitoring approaches during anticancer therapy, and
highlights specific cardiovascular toxicities linked to various cancer
treatments. These include anthracyclines, HER2-targeted agents, vascular
endothelial growth factor inhibitors, immune checkpoint inhibitors,
chimeric antigen receptor T-cell therapies, and tumor-infiltrating
lymphocytes therapies. Incorporating the Korean data, this review offers
insights into the regional nuances in managing CTRCD. Using systematic
follow-up incorporating cardiovascular imaging and biomarkers, a better
understanding and management of CTRCD can be achieved, optimizing the
cardiovascular health of both cancer patients and survivors.<br/>Copyright
&#xa9; The Author(s) 2024.

<57>
Accession Number
2030797634
Title
Thoracic endovascular aortic repair completion following frozen elephant
trunk: how it's done and device selection.
Source
Expert Review of Medical Devices. (no pagination), 2024. Date of
Publication: 2024.
Author
Capitain A.N.; Rylski B.; Berger T.; Kondov S.; Discher P.; Walter T.;
Batinkov N.; Bork M.; D'Inka M.; Czerny M.; Kreibich M.
Institution
(Capitain, Rylski, Berger, Kondov, Discher, Walter, Batinkov, Bork,
D'Inka, Czerny, Kreibich) Department of Cardiovascular Surgery, Heart
Centre Freiburg University, Freiburg, Germany
(Capitain, Rylski, Berger, Kondov, Discher, Walter, Batinkov, Bork,
D'Inka, Czerny, Kreibich) Faculty of Medicine, University of Freiburg,
Freiburg, Germany
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Since its introduction in the mid-1990s the frozen elephant
trunk (FET) technique has quickly evolved into an effective hybrid
treatment option for patients with various thoracic aortic pathologies,
acute and chronic. However, a notable incidence of and risk for distal
aortic reinterventions persists after the implementation of the FET
device. In this review, the authors analyze the indications and outcomes
of thoracic endovascular aortic repair completion following FET. Areas
covered: For this review, we looked not only at our own data but also
searched PubMed for relevant studies, comments, and current
recommendations of the European Association for Cardio-Thoracic Surgery
(EACTS) and the European Society for Vascular Surgery (ESVS).
Additionally, we outline our approach in this 2-stage-treatment plan.
Expert opinion: The treatment of acute or chronic aortic pathologies
involving the aortic arch frequently requires a 2-stage treatment
approach. Sometimes, a tertiary procedure is needed to fix the entire
aortic pathology. Thoracic endovascular aortic repair completion following
FET requires careful planning to achieve the excellent clinical outcomes
that we and numerous other aortic centers have shown. Only a dedicated
aortic clinic provides the long-term continuous follow-up required to
identify the few patients in need of a tertiary procedure.<br/>Copyright
&#xa9; 2024 The Author(s). Published by Informa UK Limited, trading as
Taylor & Francis Group.

<58>
Accession Number
2030785190
Title
State-of-the-art percutaneous coronary intervention for left main coronary
artery disease in Japan.
Source
Cardiovascular Intervention and Therapeutics. (no pagination), 2024. Date
of Publication: 2024.
Author
Warisawa T.; Sonoda S.; Yamaji K.; Amano T.; Kohsaka S.; Natsuaki M.;
Tsujita K.; Hibi K.; Kobayashi Y.; Kozuma K.
Institution
(Warisawa) Department of Cardiology, NTT Medical Center Tokyo, Tokyo,
Japan
(Sonoda, Natsuaki) Department of Cardiovascular Medicine, Saga University,
5-1-1, Nabeshima, Saga 849-8501, Japan
(Yamaji) Department of Cardiovascular Medicine, Kyoto University Graduate
School of Medicine, Kyoto, Japan
(Amano) Department of Cardiology, Aichi Medical University, Aichi, Japan
(Kohsaka) Department of Cardiology, Keio University School of Medicine,
Tokyo, Japan
(Tsujita) Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University, Kumamoto, Japan
(Hibi) Department of Cardiology, Yokohama City University Graduate School
of Medicine, Yokohama, Japan
(Kobayashi) Department of Cardiovascular Medicine, Chiba University
Graduate School of Medicine, Chiba, Japan
(Kozuma) Department of Cardiology, Teikyo University Hospital, Tokyo,
Japan
Publisher
Springer
Abstract
Percutaneous coronary intervention for left main coronary artery disease
(LM-PCI) represents a high-risk yet life-saving procedure that has evolved
significantly over the years. This review outlines the current
state-of-the-art practices for LM-PCI in Japan in detail, emphasizing the
integration of coronary physiology and intracoronary imaging alongside
with evidence-based standardized technique using latest drug-eluting
stents. These advancements enable precise lesion assessment, stent sizing,
and optimal deployment, thereby enhancing procedural safety and efficacy.
Despite discrepancies between current guidelines favoring coronary artery
bypass grafting and real-world practice trends towards increased LM-PCI
adoption, particularly in elderly populations with multiple comorbidities,
careful patient selection and procedural planning are critical. Future
perspectives include further refining LM-PCI through conducting randomized
controlled trials integrating advanced techniques and addressing the issue
of ostial left circumflex lesions and nationwide standardization of
medical care for LM disease. Graphical abstract: (Figure
presented.)<br/>Copyright &#xa9; The Author(s) under exclusive licence to
Japanese Association of Cardiovascular Intervention and Therapeutics 2024.

<59>
Accession Number
2030746677
Title
Ultrasound-Guided Versus Palpation-Guided Techniques to Achieve Vascular
Access in Children Undergoing Cardiac Surgery: A Systematic Review and
Meta-analysis of Randomized Controlled Trials.
Source
Pediatric Cardiology. (no pagination), 2024. Date of Publication: 2024.
Author
Ibrahim A.A.; Allam A.R.; Amin A.M.; Rakab M.S.; Alhadeethi A.; Hageen
A.W.; Mahmoud A.; Abuelazm M.; Abdelazeem B.
Institution
(Ibrahim, Allam) Faculty of Medicine, Menoufia University, Menoufia, Egypt
(Amin, Rakab) Faculty of Medicine, Mansoura University, Mansoura, Egypt
(Alhadeethi) Department of General Medicine, Al-Salam Teaching Hospital,
Ninevah, Iraq
(Hageen, Abuelazm) Faculty of Medicine, Tanta University, Tanta, Egypt
(Mahmoud) Faculty of Medicine, Minia University, Minia, Egypt
(Abdelazeem) Department of Cardiology, West Virginia University,
Morgantown, WV, United States
Publisher
Springer
Abstract
Pediatric heart surgery is a vital therapeutic option for congenital heart
disease, which is one of the most prevalent causes of death in children.
Arterial cannulation (AC) and central venous catheter (CVC) are required
in pediatric cardiac surgery for continuous monitoring of the central
venous pressure (CVP), replacement of fluid or blood products, close
hemodynamic monitoring, and frequent sampling for arterial blood gases
(ABG). A systematic review and meta-analysis synthesizing evidence from
randomized controlled trials (RCTs) retrieved from PubMed, Embase
Cochrane, Scopus, and WOS until February 2024. Risk ratio (RR) was used to
report dichotomous outcomes, and mean difference (MD) was used to report
continuous outcomes, both with a 95% confidence interval (CI) using the
random-effects model. Thirteen RCTs with 1060 children were included.
Regarding arterial cannulation, the ultrasound-guided technique (US) was
associated with a statistically significant increase in successful
cannulation [RR: 1.31 with 95% CI (1.10, 1.56), P < 0.0001], and
first-attempt success [RR: 1.88 with 95% CI (1.35, 2.63), P < 0.0001].
However, US was not associated with any statistically significant
difference in venous cannulation in both outcomes with [RR: 1.13 with 95%
CI (0.98, 1.30), P = 0.10], [RR: 1.53 with 95% CI (0.86, 2.71), P = 0.15]
respectively. Moreover, US was associated with a statistically significant
decrease in the number of attempts either in arterial cannulation with
[MD: - 0.73 with 95% CI (- 1.00, - 0.46), P < 0.0001] or in venous
cannulation with [MD: - 1.34 with 95% CI (- 2.55, - 0.12), P = 0.03], and
the time of attempted cannulation also either in arterial cannulation with
[MD: - 2.27 with 95% CI (- 3.38, - 1.16), P < 0.0001] or in venous
cannulation with [MD: - 4.13 with 95% CI (- 7.06, - 1.19), P < 0.0001]. US
guidance improves successful cannulation rates and first-attempt success
in arterial access and reduces the number of attempts and procedural time
for arterial and venous access. It was also associated with a lower
incidence of complications and procedure failure, particularly in arterial
access. However, it was associated with a higher incidence of venous
puncture.<br/>Copyright &#xa9; The Author(s) 2024.

<60>
Accession Number
644874319
Title
Association of Amiodarone Use Prior to Orthotopic Heart Transplant with
Post-Transplant Graft Dysfunction and All-Cause Mortality: A Systematic
Review and Meta-Analysis.
Source
Journal of cardiac failure. (no pagination), 2024. Date of Publication:
27 Jul 2024.
Author
Ko E.; Ahmed M.; Nudy M.; Bussa R.; Bussa J.; Gonzalez M.; Naccarelli G.;
Soleimani B.; Maheshwari A.
Institution
(Ko, Bussa) Penn State Hershey Medical Center, Department of Internal
Medicine
(Ahmed, Gonzalez, Naccarelli, Soleimani, Maheshwari) Penn State Hershey
Medical Center, Heart and Vascular Institute, Division of Cardiology
(Nudy) Penn State Hershey Medical Center, Heart and Vascular Institute,
Division of Cardiology; Penn State Hershey Medical Center, Department of
Public Health Sciences
(Bussa) University of Massachusetts Amherst, Department of Biochemistry
and Molecular Biology

<61>
Accession Number
2033556160
Title
Enhanced Postoperative Pain Management and Mobility Following Arthroscopic
Knee Surgery: A Comparative Study of Adductor Canal Block with and without
IPACK Block.
Source
Medical Science Monitor. 30 (no pagination), 2024. Article Number:
e943735. Date of Publication: 2024.
Author
Zeng J.; Yang X.; Lei H.; Zhong X.; Lu X.; Liu X.; Peng X.
Institution
(Zeng, Lu, Liu) Department of Anesthesiology, Guangdong Provincial Key
Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical
Research Center for Obstetrics and Gynecology, The Third Affiliated
Hospital of Guangzhou Medical University, Guangdong, Guangzhou, China
(Zeng, Yang, Lei, Zhong, Peng) Department of Anesthesiology, Longgang
District Central Hospital of Shenzhen, Guangdong, Shenzhen, China
Publisher
International Scientific Information, Inc.
Abstract
Background: Arthroscopic knee surgery (AKS) is minimally invasive,
reducing hospital stay compared to traditional surgery, but postoperative
pain remains a significant issue. This study compared the analgesic and
functional outcomes following AKS following anesthesia using adductor
canal block (ACB) with and without anesthesia using the interspace between
the popliteal artery and posterior capsule of the knee (IPACK) block under
spinal anesthesia (SA). Material/Methods: We randomly allocated 120
patients into 3 groups: IPACK+ACB+SA for Group A (n=40), ACB+SA for Group
B (n=40), and SA for Group C (n=40). The outcome was the visual analog
scale (VAS) score evaluated at rest and during activity at 3 h, 6 h, 12 h,
24 h, and 48 h postoperatively, the frequency of administration of
postoperative rescue analgesic, and the maximal walking distance at 24 h
and 48 h postoperatively. <br/>Result(s): Compared with Group C, the VAS
scores in Group A were significantly lower at 48 h postoperatively
(P<0.05). There was a significant difference in the frequency of
postoperative rescue analgesia use among the 3 groups (P=0.001). In a
subgroup analysis of meniscus shaping under arthroscopy, the resting VAS
score in Group A was lower than that in Group B and Group C at 48 h
postoperatively (P<0.05). The maximum walking distance of Group A was
longer than that of Group B and Group C at 24 h and 48 h postoperatively
(P<0.01). <br/>Conclusion(s): The effect of postoperative analgesia in the
group receiving IPACK combined with ACB after AKS was obviously superior.
In arthroscopic meniscus repair surgery, the duration of analgesia was
longer, and the maximum walking distance at 48 h postoperatively was
longer.<br/>Copyright &#xa9; Med Sci Monit, 2024.

<62>
Accession Number
2033503373
Title
Comparative Outcomes of Surgical and Transcatheter Aortic Valve
Replacement: A Meta-analysis and Parametric Extrapolation of Clinical
Trials.
Source
Journal of Surgical Research. 302 (pp 1-11), 2024. Date of Publication:
October 2024.
Author
Ahmad D.; Dawes A.; Im M.; Vishnevsky A.; Ruggiero N.J.; Plestis K.A.;
Massey H.T.; Morris R.J.; Entwistle J.W.; Tchantchaleishvili V.
Institution
(Ahmad, Dawes, Im, Plestis, Massey, Morris, Entwistle, Tchantchaleishvili)
Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson
University, Philadelphia, Pennsylvania, United States
(Ahmad) Department of Cardiothoracic Surgery, University of Pittsburgh,
Pittsburgh, PA, United States
(Vishnevsky, Ruggiero) Division of Cardiology, Department of Medicine,
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Publisher
Academic Press Inc.
Abstract
Introduction: We aimed to pool randomized clinical trials (RCTs) comparing
surgical aortic valve replacement (SAVR) with transcatheter aortic valve
replacement (TAVR) and extrapolate pooled time-to-event data to compare
long-term outcomes. <br/>Method(s): An electronic database search was
performed for RCTs comparing SAVR with TAVR. The most current longest
follow-up data for each RCT were included. Data were pooled using a
random-effects model. Survival data were pooled for Kaplan-Meier analysis
as well as parametric modeling with extrapolation. <br/>Result(s): Seven
RCTs comprising 7774 patients were included. Mean valve gradient at 5 y
was comparable between SAVR [11 mmHg (3.7; 18.3)] and TAVR [8.1 mmHg (1.9;
14.3)] (P = 0.38). TAVR had a higher mean valve area at 30 d, 1 y, and 2 y
[1.68 cm² (1.22; 2.13) versus 1.8 cm² (1.35; 2.25),
P = 0.02]. SAVR had a higher freedom from any paravalvular leak at 30 d
and 1 y [86% (81; 90) versus 39% (36; 41), P < 0.01]. All-cause death was
lower in the SAVR group at 5 y [39% (29; 50) versus 43% (31; 57), P <
0.01]. Although no differences were seen between SAVR and TAVR in the
pooled Kaplan-Meier analysis of all-cause mortality and composite of
all-cause mortality or stroke, parametric modeling with extrapolation
showed significant divergence for both outcomes. <br/>Conclusion(s):
Pooled all-cause mortality as well as pooled composite of all-cause
mortality or stroke indicated better survival with SAVR at 5 y. Long-term
parametric extrapolation also indicated superior survival with
SAVR.<br/>Copyright &#xa9; 2024 Elsevier Inc.

<63>
Accession Number
2032384438
Title
Comprehensive analysis of donor-site chest deformities after autologous
costal cartilage microtia reconstruction: A systematic review.
Source
Journal of Plastic, Reconstructive and Aesthetic Surgery. 94 (pp 128-140),
2024. Date of Publication: July 2024.
Author
Kim J.; Park C.; Oh K.S.; Lim S.Y.
Institution
(Kim, Park, Lim) Department of Plastic Surgery, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, South Korea
(Oh) Department of Plastic surgery, Kangbuk Samsung Hospital, Sungkyunkwan
University School of Medicine, Seoul, South Korea
Publisher
Churchill Livingstone
Abstract
Background: Autologous costal cartilage has gained widespread acceptance
as an important material for ear reconstruction in patients with microtia.
Despite its recognition as being "worth the trade-off," attention should
be directed toward donor-site deformities. This systematic review focused
on existing English literature related to microtia reconstruction and
aimed to reveal the incidence of chest wall deformities and assess the
effectiveness of the various proposed surgical techniques aimed at
reducing donor-site morbidities. <br/>Method(s): A comprehensive search
was conducted on Pubmed and OVID using the keywords "microtia," and "chest
deformity" or "rib harvest." Articles were screened based on predefined
inclusion and exclusion criteria. Data acquisition encompassed patient
demographics, employed surgical techniques, methods for evaluating chest
deformity, and incidence of associated complications. <br/>Result(s):
Among the 362 identified articles, 21 met the inclusion criteria. A total
of 2600 cases involving 2433 patients with microtia were analyzed in this
review. Perichondrium preservation during cartilage harvesting led to a
significant reduction in chest deformities. However, the wide incidence
range (0% to 50%) and the lack of specific assessment methods suggested
potential underestimation. Computed tomography revealed reduced chest wall
growth in the transverse and sagittal directions, resulting in decreased
thoracic area. Innovative surgical techniques have shown promising results
in reducing chest deformities. <br/>Conclusion(s): Although a quantitative
analysis was not feasible, objective evidence of deformities was
established through computed tomography scans. This analysis highlighted
the need for dedicated studies with larger sample sizes to further advance
our understanding of chest wall deformities in microtia
reconstruction.<br/>Copyright &#xa9; 2024

<64>
Accession Number
2030741664
Title
Comparative effectiveness of ultrathin vs. standard strut drug-eluting
stents: insights from a large-scale meta-analysis with extended follow-up.
Source
European Journal of Medical Research. 29(1) (no pagination), 2024. Article
Number: 388. Date of Publication: December 2024.
Author
Hassan A.; Amin A.M.; Gadelmawla A.F.; Mansour A.; Mostafa H.A.; Desouki
M.T.; Naguib M.M.; Ali B.; Siraj A.; Suppah M.; Hakim D.
Institution
(Hassan) Faculty of Medicine, October 6 University, Giza, Egypt
(Hassan) Department of Cardiology, Suez Medical Complex, Ministry of
Health and Population, Suez, Egypt
(Amin) Faculty of Medicine, Mansoura University, Mansoura, Egypt
(Gadelmawla) Faculty of Medicine, Menoufia University, Menoufia, Egypt
(Mansour) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
(Mostafa, Naguib) Faculty of Medicine, Al-Azhar University, Damietta,
Egypt
(Desouki) Faculty of Medicine, Alexandria University, Alexandria, Egypt
(Ali) University Hospitals Cleveland Medical Center, Case Western Reserve
University, Cleveland, OH, United States
(Siraj) MetroHealth Medical Center, Case Western Reserve University,
Cleveland Heights, OH, United States
(Suppah) Department of Cardiovascular Medicine, Mayo Clinic, AZ, United
States
(Hakim) Department of Cardiology, Faculty of Medicine, Suez Canal
University, Ismailia, Egypt
Publisher
BioMed Central Ltd
Abstract
Background: Newer generation ultrathin strut stents are associated with
less incidence of target lesion failure (TLF) in patients undergoing
percutaneous coronary intervention (PCI) in the short term. However, its
long-term effect on different cardiovascular outcomes remains unknown.
<br/>Objective(s): We aim to identify the effects of newer-generation
ultrathin-strut stents vs. standard thickness second-generation
drug-eluting stents (DES) on long-term outcomes of revascularization in
coronary artery disease. <br/>Method(s): We searched PubMed, Web of
Science, Cochrane Library databases, and Scopus for randomized controlled
trials (RCTs) and registries that compare newer-generation ultrathin-strut
(< 70 mm) with thicker strut (> 70 mm) DES to evaluate cardioprotective
effects over a period of up to 5 years. Primary outcome was TLF, a
composite of cardiac death, target vessel myocardial infarction (TVMI) or
target lesion revascularization (TLR). Secondary outcomes included the
components of TLF, stent thrombosis (ST), and all-cause death were pooled
as the standardized mean difference between the two groups from baseline
to endpoint. <br/>Result(s): We included 19 RCTs and two prospective
registries (103,101 patients) in this analysis. The overall effect on the
primary outcome was in favor of second-generation ultrathin struts stents
in terms of TLF at >= 1 year, >= 2 years, and >= 3 years (P value = 0.01,
95% CI [0.75, 0.96]), P value = 0.003, 95% CI [0.77, 0.95]), P value =
0.007, 95% CI [0.76, 0.96]), respectively. However, there was no reported
benefit in terms of TLF when we compared the two groups at >= 5 years (P
value = 0.21), 95% CI [0.85, 1.04]). Some of the reported components of
the primary and secondary outcomes, such as TLR, target vessel
revascularization (TVR), and TVMI, showed the same pattern as the TLF
outcome. <br/>Conclusion(s): Ultrathin-strut DES showed a beneficial
effect over thicker strut stents for up to 3 years. However, at the 5-year
follow-up, the ultrathin strut did not differ in terms of TLF, TLR, TVR,
and TVMI compared with standard-thickness DES, with similar risks of
patient-oriented composite endpoint (POCE), MI, ST, cardiac death, and
all-cause mortality.<br/>Copyright &#xa9; The Author(s) 2024.

<65>
Accession Number
2033590893
Title
Prognostic relevance of pre-procedural plasma volume status estimation in
patients undergoing transcatheter aortic valve implantation: A
meta-analysis.
Source
Current Problems in Cardiology. 49(10) (no pagination), 2024. Article
Number: 102749. Date of Publication: October 2024.
Author
Papazoglou A.S.; Moysidis D.V.; Anastasiou V.; Daios S.; Kamperidis V.;
Ziakas A.; Giannakoulas G.
Institution
(Papazoglou) Athens Naval Hospital, Athens, Greece
(Moysidis) 424 Military General Hospital of Thessaloniki, Thessaloniki,
Greece
(Anastasiou, Daios, Kamperidis, Ziakas, Giannakoulas) First Department of
Cardiology, AHEPA University Hospital of Thessaloniki, Thessaloniki,
Greece
Publisher
Elsevier Inc.
Abstract
Background: To systematically evaluate the prognostic utility of estimated
plasma volume status (ePVS) on the outcomes of patients undergoing
transcatheter aortic valve implantation (TAVI). <br/>Method(s): The
exposure variable of interest was the ePVS, enumerating the percentage
change of the actual plasma volume from the ideal plasma volume, and being
calculated on the basis of weight and hematocrit using sex-specific
constants. A random-effects meta-analysis was performed after a systematic
literature search in PubMed, Scopus and Web Of Science. <br/>Result(s):
The systematic literature search yielded 5 eligible observational cohort
studies encompassing a total of 7,121 patients undergoing TAVI. The
meta-analysis suggested that "high ePVS" status was independently
associated with increased risk for 1-year all-cause mortality (pooled
adjusted hazard ratio: 1.63, 95 % confidence intervals: 1.36-1.95)
compared to "low ePVS". Also, the pooled unadjusted odds for 1-year
mortality, 30-day mortality, peri-procedural stroke, major bleeding, and
acute kidney injury were significantly increased in the "high ePVS" group
of patients. Conversely, the unadjusted risk of pacemaker implantation and
major vascular complications did not differ significantly between the 2
groups. <br/>Conclusion(s): Plasma volume expansion appears to be linked
with a worse peri-procedural and long-term prognostic course in TAVI. Its
use in clinical practice could refine risk stratification and candidate
selection practices.<br/>Copyright &#xa9; 2024

<66>
Accession Number
2030695408
Title
Diagnostic and prognostic value of the HFA-PEFF score for heart failure
with preserved ejection fraction: a systematic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 11 (no pagination), 2024. Article
Number: 1389813. Date of Publication: 2024.
Author
Li X.; Liang Y.; Lin X.
Institution
(Li, Liang, Lin) Department of Geriatrics, The Second Clinical College of
Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of
Chinese Medicine, Guangdong, Guangzhou, China
Publisher
Frontiers Media SA
Abstract
Aim: To assess the diagnostic and prognostic performances of the Heart
Failure Association Pre-test Assessment, Echocardiography & Natriuretic
Peptide, Functional Testing, Final Etiology (HFA-PEFF) score for heart
failure with preserved ejection fraction (HFpEF) in a comprehensive
manner. <br/>Method(s): PubMed, Embase, Cochrane Library, and Web of
Science were comprehensively searched from the inception to June 12, 2023.
Studies using the "Rule-out" or "Rule-in" approach for diagnosis analysis
or studies on cardiovascular events and all-cause death for prognosis
analysis were included. The Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) tool was adopted to assess the quality of diagnostic
accuracy studies. The sensitivity (SEN), specificity (SPE), positive
likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds
ratio (DOR), and area under the summary receiver operating characteristic
(SROC) curve (AUC) were presented with 95% confidence intervals (CIs). For
CVEs and all-cause death, the hazard ratio (HR) values were calculated.
<br/>Result(s): Fifteen studies involving 6420 subjects were included,
with 9 for diagnosis analysis, and 7 for prognosis analysis. For the
diagnostic performance of the HFA-PEFF score, with the "Rule-out"
approach, the pooled SEN was 0.96 (95%CI: 0.94, 0.97), the pooled SPE was
0.39 (95%CI: 0.37, 0.42), and the pooled AUC was 0.85 (95%CI: 0.67, 1.00),
and with the "Rule-in" approach, the pooled SEN was 0.59 (95%CI: 0.56,
0.61), the pooled SPE was 0.86 (95%CI: 0.84, 0.88), and the pooled AUC was
0.83 (95%CI: 0.79, 0.87). For the predictive performance of the HFA-PEFF
score, regarding CVEs, the pooled SEN was 0.63 (95%CI: 0.58, 0.67), the
pooled SPE was 0.53 (95%CI: 0.49, 0.58), and the pooled AUC was 0.65
(95%CI: 0.40, 0.90), and concerning All-cause death, the pooled SEN was
0.85 (95%CI: 0.81, 0.88), the pooled SPE was 0.48 (95%CI: 0.44, 0.52), and
the pooled AUC was 0.65 (95%CI: 0.47, 0.83). A higher HFA-PEFF score was
associated with a higher risk of all-cause death (HR 1.390, 95%CI 1.240,
1.558, P < 0.001). <br/>Conclusion(s): The HFA-PEFF score might be applied
in HFpEF diagnosis and all-cause death prediction. More studies are
required for finding validation.<br/>Copyright 2024 Li, Liang and Lin.

<67>
Accession Number
2030542820
Title
Ischemic Stroke: From Fibrinolysis to Functional Recovery.
Source
Neuroscience. 550 (pp 1-2), 2024. Date of Publication: 09 Jul 2024.
Author
Ali C.; Vivien D.
Institution
(Ali, Vivien) Normandie Univ, UNICAEN, INSERM, INSERM UMR-S U1237,
Physiopathology and Imaging of Neurological Disorders, Institut Blood and
Brain @ Caen-Normandie, Cyceron, Caen 14000, France
(Vivien) Centre Hospitalier Universitaire Caen, Department of Clinical
Research, Caen, France
Publisher
Elsevier Ltd

<68>
Accession Number
2033538360
Title
Standard versus High Cardiopulmonary Bypass Flow Rate: A Randomized
Controlled Subtrial Comparing Brain Injury Biomarker Release.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Keiller A.C.; Axelsson M.; Bragadottir G.; Lannemyr L.; Wijk J.; Blennow
K.; Zetterberg H.; Bagge R.O.
Institution
(Keiller) Department of Perfusion, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Keiller) Department of Surgery, Institute of Clinical Sciences,
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
(Keiller, Bagge) Wallenberg Centre for Molecular and Translational
Medicine, University of Gothenburg, Gothenburg, Sweden
(Axelsson) Department of Clinical Neuroscience, Institute of Neuroscience
and Physiology at Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden
(Bragadottir, Lannemyr, Wijk) Department of Cardiothoracic Anesthesia and
Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden
(Lannemyr, Wijk) Department of Anesthesiology and Intensive Care Medicine,
Sahlgrenska Academy, University of Gothenburg, Sweden
(Blennow, Zetterberg) Department of Psychiatry and Neurochemistry,
Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the
University of Gothenburg, Molndal, Sweden
(Blennow, Zetterberg) Clinical Neurochemistry Laboratory, Sahlgrenska
University Hospital, Molndal, Sweden
(Blennow) Paris Brain Institute, ICM, Pitie-Salpetriere Hospital, Sorbonne
University, Paris, France
(Blennow) Neurodegenerative Disorder Research Center, Division of Life
Sciences and Medicine, and Department of Neurology, Institute on Aging and
Brain Disorders, University of Science and Technology of China and First
Affiliated Hospital of USTC, Hefei, China
(Zetterberg) Department of Neurodegenerative Disease, UCL Institute of
Neurology, Queen Square, London, United Kingdom
(Zetterberg) UK Dementia Research Institute at UCL, London, United Kingdom
(Zetterberg) Hong Kong Center for Neurodegenerative Diseases, Hong Kong,
Clear Water Bay, China
(Zetterberg) Wisconsin Alzheimer's Disease Research Center, University of
Wisconsin School of Medicine and Public Health, University of
Wisconsin-Madison, Madison, WI, United States
(Bagge) Department of Surgery, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Bagge) Sahlgrenska Center for Cancer Research, Department of Surgery,
Institute of Clinical Sciences, Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden
Publisher
W.B. Saunders
Abstract
Objectives: To compare brain injury biomarker release levels between two
different cardiopulmonary bypass (CPB) flow rates in elective cardiac
surgery and to explore differences in postoperative delirium between
groups and associations between age, sex, CPB time, oxygen levels, and
near-infrared spectroscopy, and biomarker levels. <br/>Design(s): A
randomized controlled substudy trial Setting: Sahlgrenska University
Hospital, Sweden Participants: Forty patients undergoing elective cardiac
surgery with CPB Intervention: Patients were assigned at random to either
a standard (2.4 L/min/m²) or a high (2.9 L/min/m²)
CPB flow rate. <br/>Measurements and Main Results: Glial fibrillary acidic
protein, neurofilament light chain, total-tau, and phosphorylated-tau217
were sampled in plasma before anesthesia induction, after 60 minutes on
CPB, and at 30 minutes, 24 hours, and 72 hours post-CPB. Mixed models for
repeated measures were used to analyze differences in biomarker levels
between groups and to assess relationships, which showed no differences
between the 2 flow rate groups. There also was no difference in the
occurrence of delirium between the 2 groups. Associations were found
between age and increased neurofilament light chain levels. Female sex,
oxygen delivery >330 mL/min/m², and near-infrared spectroscopy
level >60% were associated with lower biomarker levels.
<br/>Conclusion(s): An increased flow rate did not have any significant
effects on biomarker levels compared to a standard flow rate. Several
associations were identified between treatment characteristics and
biomarker levels. No difference in delirium was seen.<br/>Copyright &#xa9;
2024 The Author(s)

<69>
Accession Number
2033483399
Title
Infective endocarditis.
Source
The Lancet. 404(10450) (pp 377-392), 2024. Date of Publication: 27 Jul
2024.
Author
Li M.; Kim J.B.; Sastry B.K.S.; Chen M.
Institution
(Li, Chen) Division of Cardiology, the First Affiliated Hospital of
Nanjing Medical University, Nanjing, Jiangsu, China
(Kim) Department of Thoracic and Cardiovascular Surgery, Aortic Center,
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South
Korea
(Sastry) Department of Cardiology, Renova Century Hospital, Telangana,
Hyderabad, India
Publisher
Elsevier B.V.
Abstract
First described more than 350 years ago, infective endocarditis represents
a global health concern characterised by infections affecting the native
or prosthetic heart valves, the mural endocardium, a septal defect, or an
indwelling cardiac device. Over recent decades, shifts in causation and
epidemiology have been observed. Echocardiography remains pivotal in the
diagnosis of infective endocarditis, with alternative imaging modalities
gaining significance. Multidisciplinary management requiring expertise of
cardiologists, cardiovascular surgeons, infectious disease specialists,
microbiologists, radiologists and neurologists, is imperative. Current
recommendations for clinical management often rely on observational
studies, given the limited number of well conducted randomised controlled
trials studying infective endocarditis due to the rarity of the disease.
In this Seminar, we provide a comprehensive overview of optimal clinical
practices in infective endocarditis, highlighting key aspects of
pathophysiology, pathogens, diagnosis, management, prevention, and
multidisciplinary approaches, providing updates on recent research
findings and addressing remaining controversies in diagnostic accuracy,
prevention strategies, and optimal treatment.<br/>Copyright &#xa9; 2024
Elsevier Ltd

<70>
Accession Number
2030781274
Title
Paediatric postoperative acute kidney injury after non-cardiac surgery:
Protocol for a systematic review and meta-analysis.
Source
Acta Anaesthesiologica Scandinavica. (no pagination), 2024. Date of
Publication: 2024.
Author
Emami A.; Sivertsson E.; Westerbergh J.; Hultstrom M.; Danielsson J.;
Frykholm P.; Frithiof R.
Institution
(Emami, Sivertsson, Hultstrom, Frykholm, Frithiof) Anesthesiology and
Intensive Care, Department of Surgical Sciences, Uppsala University,
Uppsala, Sweden
(Westerbergh) Uppsala Clinical Research Center, Uppsala University,
Uppsala, Sweden
(Hultstrom) Department of Medical Cell Biology, Integrative Physiology,
Uppsala University, Uppsala, Sweden
(Danielsson) Department of Women's and Children's Health, Uppsala
University, Uppsala, Sweden
Publisher
John Wiley and Sons Inc
Abstract
Background: Paediatric acute kidney injury (AKI) is associated with
significant adverse outcomes such as increased mortality, progression to
chronic kidney disease and longer length of stay in hospital.
Postoperative AKI is a common and recognized complication after surgery in
adults. In the paediatric population, AKI postoperatively to cardiac
surgery has been extensively studied. However, the incidence of
postoperative AKI after non-cardiac surgery is less clear. Therefore, we
aim to assess the available literature on this topic. <br/>Method(s): We
will conduct a systematic review of observational and randomized
controlled trials assessing the incidence of paediatric postoperative AKI
after non-cardiac surgery. Pairs of reviewers will independently screen
the literature and extract data and assess risk of bias from eligible
studies. The databases Pubmed, Cochrane and Web of Sciences will be
searched. We will conduct the review in accordance with the Preferred
Reporting Items for Systematic Review and Meta-Analysis (PRISMA)
guidelines and the Grading of Recommendation, Assessment, Development and
Evaluation (GRADE) approach. If sufficient homogeneity within the included
trials we will conduct meta-analyses. <br/>Discussion(s): This systematic
review aims to investigate the incidence of postoperative AKI in the
paediatric non-cardiac surgery population. The results of this review will
provide a foundation for future research in the field of paediatric
postoperative AKI.<br/>Copyright &#xa9; 2024 The Author(s). Acta
Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on
behalf of Acta Anaesthesiologica Scandinavica Foundation.

<71>
Accession Number
644862063
Title
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-2 Trial:
Analysis of the Timing and Causes of Death in Participants Randomised to
an Infrapopliteal Vein Bypass or Best Endovascular Treatment First
Revascularisation Strategy.
Source
European journal of vascular and endovascular surgery : the official
journal of the European Society for Vascular Surgery. (no pagination),
2024. Date of Publication: 26 Jul 2024.
Author
Bradbury A.W.; Hall J.; Moakes C.A.; Popplewell M.; Meecham L.; Bate G.R.;
Kelly L.; Diamantopoulos A.; Ganeshan A.; Houlind K.; Malmstedt J.; Patel
J.V.; Saratzis A.; Zayed H.
Institution
(Bradbury, Popplewell) College of Medical and Dental Sciences, University
of Birmingham, Birmingham, United Kingdom
(Hall, Moakes) Birmingham Clinical Trials Unit, Institute of Applied
Health Research, University of Birmingham, Birmingham, United Kingdom
(Meecham) University Hospitals Birmingham NHS Foundation Trust,
Birmingham, United Kingdom
(Bate, Kelly, Ganeshan) Department of Clinical Science and Education,
Karolinska Institutet, Division of Vascular Surgery, Department of
Surgery, Sodersjukhuset, Stockholm, Sweden
(Diamantopoulos, Zayed) Guys and St Thomas NHS Foundation Trust, London,
United Kingdom
(Houlind) University Hospital of Wales, Cardiff, United Kingdom
(Malmstedt) Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
(Patel) University of Leicester, Leicester, United Kingdom
(Saratzis) Lillebaelt Hospital, University of Southern Denmark, Vejle,
Denmark
Abstract
OBJECTIVE: The Bypass versus Angioplasty in Severe Ischaemia of the Leg
(BASIL)-2 trial enrolled participants with chronic limb threatening
ischaemia who required an infrapopliteal, with or without a
femoropopliteal, revascularisation procedure to restore limb perfusion.
Participants randomised to a vein bypass (VB) first revascularisation
strategy were over one third more likely than those randomised to a best
endovascular treatment (BET) first revascularisation strategy to die from
any cause during a median follow up of 40.0 (interquartile range 20.9,
60.6) months. The aim was to describe the timing and causes of death in
BASIL-2 as a first step towards trying to better understand why
randomisation to a VB first revascularisation strategy was associated with
this excess mortality. <br/>METHOD(S): A 10 person international panel
comprising vascular and endovascular surgeons as well as vascular
interventional radiologists, who had all been principal investigators in
BASIL-2, took part in a modified Delphi consensus exercise to adjudicate
the primary cause of death and, in particular, whether the cause was
primarily cardiac or non-cardiac. <br/>RESULT(S): In 151/168 deaths
(89.9%) the Delphi panel achieved a consensus regarding the cause of death
being probably cardiac or non-cardiac. In the BET group, 16/77 deaths
(21%) were classified as probably cardiac compared with 32/91 (35%) in the
VB group (unadjusted subdistribution hazard ratio 2.16, 95% confidence
interval [CI] 1.20 - 3.87; unadjusted cause specific hazard ratio 2.15,
95% CI 1.19 - 3.90). At the point of randomisation, 64/344 (18.6%), 37/344
(10.8%), and 40/342 (9%) participants had a previous myocardial infarction
(MI), percutaneous coronary intervention (PCI), and coronary artery bypass
graft (CABG), respectively. There was no evidence of varying treatment
effects for cause of death in subgroup analyses of previous PCI, CABG, or
MI. <br/>CONCLUSION(S): The excess mortality observed in the VB first
revascularisation strategy group in BASIL-2 was largely due to deaths that
were adjudicated by the Delphi panel as probably primarily cardiac. These
excess cardiac deaths were observed throughout follow up and there was no
evidence of non-proportional hazards. Further work is ongoing to try to
better understand the reasons for these findings.<br/>Copyright &#xa9;
2024. Published by Elsevier B.V.

<72>
Accession Number
644861629
Title
Aortic Insufficiency in the Patient on Contemporary Durable Left
Ventricular Assist Device Support: A State-of-the-Art Review on
Preoperative and Postoperative Assessment and Management.
Source
The Journal of heart and lung transplantation : the official publication
of the International Society for Heart Transplantation. (no pagination),
2024. Date of Publication: 26 Jul 2024.
Author
Saeed D.; Grinstein J.; Kremer J.; Cowger J.A.
Institution
(Saeed) Department of Cardiovascular Surgery, Heart Center Niederrhein,
Helios Hospital Krefeld, Germany
(Grinstein) Department of Medicine, University of Chicago, Chicago, IL,
United States
(Kremer) Department of Cardiac Surgery, University Hospital Heidelberg,
Germany
(Cowger) Department of Cardiovascular Medicine, Henry Ford Health,
Detroit, MI, United States
Abstract
The development of aortic insufficiency (AI) during HeartMate 3 durable
left ventricular assist device support (dLVAD) can lead to ineffective
pump output and recurrent heart failure symptoms. Progression of AI often
comingles with the occurrence of other hemodynamic related events
encountered during LVAD support, including right heart failure,
arrhythmias, and cardiorenal syndrome. While data on AI burdens and
clinical impact are still insufficient in patients on HeartMate 3 support,
moderate or worse AI occurs in approximately 8% of patients by 1 year and
studies suggest AI continues to progress over time and is associated with
increased frequency of right heart failure. The first line intervention
for AI management is prevention, undertaking surgical intervention on the
insufficient valve at the time of dLVAD implant and avoiding excessive
device flows and hypertension during long term support. Device speed
augmentation may then be undertaken to try and overcome the insufficient
lesion, but progression of AI should be anticipated over the long term.
Surgical or transcatheter aortic valve interventions may be considered in
dLVAD patients with significant persistent AI despite medical management,
but neither intervention is without risk. It is imperative that future
studies of dLVAD support capture AI in clinical endpoints using uniform
assessment and grading of AI severity by individuals trained in AI
assessment during dLVAD support.<br/>Copyright &#xa9; 2024 International
Society for the Heart and Lung Transplantation. Published by Elsevier Inc.
All rights reserved.

<73>
Accession Number
644859994
Title
Effect of preoperative clopidogrel on outcomes of isolated coronary artery
bypass graft.
Source
The Annals of thoracic surgery. (no pagination), 2024. Date of
Publication: 25 Jul 2024.
Author
Choi K.; Schaff H.V.; Villavicencio M.A.; Dearani J.A.; Stulak J.M.;
Greason K.L.; Spadaccio C.; Todd A.; Crestanello J.A.
Institution
(Choi, Schaff, Villavicencio, Dearani, Stulak, Greason, Spadaccio,
Crestanello) Department of Cardiovascular Surgery, Mayo Clinic, Rochester,
MN, United States
(Todd) Division of Clinical Trials and Biostatistics, Department of
Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States
Abstract
BACKGROUND: We analyzed the Society of Thoracic Surgeons Database to
investigate risks and optimal timing for coronary artery bypass graft
(CABG) after clopidogrel administration. <br/>METHOD(S): Patients were
categorized based on clopidogrel use within five days and further
stratified by days from the last dose (0 to 5 days). Controls were
patients who did not received clopidogrel within five days of surgery. The
primary outcome was operative mortality, and secondary outcomes included
mediastinal re-exploration for bleeding and blood product utilization.
<br/>RESULT(S): Among 148,317 isolated CABG, 19,553 (13.2%) received
clopidogrel within five days. Minimal differences in operative mortality
(2.8% vs 2.1%, P<0.001), but higher rates of mediastinal re-exploration
(3.5% vs 2.1%, P<0.001) and blood product utilization (72.7% vs 56.8%,
P<0.001) were observed in the clopidogrel group. The adjusted odds ratio
of operative mortality peaked on the day of clopidogrel administration but
was comparable to controls thereafter. The odds of re-exploration was
highest on day 0, decreasing gradually to a plateau after day 3. Patients
operated on day 3 after clopidogrel administration had similar odds of
operative mortality and mediastinal re-exploration for bleeding and
shorter total and preoperative length of stays but higher blood product
utilization compared to day 5. <br/>CONCLUSION(S): CABG within five days
from clopidogrel is associated with modest increase in operative mortality
and re-exploration for bleeding and substantial increase in blood product
utilization. Risks decreased with increasing time from discontinuation,
plateauing after 3 days from clopidogrel. CABG at 3 days yields comparable
outcomes as 5 days, reducing the waiting period.<br/>Copyright &#xa9;
2024. Published by Elsevier Inc.

<74>
Accession Number
644858794
Title
Percutaneous coronary intervention versus coronary artery bypass grafting
for left main disease according to age: a meta-analysis.
Source
The Journal of thoracic and cardiovascular surgery. (no pagination),
2024. Date of Publication: 25 Jul 2024.
Author
De Filippo O.; Di Franco A.; Improta R.; Di Pietro G.; Leone A.; Pecoraro
M.; Meynet P.; Carbone M.L.; Di Lorenzo E.; Bruno F.; Demetres M.; Carmeci
A.; Conrotto F.; Mancone M.; De Ferrari G.M.; Gaudino M.; D'Ascenzo F.
Institution
(De Filippo, Pecoraro, Meynet, Carbone, Bruno, Carmeci, Conrotto, De
Ferrari, D'Ascenzo) Division of Cardiology, Cardiovascular and Thoracic
Department, AOU Citta della Salute e della Scienza di Torino and
Department of Medical Sciences, University of Turin, Italy
(Di Franco, Gaudino) Department of Cardiothoracic Surgery, Weill Cornell
Medicine, 525 E 68th St, NY, NY 10065, United States
(Improta, Di Pietro, Mancone) Department of Clinical, Internal,
Anesthesiological and Cardiovascular Sciences, Umberto I Hospital, La
Sapienza University of Rome, Italy
(Leone) Division of Cardiology, SG Moscati Hospital, Avellino, Italy;
Department of Advanced Biomedical Sciences, University of Naples Federico
II, Naples, Italy
(Di Lorenzo) Division of Cardiology, SG Moscati Hospital, Avellino, Italy
(Demetres) Samuel J. Wood Library and C.V. Starr Biomedical Information
Center, Weill Cornell Medicine, New York, NY, USA